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Abstract

ABSTRACT
Over the past decade, there has been increasing interest in the use of
multifunctional nanoparticles for applications in the fields of chemistry, physics, biology,
and medicine, as they offer unique electronic, optical, mechanical, magnetic, and thermal
properties, compared to their bulk counterparts. Of particular interest is the use of
nanoparticles in cancer treatment and cancer prevention in the form of an ultraviolet
blocker in sunscreen products. An emerging field of research is the development of
multifunctional nanoparticle systems, also called ‘theranostic systems’, which are able to
combine multiple features, such as therapeutic, diagnostic, radiation dose enhancing, and
targeting functions on one single platform. Inorganic bismuth- and tantalum-based
nanoparticles are easily synthesized, have a high effective atomic number, are known to be
biocompatible, and have not yet been well studied for cancer treatment or as potential
ultraviolet blocker. Therefore, the aim of this project was to synthesize and characterize
various bismuth- and tantalum-based nanomaterials regarding their physicochemical
properties and their biological activity in cancer and normal cells in vitro.
Part of this doctoral work is focused on the materials and biological
characterization of Bi(OH)3 and α-Bi2O3 nanoparticles. Both types of nanoparticles, which
have a particle size of 6 – 10 nm, display extreme toxicity towards gliosarcoma 9L and
MCF-7 human breast cancer cells. Clonogenic assays reveal a mortality of over 90% in 9L
and MCF-7 cells at a concentration of 50 µg/mL after incubation for 24 h. Moreover, the
nanoparticles cause significant mortality of up to 60% in the cancer cells at the very low
concentration of 6.25 µg/mL. In contrast, at the same concentration, the nanoparticles
exhibit no noticeable mortality towards normal Madin-Darby canine kidney cells. The
internalization of the nanoparticles was demonstrated using flow cytometry, and confocal
microscopy was used to investigate when the loss of cell viability starts. The nanoparticles
cause faster cell death in 9L cells compared with MCF-7 cells, demonstrated via the
iv
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identification of apoptosis through increased sub G1 levels after 24 h of nanoparticle
incubation. Cleavage is identified as the main apoptotic nuclear morphology in 9L, which
suggests the presence of reactive oxygen species.
Given the ability of Bi(OH)3 nanoparticles to kill cancer cells, while showing
biocompatibility in normal cells, these nanoparticles were further investigated as a
multifunctional ultraviolet filter for sunscreens. It was found that the absorbance of
Bi(OH)3 nanoparticles in the ultraviolet region is comparable to those of both the ZnO and
TiO2 nanoparticles used in commercial sunscreens. The in vitro photoprotection results
show that the sunscreen fabricated in this study from a combination of TiO2/Bi(OH)3 was
more efficient than TiO2/ZnO over the whole ultraviolet range, with an increase in the sun
protection factor of 28%. In addition, the homemade sunscreens show rheological
properties comparable to those of commercial sunscreens. The combination of
TiO2/Bi(OH)3 led to insignificant damage on pre-painted steel panels after exterior
exposure for twelve weeks. Furthermore, the addition of Bi(OH)3 nanoparticles reduced
the degradation of crystal violet by photocatalytically active TiO2 or ZnO nanoparticles
under ultraviolet exposure.
To further examine new possibilities regarding the development of a novel
inorganic ultraviolet filter, nanocomposite materials were synthesized, consisting of TiO2
nanoparticles with homogeneously attached (BiO)2CO3 clusters on their surfaces. The
TiO2/(BiO)2CO3 nanocomposites exhibited an absorbance in the ultraviolet-visible range
that was similar to that of TiO2 nanoparticles and photocatalytic activity that is reduced by
up to 60% compared to the TiO2 nanoparticles when exposed to ultraviolet and visible
light. In addition, the nanocomposites show high biocompatibility in normal HaCaT human
skin cells and Madin-Darby canine kidney cells in vitro, and more importantly, they are
capable of reducing the photo-generated toxicity of TiO2 in HaCaT cells upon irradiation
with simulated sunlight.
v
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Finally, a nanotheranostic system was designed based on δ-Ta2O5 nanoparticles
with a particle size of 27 nm, which were coated with poly(acrylic acid) with different layer
thicknesses of 2 – 8 nm. The capability of the δ-Ta2O5-poly(acrylic acid) nanocomposites to
provide anatomical contrast-enhancing features is demonstrated via computed
tomography. The δ-Ta2O5-poly(acrylic acid) nanocomposite was further loaded with
methotrexate, and the drug release was observed for a total of 72 h at pH values of 3.6, 5.4,
7.4, and 9.4. While the different layer thicknesses did not influence the drug release
kinetics, a decrease in pH of the release medium results in a slower release of
methotrexate. In most cases, the drug release mechanism was anomalous (non-Fickian),
and under more alkaline pH conditions, near Case II transport was observed, which
suggests a drug release mechanism highly influenced by macromolecular chain relaxation.
The work presented in this doctoral thesis highlights the multiple features of
bismuth- and tantalum-based nanoparticles, which show selective toxicity towards cancer
cells and are of particular interest, as they can deliver drugs at a sustained rate to target
cancer cells, which can result in higher therapeutic efficiency and reduced systemic
toxicity. Moreover, the examined bismuth-based compounds could potentially be applied
as alternative ultraviolet filter components in sunscreen formulations, reducing the
potential adverse effects associated with TiO2 nanoparticles. Future work establishing the
physiological relevance and mechanism of action – both on a molecular level and in the
cellular environment – will be crucial in pursuing avenues for therapeutic intervention and
prevention in cancer treatment.
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Chapter 1 – Introduction

1.1 Background and Motivation
Nanoparticles (NPs) are emerging as a promising class of therapeutics for the
treatment of malignant neoplasms, which are commonly known as cancer and are one of
the leading causes of death worldwide [1]. In 2012, over 14 million new cases of cancer
were registered, and the number is expected to rise by about 70% over the next two
decades [2]. In 2015, 8.8 million deaths were related to cancer, according to the World
Health Organization [3]. Figure 1.1 displays the estimated numbers of new cases and
deaths for the most common cancer types in the United States in 2018.

Figure 1.1. Estimated number of new cases and deaths for the most common cancer types
in the United States in 2018. The data were obtained from the American Cancer Society [4]
and the United States National Cancer Institute [2]. The breast cancer data include both
female and male; the liver cancer data include intrahepatic bile duct cancer; and the lung
cancer data include the bronchus.
Although chemotherapeutic drugs are widely applied in cancer therapy, a report in
2004 stated that “the overall contribution of curative and adjuvant cytotoxic chemotherapy
to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA.”
[5]. These numbers are very low, especially since the overall 5-year survival rate of cancer
is over 60%. The reasons for the low impact of chemotherapeutic agents alone are the
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increase in patient drug tolerance, the lack of cancer cell targeting, and altered drugreceptor sensitivity. Combinations of therapies and the design of theranostic systems seem
therefore to be a reasonable approach to improve the efficiency of cancer therapy.
Early clinical trials suggested that therapeutics based on NPs showed higher
therapeutic efficiency than commonly used anticancer drugs, while simultaneously
minimizing side effects, as they are capable of delivering drugs in the optimum dosage and
at the optimum frequency to cancerous tissue [6, 7]. Biodegradable NPs based on polymers
are of particular interest, as they provide controlled release of pharmacologically active
drugs to the action site [8]. Moreover, it is well known that NPs navigate easily across
various biological barriers to preferentially accumulate in tumour tissues due to their
enhanced permeability and retention effects [9]. This realization guided some of the work
performed for this doctoral thesis.
By designing multifunctional NP systems, additional features can be included in
these so-called theranostic systems, which also provide targeting features and enable
active cellular uptake [7]. The use of compounds with a high atomic number can enhance
the radiation dose, which ultimately maximizes the efficiency of radiation therapy. It has
been shown that the energy of the radiation beam could be reduced to orthovoltage
radiotherapy (< 500 keV), while still providing enough damage to some human tumours,
which further minimizes the destruction of normal cells [10]. It is therefore desirable to
combine as many functions as possible on one single platform, while keeping the overall
complexity, chemical instability, and fabrication costs of the theranostic system low.
Besides the treatment of cancer, the prevention of melanoma – one form of skin
cancer – is of recent interest. According to the United States National Cancer Institute,
melanoma can affect persons of any age, although it is mainly diagnosed in adulthood [11].
An alarming development is the increase in lifetime risk of being diagnosed with
melanoma over the past century: while in 1935, the lifetime risk of developing melanoma
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was 1 in 1,500, this number increased significantly to 1 in 68 individuals in 2002 [12]. The
formation of melanoma is typically linked to excessive exposure to ultraviolet (UV)
radiation from the sun, which can result in photo-aging and genetic damage through the
generation of reactive oxygen species (ROS) [13, 14].
Commonly used sunscreen formulations contain inorganic UV filters such as TiO 2
or ZnO NPs, which function through the absorption of UV light. It has been shown,
however, that these NPs are biologically more reactive than the normal microscale bulk
material, with the smaller size allowing them to penetrate the skin more readily and reach
deeper tissue layers [15]. This penetration is critical, as recent findings reveal that both
TiO2 and ZnO NPs exhibit intrinsic cyto- and genotoxicity. All these processes can be
significantly enhanced through their photocatalytic activity when exposed to UV radiation
[16, 17]. The photogenerated ROS can cause the degradation of the organic additives that
are employed in sunscreens, yielding the formation of by-products with unknown toxicity
[17-19]. In addition, after topical application, the degradation of organic UV filters results
in a continual reduction of the sun protection factor (SPF) under exposure [20, 21].
Approaches to minimizing the photocatalytic activity of the active inorganic sunscreen
ingredients include the coating of TiO2 NPs with silica (SiO2) or aluminium oxide (Al2O3),
but complete protection has not been achieved as yet [16]. It has also been shown,
however, that the composite materials TiO2/SiO2 and TiO2/Al2O3 can display enhanced
photocatalytic activity, which emphasizes the importance of the search for alternative and
less reactive inorganic UV filter [22].
The purpose of this work was to engineer and study different inorganic NPs,
including nanoceramics, based on Bi and Ta for biomedical applications, with the focus on
the prevention and treatment of cancer. Inorganic Bi- and Ta-based NPs are easily
synthesized, are known to be chemically stable, are biocompatible, and have not yet been
well studied for biomedical applications [23-25]. Due to their high effective atomic
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number, these materials are excellent candidates for the development of theranostic
systems that can provide, besides their therapeutic and targeting functions, diagnostic
features and radiation dose enhancement [26-29]. Moreover, the easily modifiable surfaces
of ceramic materials allow loading with anti-cancer drugs, which is typically achieved with
conjugation or encapsulation by a polymer layer [30]. On the nanoscale, polymers can
improve the half-life, solubility, and stability of drug delivery systems, while reducing
potential side effects [31-33]. Another component of this doctoral thesis was the
optimization of existing TiO2-based UV filters, with an emphasis on the reduction of the
photocatalytic activity associated with TiO2, and the study of a completely novel Bi-based
inorganic UV filter for sunscreen application. Therefore, the aim of this project was to
synthesize and characterize various Bi- and Ta-based nanomaterials regarding their
physicochemical properties and their biological activity in cancer and normal cells in vitro.

1.2 Thesis Structure
This doctoral work is composed of six chapters. A brief description of each
chapter’s role is outlined below:
Chapter 1 introduces the theme and motivation for this doctoral thesis, and details
its structure.
Chapter 2 provides an overview of the fundamentals of cancer, UV radiation, and
melanoma, and provides an in-depth look at the fundamental idea behind theranostic
systems. A detailed outline is given regarding different nanomaterials for the development
of theranostic systems and their mechanism of action, with the focus on therapeutics,
diagnostics, radiation dose enhancement, and targeting. A comprehensive review of the
use of NPs as UV filters in sunscreens is presented, focusing on the limitations of current
sunscreens and current strategies to improve their performance, and concluding with
likely future directions for the development of inorganic UV filters.
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Chapter 3 presents the synthesis methods used in the fabrication of the Bi- and Tabased nanomaterials studied in this work, and the various physical, chemical,
morphological, photocatalytic, and biological in-vitro characterization techniques that have
been utilized. Relevant details on the materials used, and sample preparation and analysis
are specified in the subsequent results chapters.
Chapter 4 summarizes the studies of all Bi-based compounds: the first section
discusses the study of Bi(OH)3 and α-Bi2O3 NPs regarding their physicochemical properties
and their bioactivity in 9L gliosarcoma cells, MCF-7 human breast cancer cells, and normal
Madin-Darby canine kidney (MDCK) cells in vitro. There is a specific focus on the analysis
of the oxidative features of apoptotic cells. The second section focuses on the study of
Bi(OH)3 NPs as a novel, multifunctional UV filter for sunscreens with reduced
photocatalytic activity compared to TiO2 and ZnO NPs, which are typically used as
inorganic UV filters. The photoprotection, photostability, and rheological properties of inhouse fabricated sunscreens containing Bi(OH)3 NPs are compared to sunscreen products
commercially available in Australia. The modification of TiO2 NPs for UV blocking
applications has been the target of great research interest. Hence, the third section
presents the development of TiO2/(BiO)2CO3 nanocomposites and the study of their UV
properties and photocatalytic activity, especially when exposed to HaCaT human
keratinocytes and simulated sunlight in vitro. This chapter compiles information published
in the following three journal articles: K. Bogusz et al., Materials Science and Engineering C,
2018, 93, 958-967; K. Bogusz et al., Materials Research Bulletin, 2018, 108, 130-141; K.
Bogusz, et al., Journal of Materials Chemistry C, 2018, 6, 22, 5639-5650.
Chapter 5 focuses on the development of a theranostic system based on a
composite of δ-Ta2O5 and poly(acrylic acid) (PAA), which was loaded with the anticancer
drug methotrexate (MTX). The drug release of the MTX-loaded δ-Ta2O5-PAA composites
was studied at different pH, and the contrast-enhancing properties of the composites were
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studied in vitro. This chapter is based the following manuscript, which is currently under
revison: K. Bogusz et al., submitted to Journal of Colloid and Interface Science, 2018.
Chapter 6 concludes this doctoral thesis by summarizing the conclusions and
knowledge acquired from this work, and discusses future prospects for the development of
multifunctional nanomaterials in general, and Bi- and Ta-based compounds in particular.
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2.1 Cancer Characteristics
2.1.3 Cancer Cells and Normal Cells
Cancer is a group of diseases that are characterized by the uncontrollable,
abnormal, rapid, and indefinite proliferation of cells with the potential to invade other
body parts [1]. In contrast to normal cells, cancer cells are less specialized and are able to
avoid programmed cell death or apoptosis by ignoring signals, which ultimately results in
the continuous growth and division of cells [2]. In addition, cancer cells promote the
construction of blood vessel and often invade the immune system, inhibiting immune
responses and consequently, removing another control mechanism for the detection and
removal of damaged and abnormal cells [1, 2].
Not every change in the body’s tissue, however, is directly linked to cancer.
Hyperplasia, for instance, is defined as the process by which cells within a tissue divide
faster than normal cells [1]. As a consequence, extra cells build up that exhibit the
properties of normal cells, when examined via microscopy. Dysplasia, in contrast, is
characterized by a build-up of cells that show abnormal cell properties [1]. If not treated,
the abnormal cells are likely to develop into cancerous structures. The different forms of
normal cell growth and the transition to malignant cell growth are shown in Figure 2.1.
Almost every type of cell in the human body can develop into cancer cells, typically
after they are genetically altered, which increases the complexity of treatment. Many
cancers form solid neoplasms or tumours, which are masses or lumps of tissue [3]. Once a
cancerous tumour is formed, it can spread within the body via both the lymphatic system
and the bloodstream, forming metastatic tumours (Figure 2.2). Unlike malignant tumours,
benign tumours typically do not spread into nearby tissues, and they do not tend to grow
back once they have been removed [1].
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Figure 2.1. Development of cancer from normal cells, adapted from [1]. Before cancer cells
form in tissues of the body, the cells go through abnormal changes (hyperplasia and dysplasia).

Figure 2.2. Schematic illustration showing how cancer cells spread all over the body.
Adapted from [4].
2.1.4 Causes of Cancer
Cancer is a genetic disease and can be inherited or arises as a result of external
influences that cause changes to the genes, which is schematically shown in Figure 2.3 [1].
Typical environmental exposures that can trigger genetic mutations include [5, 6]:


Physical carcinogens: ultraviolet (UV) and ionizing radiation.
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Chemical carcinogens: components of tobacco smoke, aflatoxin, heavy
metals, or polycyclic aromatic hydrocarbons.



Biological carcinogens: bacteria and parasites.

Figure 2.3. Cancer is caused by certain changes to genes, which are the basic physical units
of inheritance and are found in each cell in the nucleus. Adapted from [1].
The genetic changes that contribute to the formation of cancer typically affect three
main types of genes: proto-oncogenes, tumour suppressor genes, and deoxyribonucleic
acid (DNA) repair genes [1]. Proto-oncogenes are involved in the growth and division of
normal cells, but may become oncogenes once these genes are altered [1]. An alteration of
tumour suppressor genes, which are involved in controlled cell growth, can lead to
uncontrolled cell division [1]. Mutations in DNA repair genes typically result in the
development of mutations in other genes [1].
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2.1.5 Types of Cancer
In total, there exist over 100 different types of cancer, typically named after the
organs of origin. Figure 2.4 displays a selection of cancer types, categorized by the original
cells where they arise [1].

Figure 2.4. Types of cancer, categorized by the cellular origin of the tumour. The
information was collected from the U.S. National Cancer Institute [1].
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2.1.6 Current Cancer Prevention Strategies and Anti-Cancer Treatments
The risk of cancer can be controlled and reduced by implementing prevention
strategies, such as evasion of risk factors, including the reduction of exposure to UV
radiation (see section 2.2.4 and 2.2.6) [7]. Furthermore, early detection of cancer can
significantly increase the chances of surviving. Typical screening methods are
mammography screening for breast cancer or visual inspection for cervical cancer [7].
Depending on the location, type, and size of the tumour, different types of cancer
treatments are currently applied in hospitals. These treatments include:


Surgery,



Chemotherapy, and



Radiation therapy.

Surgical removal of the tumour is usually preferred if no metastases are formed
and the tumour is large in size and easy to reach. There are typical risks associated with
the surgical treatment, however, such as bleeding and infection [8].
In chemotherapy, highly-effective drugs are given to the patient, which can spread
to various parts of the body, where they destroy cancer cells and stop or slow-down their
growth [8]. Such treatment is recommended if metastatic tumours are formed. This
treatment is associated with many side effects, however, such as anaemia, infections, and
nerve changes [8]. Furthermore, chemotherapy cannot completely kill all cancer cells in
vivo within a certain time, so that the cancer can relapse or metastases are formed [8].
Radiation therapy uses ionizing radiation to control or kill cancer cells and causes
less severe side effects in comparison to chemotherapy. The success rate of radiation
therapy, however, depends strongly on the type and progress of the tumour: while the
chances are high that single and very localized tumours will be destroyed, a synergistic
therapy with chemotherapeutic drugs is used for less manageable tumours [8].
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Besides these classical therapies, a number of individually applied methods exists,
such as biological therapy, hormone therapy, and photodynamic therapy [8].

2.2 Ultraviolet Radiation and Melanoma
2.2.1 Ultraviolet Light Irradiation
UV light has wavelengths of 10 – 400 nm and can be subdivided into a number of
ranges as per the recommendation from the International Organization for Standardization
(ISO) standard ISO-21348 [9]. Their selection of UV ranges is shown in Table 2.1.
Table 2.1. Subdivision of ultraviolet (UV) light according to the International Organization
for Standardization (ISO) standard ISO-21348 [9].
Ultraviolet range

Abbreviation

Wavelength (nm)

Near ultraviolet

NUV

300 – 400

Middle ultraviolet

MUV

200 – 300

Far ultraviolet

FUV

122 – 200

Extreme ultraviolet

EUV

10 – 121

The ability to see UV rays strongly depends on the eye’s development of colour
receptors for UV rays. Typically, UV rays are invisible to humans, although, under certain
conditions, children are able to see UV down to a wavelength of 310 nm [10]. In addition,
NUV radiation is visible to insects, some mammals, and birds [10].
2.2.2 The Human Skin Barrier
Human skin is composed of the epidermis and dermis. The upper epidermal layer,
the stratum corneum, is the skin’s primary protection against percutaneous penetration of
exterior substances [11] and is densely packed with approximately 15 layers of dead cells
(corneocytes), which are embedded in a lipid matrix and are mainly filled with keratin,
water, and enzymes [12] (Figure 2.5). The unique lipid organization in the intercellular
stratum corneum is essential for the functioning of the skin barrier. The viable epidermis
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consists of three layers: the stratum basale, the stratum spinosum, and the stratum
granulosum. Cells proliferate in the stratum basale and start to differentiate and migrate
into the stratum spinosum and stratum granulosum [13]. At the interface between stratum
granulosum and stratum corneum, viable cells are transformed into dead corneocytes [13].

Figure 2.5. Schematic representation of a skin cross-section, adapted from [13].
The skin barrier regulates the production of lipids, stops excessive water loss, and
prevents stressors from entering deeper skin layers. These stressors can be [14]:


Physical assaults: mechanical injury, UV radiation.



Microbial assaults: pathogens such as bacteria, fungus, viruses.



Chemical assaults: allergens, oxidative substances, irritants, toxins.

The corneocytes are oriented parallel to the surface and allow for substances to
permeate along indirect pathways through the intercellular areas [13]. Besides the
transcellular and paracellular routes, the transappendageal route includes the penetration
of substances along hair follicles, sebaceous glands, and sweat pores [11]. Compromised
skin often shows a reduced skin barrier efficiency, which can be linked to changes in the
lipid composition or altered tight junctions [15, 16]. Once the skin barrier is altered,
substances can pass into deeper skin layers and potentially cause harm, locally or
systematically.
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2.2.3 Effects of Solar Ultraviolet Radiation on the Human Skin
With regards to the penetration of solar UV radiation into the skin, a further
subdivision of UV radiation is made into: ultraviolet A (UVA), ultraviolet B (UVB), and
ultraviolet C (UVC) radiation (Figure 2.6). In contrast to solar UVA and UVB, solar UVC
radiation has a wavelength of typically 100 – 280 nm, is completely absorbed by
stratospheric oxygen, and hence does not reach the human skin.

Figure 2.6. Electromagnetic spectrum of visible and ultraviolet solar radiation and the
effects on the human skin. Adapted from [6].
2.2.3.1 Solar Ultraviolet B Irradiation
More than 90% of the solar UVB rays with a wavelength of 280 – 320 nm are
absorbed by ozone and thus, do not reach the human skin [6, 9]. The small percentage that
penetrates the skin, however, is typically absorbed by the epidermis and does not reach
deep skin layers [6].
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The energy is absorbed by DNA and causes genetic damages and mutations via
molecular rearrangements and the formation of cyclobutane-pyrimidine dimers (CPDs)
and the more mutagenic 6,4 pyrimidine-pyrimidones [17]. UVB rays lead, besides their
potential to cause cancer, to the formation of redness, sunburn, freckles, and eye damage.
The occurrence of sunburn is particular high amongst children, which ultimately increases
the risk of developing melanoma in adulthood [18, 19].
2.2.3.2 Solar Ultraviolet A Irradiation
Higher wavelengths of 320 – 400 nm are classified as UVA, with further distinction
of UVA1 (340 – 400 nm) and UVA2 (320 – 340 nm). Solar UVA rays can deeply penetrate
into the dermis, up to the dermis stratum papillare [9, 20]. Visible light penetrates even
deeper into the tissue, which leads – together with the penetration of UVA rays – to genetic
mutations and base pair breakage of the DNA, base modifications, and the generation of
ROS [6, 20].
An excessive exposure to solar UVA radiation can therefore result in photo-aging
by shrinking and depletion of collagen and elastin, immune-suppression, and sunburns,
which can cause the formation of skin cancer, especially melanoma [20, 21].
The damage to the skin through solar UV radiation can further damage the skin
barrier and lead to increased epidermal permeability, which ultimately increases the
chances for particles to reach viable cells in the skin [22].
2.2.4 Impact of Ionizing Radiation on Deoxyribonucleic Acid
High-energy UV radiation is considered to be ionizing radiation and can cause,
together with many other substances such as some chemicals or heavy metals, direct and
indirect damage to DNA [23, 24].
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2.2.4.1 Direct Impact of Ionizing Radiation on Deoxyribonucleic Acid
Alpha particles, beta particles or X-rays, due to their high energy, easily produce
ions if in contact with living tissue, causing direct damage to DNA by physically breaking its
sugar phosphate backbones [23, 25].
As a result, single and double strands can break, which can lead to the loss of DNA
fragments and the formation of tumour cells, if for instance the deleted chromosomal area
encoded a tumour suppressor or a protein with oncogenic potential (Figure 2.7) [25].
Furthermore, DNA base pairs can be damaged, as they are held together by weak hydrogen
bonds. UV radiation can induce the formation of covalent linkages between consecutive
bases along the nucleotide chain, which then causes the formation of CPDs and 6-4
photoproducts [23, 26-28].

Figure 2.7. Schematic representation of direct damage to deoxyribonucleic acid (DNA).
2.2.4.2 Indirect Impact of Ionizing Radiation on Deoxyribonucleic Acid
Indirect damage to DNA occurs typically through free and highly reactive radicals,
as shown in Figure 2.8 (see section 2.3.4). The high-energy radiolysis of H2O molecules into
H+ and OH- radicals can result in the formation of superoxide (HO2) and peroxide (H2O2)
molecules, which can produce oxidative damage to DNA, lipids, proteins, and many
metabolites [23, 24]. For instance, the DNA lesion 7,8-dihydro-8-oxoguanine can be caused
through oxidative alterations and results in a mismatched pairing with adenine[29].
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Figure 2.8. Schematic representation of indirect damage to deoxyribonucleic acid (DNA).
2.2.4.3 Repairing Mechanisms of Deoxyribonucleic Acid after Exposure to
Ionizing Radiation
When DNA strains break, DNA typically repairs itself through a number of different
processes [23, 25]:


Photoreactivation,



Base excision repair (BER),



Nucleotide excision repair (NER),



Mismatch repair (MMR).

Typically, damaged DNA is firstly removed by endonuclease, followed by a DNA
synthesis by DNA polymerases. Besides these repair mechanisms, the cell has also cellcycle checkpoints and programmed cell death [23, 27].
Although these DNA repair mechanisms are highly efficient, they are not always
flawless. As a consequence, insertions of incorrect nucleotides are often observed, which
can lead to cell death or mutation such as substitutions, transitions, transversions,
frameshift mutations, insertions, or deletions [23, 27, 28]. During the repairing of doublestrand breaks, for instance, the joining of non-homologous chromosomes can occur, which
in the long term, can lead to tumorigenesis.
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2.2.5 Melanoma Risk Factors and Special Situation in Australia
The amount and strength of solar UV radiation depends on the altitude and
proximity to the equator. Before the sunlight reaches the surface of the Earth, it can be
absorbed, reflected back into space, or scattered by atmospheric particles. The greater the
atmospheric interference on the way to the Earth’s surface, the lower the corresponding
UV content of the sunlight is (Figure 2.9). The equator is most closely located to the sun,
resulting in low atmospheric interference and high UV content. Towards the North Pole
and South Pole, the sunlight has to travel longer, which results in greater scattering and
lower UV doses from sunlight.

Figure 2.9. Variation of ultraviolet dosage with geographical location. Adapted from [6].
The increased UV doses in areas close to the equator such as Australia are directly
linked to the highest melanoma rates. As such, the lifetime risk of developing melanoma in
Australia in 2002 was 1 in 50 individuals [30]. Due to the hot weather, people typically
wear less clothes and spend more time outside, which ultimately increases the UV
exposure and risk of developing melanoma [31]. In addition, the majority of the Australian
population is composed of fair skinned people, who are known to have a higher risk of
developing melanoma, as opposed to dark-skinned people [32].
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Besides the exposure to solar UV radiation, a large number of risk factors exist that
influence the formation of melanoma. These risk factors are: indoor tanning and ultraviolet
A (PUVA) therapy, skin pigmentation and pre-existing moles, sunburns, old age,
immunodeficiency, chemical carcinogens, and genetic factors [6].
2.2.6 Current Methods of Protection from Solar Ultraviolet Radiation
While not all risk factors, such as genetic predisposition, can be controlled, the awareness
of other risk factors is important for significantly reducing possible exposure to them.
Being one of the highest risk factors, reduction of exposure to harmful solar UV radiation
can be achieved by various methods, including: seeking of shade [33], application of broadspectrum sunscreens with a SPF of 50+, and wearing of clothes, a broad-trimmed hat, and
sunglasses [6, 33, 34].
The most effective method of protection is the complete avoidance of sun exposure.
When sun exposure cannot be avoided, it is preferable to pursue sun contact when the UV
index is low. The UV index is used to categorize the strength of solar UV radiation at a
particular time and place, and is an international standard measurement that aims
primarily to inform the general public about the need for protection [35]. Typically, the UV
index is highest between 10 am and 4 pm when the sun is the most intense [33].
These control mechanisms are of special importance to fair skinned people, who
have to be more careful with solar UVA and UVB radiation due to their lack of epidermal
melanin [6]. Moreover, indoor tanning should be avoided, and pre-existing moles should be
monitored from an early age. Especially in older age groups, screening and monitoring of
skin changes is important. With regard to chemical and biological carcinogens, the careful
handling of all chemicals and attentive reading of ingredient labels and their associated
side effects are strongly advised.
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2.3 Theranostic Nanomaterials for Cancer Treatment
2.3.1 Definition of Nanomaterials
A new direction of anti-cancer treatment involves the development of drugs that
are based on NPs. Nanosized materials are defined as materials with a size ranging from 1
to 100 nm (Figure 2.10), and they exhibit unique and versatile physicochemical properties
that are attributable to their elemental composition, crystallinity, size, shape, and surface
features [36-38].

Figure 2.10. Examples of different-sized materials, including the classification of
nanoparticles (red arrow). Adapted from [36].
The unique properties of nanocrystalline materials led to their use in
microelectronics and as components in sensors and for the aerospace industry [39]. NPs
are also applied in catalysis, photocatalysis, and in the mechanical industry, particularly as
coatings, lubricants, and adhesives [40-43]. An emerging field of research is the energy
sector, including the generation of energy through renewable sources and energy storage
[40]. Other applications include pollution prevention, and the removal of hazardous
substances [40, 44]. Applications of NPs in biology and medicine include labelling,
biosensors, drug and gene delivery, detection of pathogens and proteins, and tissue
engineering [45-51]. Moreover, as the growing use of engineered NPs increases their
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release into the environment, NPs are thoroughly investigated for their geno-, eco-, and
cytotoxicity, and their persistency and reactivity [52].
Various NPs have been studied for their toxicity in numerous different cancer cell
types, both in vitro and in vivo [37]. Typically, NPs are characterized by their ability to
easily perfuse out of the bloodstream and their high tissue permeability. More importantly,
NPs typically exhibit the Enhanced Permeability and Retention (EPR) property, in which
molecules with a certain size tend to accumulate in tumour tissue to a larger degree as
compared to normal tissue [53]. The increased accumulation of NPs is typically linked to
the increased need for stimulation to produce blood vessels for fast cell growth [53, 54].
2.3.2 Definition of a Theranostic System
The term ‘theranostics’ is defined as the combination of a therapeutic agent and an
imaging agent in a single system, which can be, for instance, achieved by combining
materials with different properties in form of a composite material. Besides these two
fundamental properties, even more functionalities can be added to the system, such as a
targeting agent, as displayed in Figure 2.11.
The design of a theranostic system typically includes a drug carrier on which
biologically active materials, such as antibodies or anti-cancer drugs, are attached. In
particular, the use of nanomaterials is of interest, since they provide, besides their small
size and the associated ability to easily pass through cell membranes, a high surface area
that allows functionalization [38, 55].
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Figure 2.11. Examples of compositions of theranostic systems. Abbreviations:
deoxyribonucleic acid (DNA), short interfering ribonucleic acid (siRNA).
Moreover, by tailoring the size of the nanomaterials, their tissue accumulation can
be controlled. NPs with a diameter of ≤ 5 nm either accumulate in tissue through
pinocytosis or extravasation, or are cleared from the blood through the kidney. The fast
clearance can have the advantage of reducing the total exposure of the human body to the
NPs, as in the case of drug delivery systems that have released their active components
[38]. If the NPs reach diameters ≥ 200 nm, however, their potential to accumulate in tissue
significantly decreases, making them less favourable as drug carriers [56].
2.3.3 Nanomaterials for Theranostic Systems
The nanomaterials that are applied for cancer therapy can have various different
natures, ranging from simple inorganic gold (Au) NPs to more complex nanographene.
More recently, organic structures, such as dendrimers and polymer-drug conjugates have
emerged, with the aim of combining multiple features of nanomaterials. As a matter of fact,
the use of single therapeutic agents has been shown to not be as effective as desired [57].
Therefore, modern approaches try to combine the use of multiple drugs and the use of
inorganic and organic nanomaterials on one single platform [58].
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2.3.3.1 Organic Nanoparticles
In general, the use of polymer-based materials can offer various advantages, such
as a high biodegradability, biocompatibility, high functionality, and prolonged circulation
of the nanomaterials. Moreover, the use of pH-sensitive polymers is promising due to the
different pH values present in the tumour environment, endosome, and lysosome [59, 60].
Polymeric micelles are spherical structures with a hydrophobic core and a
hydrophilic shell, which enables them to load and deliver anti-cancer drugs to the
appropriate site (Figure 2.12) [38]. Similar to polymeric micelles, polymeric NPs provide
superior pharmacokinetic properties, such as drug loading and drug stability. Typically, the
NPs are surrounded by a polymer matrix that can adsorb, dissolve, or entrap drugs, or
incorporate diagnostic agents, such as gadolinium complexes and magnetic NPs [61-63].
By combining drugs and water-soluble polymers on a single platform through a direct
linkage or a spacer, polymer-drug conjugates can be obtained, which are the most
successful nanotherapeutics that have been studied in regard to cancer therapy [64].

Figure 2.12. Different types of organic nanomaterials that are applied in cancer therapy.
Adapted from [38].
Dendrimers typically have a highly branched three-dimensional structure, which
provides empty holes, the surfaces of which have a high density of functional groups. This
high functionality allows drugs, proteins, genes, or imaging agents to be loaded onto
dendrimers through electrostatic interactions, encapsulation, or covalent bonding [65, 66].
Liposomes consist of closed three-dimensional membrane structures, which are
made through self-assembly of materials with hydrophobic and hydrophobic ends, such as
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phospholipids. The core is generally an aqueous phase, in which water-soluble drugs,
enzymes, and nucleic acids can be incorporated [67]. The membrane layer itself is
hydrophobic and allows the entrapment of water-insoluble bioactive components [68].
2.3.3.2 Inorganic Nanoparticles
There are a great number of inorganic-based nanomaterials that have been
explored as active components of theranostic systems, including quantum dots, metal NPs,
metal oxides, carbon-based nanomaterials, and magnetic NPs (Figure 2.13).
Quantum dots are normally semiconductor nanocrystals with a tunable particle
size ranging from 2 to 100 nm, which enables them to display narrow emission spectra
with emission maxima at 450 – 850 nm [69]. They are excellent imaging agents, as they
provide bright signals and are photostable over long-time imaging. Quantum dots can
further act as either photosensitizers or activators for other photosensitizers by energy
transfer [70].

Figure 2.13. Different types of inorganic nanomaterials that are applied in cancer therapy.
Adapted from [38].
Au NPs are biocompatible, tailorable in size and shape, and can easily be
functionalized by surface coatings. Moreover, they have been explored in cancer therapy
due to their labelling and sensing properties, and can act as a radiosensitizer due to their
high X-ray absorption [71, 72]. Ceramic materials, such as silicon dioxide (SiO2) can be
synthesized in various nanostructures, including rigid porous structures with high surface
areas and high density of functional groups, which enables the entrapment of anti-cancer
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drugs or imaging agents [73, 74]. In addition, these ceramic materials are typically
photostable and show high biocompatibility [38].
Carbon-based nanomaterials include carbon nanotubes (CNTs), fullerenes, and
graphene, and offer biocompatibility, thermal conductivity, and unique electrical, optical,
and mechanical properties [75]. The modifiable surface of these structures allows π-π
stacking, hydrophobic interactions, covalent conjugation, hydrogen bonding, and
electrostatic interaction with various drug molecules [76]. Due to their strong absorbance
in the near-infrared region, these materials can be used as a contrast agent, and more
importantly, they can be used for as photothermal agents that can cause ablation of cancer
cells via the induction of hyperthermia [38, 77, 78].
Various types of magnetic nanomaterials with tuneable particle size exist, such as
iron oxides, pure metals, spinel-type ferromagnets, and alloys [79]. Bioactive components
are typically introduced into the system through coating with surfactants or polymers [38].
Magnetic nanomaterials are of particular interest, as they provide magnetic targeting,
magnetic resonance imaging (MRI), and can induce cell death in hyperthermia therapy
[80].
2.3.3.3 Core-Shell Structures
Similar to polymer-drug conjugates, liposomes, and magnetic nanomaterials,
inorganic nanomaterials, such as quantum dots, metal NPs, and ceramic NPs, can be
functionalized by a polymer to form a core-shell structure. Typically, the core provides
imaging capabilities, while the polymer shell enables further attachment of bioactive
materials, such as anti-cancer drugs or antibodies [58].
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Figure 2.14. Exemplary core-shell structure.
The biocompatibility and stability of core-shell structures is significantly improved
with polymer coatings such as poly(ethylene glycol) (PEG) or dextran [38]. Moreover, due
to the great variety of polymers, tailored attachment, encapsulation, or covalent bonding of
particular bioactive components can be achieved [58]. Moreover, the coating itself can
provide features, such pH-dependent swelling properties or reversible drug loading and
release [81-84]. These controllable drug delivery systems are essential to reduce the
dosage frequency and systemic toxicity [85].
Despite these advantages, core-shell nanomaterials suffer from characteristic
limitations, arising from attempts to combine different features. On the one hand,
diagnostic nanomaterials are designed to provide quick disease monitoring, which favours
short circulation times to minimize exposure to the human body and the associated
possible side effects. On the other hand, therapeutic nanomaterials require good
biodistribution, good biodegradation and long-circulation times to ensure an effective
therapeutic response and avoid multiple dosage [58].
Physically tethered surface coatings
Generally, there are two different approaches that are used to apply surface
coatings onto substrates such as nanoceramic materials. In one case, the substrate does not
provide any linking functional groups, so that the coating is physically adsorbed onto the
nanomaterial’s surfaces, where it can further react to form a complete shell. The
disadvantage of that technique lies in the possible formation of lumps or cross-linking,
increasing the overall size of the composite [86, 87].
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Chemically tethered surface coatings
In the other case, the substrate has functional groups on its surfaces, allowing the
surface coating to be covalently attached to the substrate, which yields much stronger
stability and a stronger structure that can withstand aggressive processing conditions. In
addition, the coating is usually formed more evenly and homogeneously with a reduced
risk of clump formation [88-90].
2.3.4 Therapeutic Effects of Nanoparticles
Chemotherapeutic drugs provide therapeutic effects, making them desirable for
theranostic systems. The use of anti-cancer drugs is associated with multiple side effects,
however, such as hair loss, nausea, and fatigue, and more importantly, these drugs show
low stability [91]. Therefore, current research is focussed on the development of
alternative therapeutic resources that are capable of overcoming the above-mentioned
drawbacks.
Anticancer drugs can affect cancer cells by interfering with processes involved in
the cell cycle or through apoptosis, the latter one being of particular interest for novel
strategies that include the selective activation of apoptosis in malignant cells or its
suppression in normal cells [92]. It is commonly known that NPs mediate their toxicity
through the generation of ROS and that the level of oxidative stress depends on the
structure and chemistry of the NPs [93].
2.3.4.1 Definition of Reactive Oxygen Species
ROS are radicals, ions, or molecules that have a single unpaired electron in their
outermost electron shell, making them highly reactive. Generally, ROS can be categorized
into two groups: radical ROS and non-radical ROS, as displayed in Table 2.2.
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Table 2.2. Examples of different types of reactive oxygen species.a)
Free oxygen radicals
Molecular formula

RSSR

Chemical name

Non-radical reactive oxygen species
Molecular formula

Chemical name

Superoxide

Hydrogen peroxide

Hydroxyl

Singlet oxygen

Disulfides

Peroxynitrate
Nitrosoperoxycarbonate

Nitric oxide
anion
Peroxyl

Organic hydroperoxides

Alkoxyl

Ozone

Sulfonyl

Nitrocarbonate anion

Thiyl

Nitronium

Organic radicals

Dinitrogen dioxide

Thiyl peroxyl
a) R

ROOH

HOCl

Hypochloride

stands for R group, an abbreviation for any group in which a carbon or hydrogen atom

is attached to the rest of the molecule.

2.3.4.2 Significance of Reactive Oxygen Species
Low levels of ROS are important for cellular function and survival signalling [94,
95], but excessive ROS can lead to damage to DNA, lipid peroxidation, and protein
oxidation [96, 97], underlining that, for optimal cell function, a well-balanced level of ROS
is essential. In addition, the type of generated ROS, the location where it is generated, and
its local concentration are of importance for cellular functions. Normal cells have typically
lower ROS contents, while the ROS level increases in cancer cells (Figure 2.15), where ROS
promote many aspects of tumour development and progression [98].
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Figure 2.15. Overview of the role of reactive oxygen species in cancer cells and the
induction of apoptosis. Adapted from [99].
The major endogenous source of cellular ROS is the mitochondrial electron
transport chain [100], whereas exogenous sources can be UV and ionizing radiation [101,
102], chemical irritants [103], and environmental toxins [104].
Novel therapeutic strategies aim to increase the ROS production in cancer cells,
which consequently changes the ROS balance and can lead to apoptosis, which is typically
mediated through the mitochondrial death pathway including the release of cytochrome c
and the activation of kinases [105]. Prolonged treatment with the same drug reduces ROS
levels and increases the drug resistance [99]. Exogenous ROS are applied in combination
with drugs to sensitize resistant cancer cells and induce apoptosis [99].
Alternatively, the use of antioxidants in early stages of tumour development, where
high levels of ROS are essential, might prevent further growth of cancer cells. It still
remains a challenge, however, to target specifically cancer cells and further research is
needed to fully understand the diverse stress-regulated cellular functions [98].
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2.3.4.3 Nanoparticles as Reactive Oxygen Species Generators
The various physicochemical properties of engineered nanomaterials allow for the
design of tailored nanomaterials that can be used to induce elevated levels of ROS in vitro.
Silver (Ag) NPs with particular particle sizes, for instance, have caused an increase
of more than 10-fold in ROS levels in alveolar macrophages [106]. The induction of
apoptosis in a human monocytic cell line (THP-1) by Ag NPs and Ag+ ions was associated
with a drastic increase in ROS after an incubation period of 6 – 24 h [107].
Another widely investigated material is nanosized titanium dioxide (TiO2), which
has been shown to cause inflammation, cytotoxicity, and genomic instability in mammalian
cells [108]. A study by [109] showed that TiO2 NPs induce the generation of ROS in
immortalized mouse brain microglia (BV2). The toxicity of TiO2 NPs is further elaborated
in section 2.5.2.2.
ZnO NPs have shown a selective toxicity towards human liver cancer (HepG2) and
human lung adenocarcinoma (A549), while no impact on normal rat astrocytes and
hepatocytes was observed. The toxicity was found to originate from the generation of ROS
via the p53 pathway [110]. It was also shown that ZnO NPs intrinsically produce only a
small amount of ROS, and the cytotoxicity in mouse macrophage Ana-1 cells is attributed to
internalized ZnO NPs and dissolved Zn2+ ions [111].
2.3.4.4 Nanoparticles as Scavenger of Reactive Oxygen Species
Attempts have been made to not only design NPs that can be used as generators of
ROS, but to also focus on the exploration of their use as scavengers of ROS, providing cell
repair mechanisms, for instance, to normal cells that are exposed to harmful
chemotherapeutic agents or radiation. The neutralization of intracellular excess ROS is
typically realized via the addition of antioxidants such as vitamin C (ascorbic acid), vitamin
E (tocopherols and tocotrienols), or extracts from various plant species [112].
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A typical class of NPs that exhibit free radical scavenging properties is based on
cerium oxide (CeO2) [113-115]. Cerium (Ce) has the ability to exist in both +3 and +4
oxidation states. This property is important in the case of CeO2 NPs, which are known to
boost cell viability due to their ability to repair cellular damage [116-119]. It was shown
that Ce3+ states can be oxidized to Ce4+ due to oxygen deficiencies, which can be found on
the surfaces of CeO2 NPs for particular particle sizes [120, 121].
For instance, the anti-oxidant process involving the decomposition of hydrogen
peroxide in the presence of CeO2 takes place as follows: first, H2O2 is adsorbed onto the
surfaces of CeO2 (Equation (2.1)). Then, the adsorbed H2O2 reacts with Ce4+ to yield Ce3+
states and oxygen vacancies ( ) (Equation (2.2)), which can react with molecular oxygen
or H2O2 to form Ce4+ states again (Equation (2.3) and Equation (2.4)):
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Besides CeO2, it is widely known that carbonate ions can act as scavengers of ROS,
hydroxyl radicals in particular. Once the carbonate is in contact with hydroxyl radicals, the
formation of carbonate radicals is observed, as shown in Equation (2.5) [122, 123]:
(

)

(

)

→
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)
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)

(2.5)

In contrast to hydroxyl radicals, which react rapidly with organic compounds, the
carbonate radical is very selective and prolongs degradation processes, as typically
observed in the purification of waste water [124-126].
2.3.5 Chemotherapeutic Drugs
Many chemotherapeutic drugs exist, such as MTX, doxorubicin (DOX), paclitaxel
(PTX), and 5-fluorouracil (5-FU). Besides their individual use, there are many approaches
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to combining the use of multiple drugs via either their simultaneous or sequential
administration [127, 128]. It was shown that sequential treatment with MTX and 5-FU was
the most effective in L1210 leukaemia and the mouse osteosarcoma C22LR, but also
resulted in side effects, such as weight loss and early death [128].
Although chemotherapeutic drugs are widely applied in chemotherapy, a report in
2004 stated that “the overall contribution of curative and adjuvant cytotoxic chemotherapy
to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA.”
[129]. These numbers are very low, especially since the overall 5-year survival rate of
cancer is over 60%. Reasons for the low impact of chemotherapeutic agents alone are the
increase in patient drug tolerance, the lack of cancer cell targeting, and altered drugreceptor sensitivity. Combinations of therapies and the design of theranostic systems seem
therefore to be a reasonable approach.
2.3.5.1 Structural Properties of Methotrexate
MTX was originally developed and continues to be used for chemotherapy to treat
cancers, including breast cancer, leukaemia, lymphoma, lung cancer, osteosarcoma, and
bladder neoplasms [130]. It typically enters cells through endocytosis, via an energydependent carrier protein, or through passive diffusion when the extracellular
concentration of MTX is increased [131-134].
Structurally, MTX is an analogue of folic acid (FA, Figure 2.16), which is known to
irreversibly bind to dihydrofolate reductase (DHFR) [135]. By actively competing with FA,
MTX can bind to DHFR and inhibit the production of reduced folates, which results in a
decrease in synthesis of purines, thymidylic acid, methionine, and serine [136-139]. The
lack of protein synthesis consequently causes damage to DNA and RNA, and inhibits the
further proliferation of cells. More importantly, DHFR receptors are typically
overexpressed on the membranes of cancer cells in comparison to normal cells, making
MTX not only a chemotherapeutic agent, but also a targeting agent [140, 141].
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Figure 2.16. Chemical structure of methotrexate.
MTX has two different types of functional groups: two carboxylic groups on one
end, and two amine groups at the other end of the molecule. These functionalities enable
the MTX molecule to be conjugated with other bioactive compounds via covalent bonding.
In addition, it can also be loaded onto drug carriers via physical adsorption, ionic bonding,
or encapsulation in polymer shells [142].
2.3.5.2 Application of Methotrexate in Cancer Therapy
MTX is an antineoplastic agent that is used not only in cancer treatment, but also
for autoimmune disorders such as arthritis and other rheumatic conditions [143]. In the
clinical setting, the applied doses of MTX vary from patient to patient and have to be
evaluated depending on the patient’s state of health, individual needs, and the location,
size, and type of tumour. Patients with leukaemia or high-risk lymphoma are typically
intravenously administered high doses of MTX (≥ 500 mg/m2) in several cycles within a
single day [144]. Gestational trophoblastic disease requires usually medium doses of MTX
ranging between 50 – 500 mg/m2, while bladder, breast cancer, and T-cell large granular
lymphocyte leukaemia are treated with low doses of MTX (< 50 mg/m2) [144].
Depending on the administered dose, MTX can cause side effects, such as the loss of
hair, nausea, fatigue, liver damage, low blood cell counts, acute pneumonitis, or kidney
failure. In addition, MTX is known to be prone to drug resistance, which, together with its
rapid distribution within the body and its relatively short half-life, leads to multiple
administrations of the drug, which are extremely painful for the patient [145, 146].
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Hence, the development of controllable drug delivery systems is required, to not
only reduce the dosage frequency, but also the systemic toxicity [85]. Compared to free
MTX, the circulation half-life of MTX in blood has been increased over 180-fold via an
attachment to human albumin [147]. In addition, the conjugation of MTX with polymers
has been shown to increase the cellular toxicity [148, 149].
2.3.6 Radiation Therapy
Radiation therapy can either be applied externally through beam radiation, or can
be applied from sources within the body, which is then called brachytherapy. The external
beam radiation typically includes radiation with kilovoltage X-rays or megavoltage X-rays,
depending on the type, stage, and location of the tumour. For superficial tumours that are
easily reached, such as skin cancers, the kilovoltage X-ray irradiation is generally sufficient.
For deeper-located tumours, such as in lung, brain, or prostate cancer, however,
megavoltage X-rays are required to induce irreparable cell damage.
The cell ablation occurs either directly through the high-energy beam, or via the
generation of reactive particles that can reduce the tumour size [150]. In general, the
probability that tumours can be removed via radiation therapy is high, but due to the
variation of different cancer types, their different natures, locations, and more importantly,
their potential resistance, some cancers cannot fully be destroyed by radiation alone [91,
151]. More importantly, radiation therapy targets not only cancerous tissue, but also the
normal cells that are usually exposed to radiation, which can, in turn, lead to side effects,
such as skin changes, hair loss, nausea, vomiting, and fatigue [91, 151].
2.3.6.1 Radioprotectors and Radiosensitizers
There are approaches to maximize the efficiency of radiation therapy in cancerous
tissue and, at the same time, to minimize the destruction of normal cells due to harmful
radiation. The attempts typically involve the application of radioprotectors and
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radiosensitizers prior to radiation therapy with the aim of better controlling the cell
responses to the delivered radiation.
Radioprotectors
Radioprotectors are drugs that aim to protect normal cells from radiation damage.
In particular, these materials can promote cell repair mechanisms, and they can neutralize
harmful ROS that are generated during the exposure to high-energy beams. Recently, CeO2based NPs have been investigated as potential radioprotectors, which were able to
promote a boost in cell growth in normal tissue [116-119].
Radiosensitizers
Radiosensitizers, in contrast, are drugs designed to target cancer cells and to
enhance their susceptibility to damage by radiation. Typically, radiosensitizers contain
elements with high Z, which are able to locally increase the effect of the applied radiation
dose by interfering with the incident energy beam. The number of photoelectron
interactions increases with the atomic number for a given incident photon energy E with
( ⁄ ) [152]. Moreover, by functionalizing these materials with bioactive ligands, such as
DNA, proteins, or antibodies, the targeting function can be improved even further.
It has also been shown that the energy of the radiation beam could be reduced to
orthovoltage radiotherapy (< 500 keV), while still providing enough damage to some
human tumours, which further minimizes the destruction of normal cells [153].
2.3.6.2 Mechanism

of

Radio-Dose

Enhancing

Therapy

Based

on

Nanoparticles
The NPs that are located inside the cytoplasm of cancer cells represent an active
interaction component when the cells are exposed to an X-ray beam, as displayed in Figure
2.17. Typically, the energy of the X-ray beam can be absorbed by the NPs, which can lead to
the ejection of an outer shell electron from its orbital with a kinetic energy equivalent to
the absorbed energy minus the binding energy of the electron. This kinetic energy can be
39

Chapter 2 – Literature Review

released to the surrounding tissue, which effectively increases the absorbed radiation dose
in the cell.

Figure 2.17. Possible interactions of intracellular radiosensitizing nanoparticles with high
effective atomic number Z, adapted from [154]. Abbreviation: deoxyribonucleic acid (DNA).
The energy beam can also lead to the ejection of an inner-shell electron, leaving a
vacancy that can be filled by electrons from the outer shell, causing distinctive secondary
radiation [152]. The emissions include fluorescent photons, Rayleigh scattering, the
production of charged particles, Compton scattering, or the scattering of X-rays and
photons. All these emissions lead to direct damage to the DNA [152]. In addition, ROS can
be generated, which causes indirect DNA damage through a cascade of processes.
2.3.6.3 Radiosensitizers Based on Nanoparticles
Besides a high effective Z, to be suitable as a radiosensitizer, the NPs need to be
biocompatible and tailorable. In addition, their clearance pathways need to be thoroughly
studied.
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One of the first types of NPs that were studied for their radio-dose enhancing
properties was Au NPs (Z = 79), which have been widely investigated for biological
applications, such as for contrast agents (see section 2.3.7.3) [152]. In fact, it has been
shown that Au NPs can successfully enhance the effects of radiation therapy, in particular,
for radio-resistant cells, such as SCCVII squamous cell carcinoma [155, 156]. In addition,
Au NPs are biocompatible, show low systematic clearance out of the body, and can be
easily attached with surfactants [156].
Besides Au, platinum (Pt, Z = 78) NPs have been widely investigated as
radiosensitizing materials. Pt finds applications in biomedical areas due to its antibacterial
properties, biocompatibility, and its facilely modifiable surface properties that allow
coating with polymers or the attachment of further bioactive materials. In particular,
coatings with PAA have been widely reported, enabling easy diffusion through cell
membranes and binding to DNA fragments, which were damaged via the generation of
secondary particles during radiation [157, 158].
A big drawback of the use of both Au and Pt NPs is their associated high cost, giving
an impetus to research to find cheaper materials that can be applied in a wide range of
applications. As mentioned in CHAPTER 4 and CHAPTER 5, metal oxides based on Ta and
Bi offer highly effective atomic numbers and are therefore promising potential
radiosensitizing materials. These compounds are usually biocompatible in the cellular
environment and Bi2O3 in particular is cheap to produce [159].
2.3.7 Diagnostics and Imaging
Various non-invasive imaging modalities are currently used to not only detect
cancer at early stages, but to also monitor drug responses and migration in real time. These
medical imaging techniques include magnetic resonance imaging (MRI), X-ray computed
tomography (CT), ultrasound (US), positron-emission tomography (PET), single-photon
emission CT (SPECT), and optical fluorescence imaging, as shown in Figure 2.18 [160, 161].
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Figure 2.18. Overview of imaging modalities for biomedical applications. Adapted from
[161].
2.3.7.1 Computed Tomography
CT is the one of the most prevalent and important diagnostic tools in hospitals with
regards to availability and frequency of usage [162]. As estimated, over 45,000 CT scanners
are currently operated worldwide, and their usage is still on an upward trend [163].
CT consists of computer-based programs able to process X-ray measurements
taken from several angles to yield a tomographic image (‘slice’) of a particular area of a
scanned object. These slices are collected and stacked together to generate a threedimensional image of the object. The patient lies on a bed that slowly moves through a
gantry, while simultaneously, the X-ray tube rotates around the patient (Figure 2.19) [164].
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Figure 2.19. Working principle of computed tomography scans. Adapted from [164].
CT scans can provide images of different body structures, such as bones and soft
tissue, and can be crucial to identify abnormalities and tumours. The anatomical contrast
strongly depends on the ability to absorb the incoming X-rays, which have energies
ranging from 80 to 140 keV. A high tube potential is usually applied in larger patients to
ensure quality images, while children are imaged with smaller energies, which increases
the contrast [165].
While bone structures typically have a high electron density and provide sufficient
contrast, CT imaging of internal soft tissue requires the addition of contrast-enhancing
agents [166]. The difference in contrast is based on the degree of X-ray attenuation of the
different body structures, as shown in Equation (2.6) [167]:
(2.6)
where I is the transmitted x-ray intensity,

is the incident x-ray intensity, µ is the linear

attenuation coefficient (m-1), and x is the thickness of the absorber medium (cm). The
linear attenuation coefficient is characteristic of each material and depends on the X-ray
energy E (eV), the atomic number Z, the density ρ (g ∙ cm-3), and the atomic mass
as shown in Equation (2.7):
(2.7)
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2.3.7.2 Classical Contrast-Enhancing Agents
To obtain images of soft tissues, materials based on iodine (atomic number, Z = 53)
and barium sulphate (Z = 56) are typically used [168]. The iodine-based compounds are
either small molecules with short imaging time or more complex systems based on
liposomes, polymers, and micelles that can provide longer blood circulation times [169,
170].
Figure 2.20 shows axial CT images taken from dogs which were either not treated
with a contrast agent (left images) or treated with Iohexol (right images), which is a
conventional contrast agent [171]. After the administration of the contrast agent, the
visibility of the hepatocellular carcinoma is significantly improved.

Figure 2.20. Axial computed tomography (CT) scans of dogs without administration of a
contrast agent (left images) and after administration of 660 mg /kg Iohexol (right images)
[171]. In the top row, a small (0.5 cm) hepatocellular carcinoma is identified via the white
arrows. In the bottom row, a large hepatocellular carcinoma (12.5 cm) is visible.
2.3.7.3 Contrast-Enhancement Agents Based on Nanoparticles
The design of NPs for the use as contrast agent is focused on three main areas,
depending on their target function to reach the diseases sites:
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Blood pool CT contrast agent,



Passive targeting, and



Active targeting.

Passive targeting utilizes non-specific pathways, such as the reticulo-endothelial
system or the EPR effect. Active targeting, in contrast, can be achieved by conjugation of
NPs with peptides, antibodies, or other bioactive materials, which can improve the
accumulation of the NPs in specifically targeted tissue.
Besides their tailorable size, biocompatibility, and bioactivity, NPs offer tuneable
blood circulation times and controllable clearance pathways, which is of interest for
patient-specific diagnostic imaging.
Some metal NPs such as Au (Z = 79) have a much higher atomic number than
iodine-based agents and provide greater chemical stability and electron density, which
ultimately results in stronger X-ray attenuation and greater contrast [172]. In addition,
these NPs can be functionalized introducing active targeting capabilities: the conjugation of
Au NPs with antibodies resulted not only in a 1.6 times increase in the visibility of
millimeter-sized breast tumours in comparison to passive targeting, but also in a 22 times
greater accumulation in the tumour periphery than in the surrounding tissue [95].
Generally, the use of Au NPs is considered to be safe, although recent in vivo studies
indicated that Au NPs might exhibit toxicity in certain particle sizes [173]. In addition, the
use of Au NPs is associated with high costs, which is driving research on cheaper
alternative materials with high Z [168].
Metal oxide NPs are usually cheap, widely available, can be easily synthesized, are
biocompatible, and their size and surface properties are tailorable. High Z metal oxides
include tantalum (Ta)-based (Z = 73) and bismuth (Bi)-based (Z = 83) materials, such as
tantalum (V) oxide (Ta2O5) and bismuth (III) oxide (Bi2O3), respectively [174, 175].
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Particular examples of contrast-enhancement agents based on Ta and Bi are presented in
CHAPTER 4 and CHAPTER 5.
2.3.8 Examples of Theranostic Systems
Currently, the design of theranostic systems is focused on the implementation of
multiple features on one single platform. While the original systems mostly contained only
diagnostic and chemotherapeutic features, new approaches aim to combine even more
features, such as targeting, sensing, photodynamic therapy, or enhancement of radiation
therapy. The strategies include the use of both organic nanomaterials and inorganic
nanomaterials. Compositions of some typical theranostic systems are shown in Table 2.3.
Table 2.3. Composition of exemplary theranostic systems for biomedical applications.a)
Imaging
agent

Therapeutic
agent

Additional
Further features

components

DOX,
Gold

References

Targeting, radiation
–

[176, 177]

cisplatin, FA

therapy,
Targeting, drug delivery,

siRNA, DOX,
Iron oxide

[140, 178,
PEG, APTES

photodynamic therapy,

MTX

179]
hyperthermia therapy

Silica

siRNA, DOX

PEI-PEG

Targeting

Carbon

PTX,

antibody,

Targeting, drug delivery

nanotubes

salinomycin

PEG, MnO

photothermal therapy

Quantum

DOX,
DNA aptamer

Targeting, sensing

dots

mitoxantrone

[180]

[181, 182]

a)

[183, 184]

Abbreviations: short interfering ribonucleic acid (siRNA), doxorubicin (DOX), methotrexate

(MTX), paclitaxel (PTX), polyethyleneimine (PEI), polyethylene glycol (PEG), (3-aminopropyl)
triethoxysilane (APTES)
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2.4 Nanomaterials for Sun-Blocking Applications
2.4.1 Sunscreen Products
Conventional sunscreen products are available as sticks, gels, ointments, or
aerosols, and are based on an oil-in-water or water-in-oil emulsion. Emulsions are
preferred as they offer cost efficiency, good rheological properties, and can provide skin
smoothness in contrast to oil-based sunscreens, which leave an unpleasant residue on the
skin [115, 185].
Sunscreen formulations contain either physical or chemical UV filters that can
protect against both UVA and UVB radiation (Figure 2.21). The active ingredient is
normally dissolved or dispersed in the hydrophobic oil-phase of the sunscreen
formulation.

Figure 2.21. Working principles of chemical and physical sunscreens.
Physical sunscreens, which are often referred to as ‘mineral’ sunscreens, contain
inorganic UV filters, such as TiO2 or ZnO particles, that reflect, scatter, or absorb the
incoming UV rays, depending on their particle size. Once applied, physical sunscreens form
a protective layer on the skin’s surface, so that harmful UV rays cannot penetrate into the
skin [186, 187]. Chemical sunscreens, in contrast, have solely UV absorbing organic
ingredients and are absorbed into the skin [11, 186-188]. Modern sunscreens often have a
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combination of organic and inorganic UV filters to fully maximize the UV protection. A
small overview of active sunscreen ingredients is presented in Table 2.4.
Table 2.4. Selection of sunscreen ingredients and their amount of ultraviolet (UV)
radiation protection, as approved by the US Food and Drug Administration (FDA) as of 7
December 2009 [185].
Active sunscreen

Maximum FDA-approved

Range of

Protection

concentration (%)

protection (nm)

(UVA, UVB)

15

260 – 313

UVB

Octinoxate

7.5

280 – 310

UVB

Homosalate

15

290 – 315

UVB

Octylocrylene

10

287 – 323

UVB

Oxybenzone

6

270 – 350

UVB, UVA2

Sulisobenzone

10

250 – 380

UVB, UVA2

Dioxybenzone

3

206 – 380

UVB, UVA2

Avobenzone

3

310 – 400

UVA1, UVA2

Titanium dioxide

25

290 – 350

UVB, UVA2

Zinc oxide

25

290 – 400

UVB, UVA1

ingredient
Organic UVB
Para-aminobenzoic
acid

Organic UVA

Inorganic

Besides the base emulsion and the addition of the active UV filter, sunscreen
formulations contain preservatives and additives, such as emulsifiers or thickeners, to
combat microbial attacks and increase the stability of the emulsion, which prevents the
separation of phases [115]. Emulsifiers are amphiphilic molecules, such as fatty acid soaps,
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that reduce the interfacial tension between the water and oil phase. Thickeners, such as
alginates, natural gums, cellulose derivatives, bentonite, and fumed silica, increase the
viscosity, which reduces the coalescence and segregation rate [115].
2.4.1.1 Organic Ultraviolet Filters
The active ingredients of chemical sunscreens are based on organic structures,
which are typically less photostable than physical sunscreens, since organic compounds
can lose their stability over time [17, 186]. Organic-based sunscreens are usually
colourless with a thin consistency, which enables easy application onto the skin. Typically,
20 min is required before organic-based sunscreens provide full protection, but they are
less likely to be washed away, since they are absorbed into the skin. More importantly,
however, is the fact that individual organic UV filters do not provide full broad-band UVA
and UVB protection, resulting in the use of combinations of different organic UV filters
[186].
2.4.1.2 Inorganic Ultraviolet Filters
While there are many organic UV absorbers approved by regulatory bodies, only
two inorganic UV filters can be used, namely TiO2 and ZnO [186, 189]. Their UV blocking
properties are determined by their particle size, dispersion in the base emulsion, refractive
characteristics, and film thickness [187].
Traditional sunscreens employing either of these two materials appear white on
the skin because the particle size is greater than 100 nm. TiO2 NPs, for instance, have been
shown to reflect visible light the best when present in particle sizes of 200 – 500 nm [11].
This white coating acts as a ‘physical blocker’, functioning by scattering and reflecting the
incident light.
Modern sunscreens employ nanosized materials, typically, NPs of ZnO or TiO2,
since, at suitable concentrations when well dispersed, their emulsions are transparent in
the visible range and are thus invisible after topical application, a factor highly desirable
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from a cosmetic standpoint [186, 190]. When they are in nano-particulate form (e.g. 10 –
40 nm), however, they are too small to reflect and scatter efficiently and thus, they function
as inorganic UV absorbers, relying on their UV absorption spectrum for effectiveness. They
only become physical blockers when poorly dispersed and agglomerated, and
consequentially appear visibly white.
In fact, TiO2 absorbs UV light much more strongly than it scatters UVA and UVB
radiation [187]. Figure 2.22 displays the absorbance spectra of bulk TiO2 and ZnO at room
temperature. With regard to the recommended broad UVA/UVB protection, TiO2 NPs
provide good UVB protection, while ZnO NPs cover the UVA range.

Figure 2.22. Absorbance of bulk TiO2 and ZnO at room temperature. Adapted from [11].
Since the TiO2 and ZnO NPs are typically dispersed in the hydrophobic oil-phase of
the sunscreen formulation, they are usually coated with organic-based dispersants to
stabilize the dispersion, which ultimately enhances the stability of the sunscreen
formulation [115]. The coatings include very thin layers of stearic acid in the case of TiO 2
(Eusolex® T-S TiO2) or triethoxycaprylylsilane in the case of ZnO (Z-COTE® HP1). To
improve the visual appearance of the sunscreen products, iron (III) oxide (Fe2O3) pigments
are occasionally added [187].
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The great advantage of inorganic UV filters is their immediate protection once they
are applied on the skin, their photostability, and their limited skin penetration [191]. As
such, it has been shown that most particles are found in the first 1 µm of the upper layer of
the stratum corneum [11, 190]. Furthermore, inorganic UV filters tend to cause less
allergic reactions than organic UV filters, making them particularly suitable for sensitive
skin [186, 191]. The thick consistency of TiO2 and ZnO based sunscreens, however, can
complicate correct application onto the skin. In addition, the layer of sunscreen may rub off
easily.
2.4.2 Sun Protection Factor
The SPF is a universally accepted measure to express the efficiency of sunscreen
products and is based on the definition of the minimum erythematous dose (MED), which
is the smallest dose of energy necessary to result in the formation of erythema within 1 – 6
h that disappears within 24 h [192, 193]. By using the MED, the SPF can be determined by
the following Equation (2.8) [194]:
(2.8)
The efficiency of UV protection of sunscreen products typically increases with
increasing SPF, as shown in Figure 2.23. Once correctly applied onto the skin, the period of
protection is the product of the period of natural protection multiplied by the SPF.
Considering the different sensitivity of human skin tones to UV radiation, it is of great
importance to first determine the period of natural protection, before obtaining sunscreen
products with different SPF.

51

Chapter 2 – Literature Review

Figure 2.23. Increase in ultraviolet protection with increasing sun protection factor (SPF).
Adapted from [195].
2.4.2.1 In Vivo Determination of Sun Protection Factor
The SPF can be determined in vivo or in vitro, but is ideally evaluated in human
volunteers to consider the real conditions of use in practice [192]. The in vivo tests usually
involve human volunteer subjects onto whose skin 2 mg/cm2 sunscreen formula is applied
to an area on the mid-back [193]. The sunscreen is then dried for 15 min and five
increasing UV radiation doses are applied to the treated area. The same series of UV doses
is administered to untreated skin [193]. After 16 – 24 h, the irradiated skin sites are
analyzed and the SPF is determined following Equation (2.8) [193].
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According to the FDA, the SPF protection must be clinically tested on at least ten
human volunteers, which is associated with high costs, long waiting periods, and more
importantly, health risks due to the direct application of UV radiation to the skin [193,
196]. Thus, in vitro methods are emerging as non-invasive way to determine the SPF.
2.4.2.2 In Vitro Determination of Sun Protection Factor
The SPF describes the protection solely from UVB radiation and does not consider
UVA radiation. Based on regulations that have been approved by the FDA in 2011, in vivo
UVA testing is no longer required [197]. Instead, a simple in vitro critical wavelength
reading based on spectrophotometry has been accepted as a replacement [194, 196, 198]:
1. First, sunscreen products are placed onto substrates such as quartz, and the
UV absorbance is measured over the entire UV spectrum [194, 198].
2. The area beneath the obtained spectral absorbance curve is then calculated
via mathematical integration [198].
3. The critical wavelength ( ) is defined as the wavelength below which 90%
of the area under the absorbance curve resides [198].
Critical wavelength and broad-spectrum UV protection
The critical wavelength is crucial to evaluate the UV absorbing properties of active
UV filters and provides information about broad-spectrum protection, which includes
larger wavelengths in the UVA region. UVB filters, for instance, have critical wavelengths
that are smaller than those of UVA filters (see Figure 2.24). The higher the critical
wavelength, the better is the broad-spectrum photoprotection. In 2012, the FDA has
introduced new regulations that allow the claim of ‘broad-spectrum’ protection only when
the critical wavelength is > 370 nm [197, 199].
The determination of SPF and critical wavelength is considered to provide a
sufficient description of the photoprotective properties of a sunscreen product: while the
SPF describes the amplitude of protection at a given application thickness, the critical
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wavelength provides information about the absorption capability over the entire UV
spectrum, which is independent of application thickness [198].

Figure 2.24. Absorbance spectra of sunscreen products with a critical wavelength (a)
smaller and (b) greater than 370 nm. Adapted from [198].
A study published in 2000 showed that only 10% of the studied 59 commercially
available sunscreen products provide a critical wavelength ≥ 370 nm [200]. These
products all contained UVA1 filters, such as ZnO, TiO2, or avobenzone, but not all of the
tested sunscreens with these ingredients displayed a sufficient critical wavelength. These
findings underline the point that the simple addition of UVA1 filters does not necessarily
ensure true broad-spectrum protection, but instead, a thorough study of the entire
formulation is essential [200].
2.4.3 Photochemistry and Photobiology
TiO2 and ZnO are both semiconductors, meaning that an energy band gap separates
the orbitals that form the valence band (VB) and the conduction band (CB). If light is shone
on TiO2 with energy that equals or is larger than the band gap, an electron (
excited from the VB to the CB, leaving a hole (

) can be

) in the VB [11], as shown in Equation

(2.9), where h Planck’s constant (6.626 × 10-34 (m2 ∙ kg ∙ s-1) and ν = frequency (s-1):
→

(2.9)
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The e─ and h+ either recombine, or they can be transported to the surface of the
particle, where they can participate in redox reactions, mostly with pre-adsorbed
substrates such as molecular oxygen or water, as shown in Figure 2.25 [11].

Figure 2.25. Mechanism of formation of electron-hole pairs, their recombination, and their
transport to the particle surface of a semiconductor. Adapted from [201].
The photoactivity of semiconducting NPs is linked to a number of factors, the most
essential of which is the surface of the particles [187]. When reduced to nanometer scale,
the band gap of semiconducting NPs increases since the electronic energy levels are
interpreted as discrete energy levels. This ultimately leads to a blue shift of the absorption
threshold [202]. Due to the high interfacial energy, however, NPs tend to agglomerate and
aggregate, which ultimately influences their size and the band gap width [11].
2.4.3.1 TiO2
TiO2 is a naturally occurring mineral that is typically nontoxic, inexpensive, and
crystallizes in three common polymorphs: anatase (tetragonal, space group: I41/amd),
rutile (tetragonal, space group: P42/mnm), and brookite (orthorhombic, space group: Pbca)
[203, 204]. Ball-models of their crystal structures are shown in Figure 2.26. The rutile
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phase is the most stable among all the structures, while the anatase and brookite
structures are metastable at room temperature [204].

Figure 2.26. Crystal structures of anatase, rutile, and brookite TiO2; obtained via Materials
Studio software using Crystallography Open Database files 1010942, 1532819, and
8104269.
Under particular conditions, there are also less common structures possible, such
as TiO2 II (columbite), TiO2 III (baddeleyite), TiO2 (H) (hollandite), TiO2 (R) (ramsdellite),
and TiO2 (B) (monoclinic) [204].
TiO2 is a known photocatalyst, with the band gap for bulk TiO2 ranging from
approximately 3.0 eV (rutile), to 3.13 eV (brookite) and 3.2 eV (anatase) [205]. Only the
rutile and anatase polymorphs are relevant, however, in the preparation of sunscreens or
in heterogeneous catalysis [187]. More importantly, anatase is photocatalytically more
active than rutile TiO2 [206, 207].
TiO2 particles have been used as a white pigment, partly due to their refractive
properties [11]. Polycrystalline and epitaxial films of rutile have an average refractive
index of 4.0, while anatase has a refractive index of 3.6 [208]. TiO2 was first reported as an
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active sunscreen agent in 1952 [209]. Currently, TiO2 NPs are still widely used as an active
UV filter ingredient in sunscreens that protect from UVB and UVA2 (see section 2.4.1).
2.4.3.2 ZnO
ZnO is a naturally occurring mineral that can be found in the Earth’s crust, although
most ZnO is manufactured synthetically [11]. Three crystalline structures of ZnO exist:
rocksalt (cubic, space group: Fm3m), zinc blende (cubic, space group: ̅

), and wurtzite

(hexagonal, space group: P63mc), with wurtzite being the most stable and common form at
room temperature [210]. The crystal structures of ZnO are displayed in Figure 2.27.

Figure 2.27. Crystal structures of rocksalt, wurtzite and zinc blende ZnO; obtained via
Materials Studio software using Crystallography Open Database files 1534836, 1537875,
and 9008877.
In contrast to TiO2, ZnO exhibits significant mammalian toxicity, which can be
related to the compound’s solubility (see section 2.5.2) [211]. Furthermore, ZnO is
associated with induction of oxidative stress and mitochondrial dysfunction [110, 111,
211].
The band gap of ZnO ranges from 3.2 eV (wurtzite) to 3.3 eV (zinc blende) [212]
and the refractive index of ZnO was found to range between 2.3 and 2.0, which reduces the
whitening effect of ZnO in comparison to TiO2 [213]. In modern sunscreen formulations,
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ZnO NPs are typically used together with TiO2 NPs, as they offer the UVA1 protection that
is essential for broad-spectrum protection (see section 2.4.1).
2.4.3.3 Photocatalytic Activity of Semiconducting Nanoparticles
The photocatalytic activity of TiO2 has been used to explore possible applications in
the purification of waste water, the removal of organic pollutants such as hydrocarbons,
chlorinated hydrocarbons, and heavy metals, including Pt4+, Pd2+, Au3+, Rh3+, and Cr3+, and
the destruction of biological species such as bacteria, viruses, and moulds [214, 215]. The
highly reactive radicals that are formed during the process, however, can pose health
concerns when applied to the human body.
The photocatalytic reactions of TiO2 are shown in Equation (2.10), Equation (2.11),
Equation (2.12), and Equation (2.13), and can also be found for ZnO NPs [215]:
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Upon photoexcitation of TiO2 an electron transfer from TiO2 to molecular O2 results in the
formation of the superoxide anion radical

. In contact with water, TiO2 catalyses the

release of an electron from H2O, which ultimately leads to the formation of the hydroxyl
radical

. In acidic medium, the superoxide anion radical is protonated, which

ultimately leads to the formation of the hydroperoxyl radical

and hydrogen peroxide

H2O2 [187]. Hydrogen peroxide can also be generated following radical chain steps
involving hydroxyl radicals [187].
The photocatalytic activity depends on various factors, such as the crystalline state,
textural properties, and surface properties, such as the surface area. For instance,
amorphous TiO2 is rarely photocatalytically active, which is related to the presence of non58
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bridging oxygen atoms. The Ti-O atomic arrangement defects could cause the
recombination of photogenerated electron-hole pairs [215, 216].
In addition, it has been shown that the calcination atmosphere can have an impact
on the photocatalytic activity of TiO2: nitrogen atmosphere or vacuum can lead to defects
and low surface hydroxyl density, which reduces the photocatalytic activity [217]. In
contrast, calcination in argon atmosphere promotes high surface coverage with hydroxyl
groups, elevating the photoactivity [217].
2.4.3.4 Determination of Photocatalytic Activity
The hydroxyl radical is a very powerful oxidizing agent amongst the ROS and can
easily attack organic compounds that are close to the surface of the photocatalyst [215].
The reactions that take place during the oxidation and decomposition of organic matter
(OM) are shown in Equation (2.14) and Equation (2.15):
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(

(2.14)
)

(2.15)

The degradation products are typically less toxic than the initial organic material,
although there is the associated risk that by-products can also be formed, the toxicity or
biological effects of which are unknown [215].
To assess the photocatalytic activity of materials, organic dyes are used, whose
colour fades upon degradation, which is directly linked to the photogenerated ROS. The
dyes can be categorized into five groups: azo compounds (monoazo, diazo, and polyazo
dyes), indigoid dyes, anthraquinone dyes, triarylmethane dyes, and xanthene dyes. In the
presence of solar/UV light and a photocatalyst such as TiO2, the photogenerated reactive
species usually attack sites near the chromophore, which results in fading of the dye [108,
215]. Table 2.5 displays a selection of dyes that are used to assess the photocatalytic
degradation of TiO2.
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Table 2.5. Selection of dyes that are commonly used to assess the photocatalytic activity of
TiO2 in combination with solar/UV irradiation [209].
Colour Index name

Chemical structure

λmax (nm)

Reference

430

[218-220]

610

[221]

596

[222, 223]

550

[218, 224]

550

[225, 226]

Azo dyes

Acid Red 2 (Methyl
Red, MeRed)

Indigoid dyes

Indigotin (Indigo)

Anthraquinone dyes
Reactive Blue 4
(Procion blue, MX-R,
RB4)
Triarylmethane dyes

Basic Violet 3
(Crystal Violet)

Xanthene dyes
Rhodamine-B
(Basic Violet 10,
Brilliant Pink B)
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The chemical structure of the dye can have an impact on its reactivity in a TiO2based system. The use of monoazo dyes, for instance, results in increased photocatalytic
degradation rates compared to anthraquinone dyes [215]. In addition, the degradation rate
is increased when methyl and chloro groups are present in the dye molecule. Hydroxyl
groups increase the electron resonance in the dye molecule. Nitrile groups and alkyl side
chains lead to a decrease in the photocatalytic degradation rate, as, for instance, the latter
ones decrease the solubility of the dye in water [215].
2.4.3.5 Determination of Reactive Oxygen Species
There are multiple ways of detecting intracellular and extracellular ROS, such as
electron spin resonance (ESR) spectroscopy, chemiluminescent and fluorescent probes,
and immunoassays [227].
ESR spectroscopy
ESR spectroscopy is used to investigate materials with unpaired electrons and is of
particular interest for studies involving metal complexes or radicals [108, 228]. The spintrapping technique includes spin traps that covalently bind free radicals, resulting in the
formation of products that are detectable by ESR [229]. Spin probes, in contrast, are
oxidized by ROS without binding [227]. 5,5-dimethyl-1-pyrroline-N-oxide (DMPO), for
instance, is used as a spin-trap to detect superoxide anion radicals, although the associated
reactions are very slow, which has led to the development of better methods [227].
Chemiluminescent and fluorescent probes
Superoxide anion radicals can also be detected by chemiluminescent and
fluorescent probes. Various chemiluminescent probes exist, such as lucigenin, luminol, and
coelenterazine. It has been reported, however, that the generation of radicals might be
overestimated for particular probes, due to the observed redox-cycling, in which the probe
radicals react with oxygen to form superoxide anion radicals [227].
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Fluorescent probes such as dihydroethidium and red mitochondrial superoxide
indicator (mitoSOX) have been used to evaluate mitochondrial and intracellular ROS. Other
fluorescent probes are the popular 2’,7’-dichlorodihydrofluorescein diacetate (DCFH2-DA)
for the detection of intracellular hydrogen peroxiode, dihydrorhodamine for the detection
of peroxynitrite, and N-acetyl-3,7-dihydroxyphenoxazine for the detection of extracellular
hydrogen peroxide [227].
A double-labelling method has been developed that detects intracellular ROS using
DCFH2-DA and visualizes nuclear fragmentation, in particular budding and cleavage types,
using Hoechst dye [121]. While the budding type is associated with an ROS-independent
apoptotic pathway, the cleavage type indicates a ROS-dependent apoptotic pathway [121].
Figure 2.28 displays the fluorescence microscopy analysis of human tumour monocytes
U937 double-labelled with DCFH2-DA and Hoechst dye [121]. The 2’,7’-dichlorofluorescein
(DCF) signal in budding cells is comparable to that in viable cells, while cells in cleavage
exhibit stronger staining [121].

Figure 2.28. Fluorescence microscopy images of U937 human tumour monocytes doublelabelled

with

Hoechst

dye

(nuclear

morphology,

top

row)

and

2’,7’-

dichlorodihydrofluorescein diacetate, showing the 2’,7’-dichlorofluorescein (DCF) signal
(reactive oxygen species content, bottom row). The left column represents viable cells,
while the centre and right columns show apoptotic cells in budding and cleavage,
respectively. Adapted from [121].
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2.5 Limitations of Current Sunscreens and Suggested Solutions
2.5.1 Skin Penetration of Inorganic Ultraviolet Filters
Commonly used sunscreens protect against UV radiation, but have also raised
concerns regarding both organic and inorganic UV filtering additives. When evaluating the
possible drawbacks of sunscreen products, many factors have to be considered, besides
their cosmetic properties, such as the spreadability and the transparency of the products.
The skin penetration of a particle typically depends on its ability to penetrate the
alternate hydrophobic and hydrophilic layers of the stratum corneum. The penetration of
the stratum corneum is determined by many factors, such as the polarity, size, molecular
weight, solubility, and lipophilicity of the particles [230]. Furthermore, the capacity of the
particles to form hydrogen bonds and, in the case of acidic or alkaline particles, their acid
dissociation constant (pKa) values are of importance when evaluating percutaneous
absorption [230].
It is well known that organic UV filters have some of the highest penetration rates
into the skin and can be found in viable skin layers [186]. There are a great number of
studies involving the skin penetration of both TiO2 and ZnO NPs. Although some past
studies failed to specifically identify the presence of TiO2 and ZnO NPs in deep skin layers
[231, 232], more recent studies confirm their skin penetration, especially in the case of
TiO2 NPs [11]. Furthermore, some surfactants that are added to sunscreen formulations
may alter the skin barrier, which can cause an increase in the skin penetration of NPs [11].
Typically, TiO2 and ZnO NPs are found within the stratum corneum and/or hair
follicles [11]. Some studies have shown that these NPs can also be detected in viable skin
layers, much deeper than the stratum corneum [11, 233-235]. For instance, after the skin
of Yucatan mini-pigs was repeatedly treated with sunscreen emulsions with 5 wt.% TiO2 in
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particle sizes of 20 – 500 nm, measureable levels of NPs could be located in the dermis
[235].
When the skin barrier is damaged, however, NPs have been detected in much
deeper skin layers. More interestingly, in vivo experiments with hairless mice revealed not
only the transport of TiO2 NPs with particle sizes of 10, 25, and 60 nm to viable skin layers,
but long-term exposure of 60 days also showed that detectable levels of NPs were found in
lung, liver, and spleen tissues, as shown in Figure 2.29 [233].

Figure 2.29. Histopathological evaluation of the skin, liver, spleen, and lung tissue of
hairless mice after dermal exposure to TiO2 with particle sizes of 10, 25, and 60 nm for 60
days. The black arrows indicate pathological changes in the tissue. Adapted from [233].
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Another study included patients with atopic dermatitis, onto whose skin
commercial ZnO emulsions were applied for a total of two weeks [233]. ZnO NPs with a
size of 80 nm were found mostly in the stratum corneum and the stratum spinosum, which
can further facilitate the transport to deeper viable skin layers [233].
2.5.2 Inconclusive Toxicity of Inorganic Ultraviolet Filters
Organic UV filters are known to interfere with hormones and cause allergic
reactions [186]. Considering that they penetrate easily into the skin and are less
photostable than physical UV filters, organic UV filters can lose their stability over time
resulting in decomposition and release of heat [11, 186]. Since, in order to achieve broad
UVA and UVB protection, multiple organic UV filters have to be added to the sunscreen
base emulsion; these side effects have an even wider remit.
It was proved that, during exposure to UV-visible (UV-vis) irradiation, ZnO and
TiO2 NPs produce ROS, which can react with the organic filters in sunscreens, resulting in
their degradation [236, 237]. This ultimately not only leads to compromised filtering
activity, but also to the formation of side products with unknown toxicity [236, 238].
Furthermore, these radicals can induce DNA damage and cell death [187, 196].
The fundamental requirement that must be met to cause DNA damage and further
toxicological effects is the transport of NPs through the skin barrier to deeper, viable skin
layers [11, 187]. More importantly, the NPs must penetrate the cell nucleus [187]. As a
matter of fact, to fully establish the connection between NPs and their genotoxicity, their
size, shape, and surface properties are undeniable factors that need to be considered.
There are many reports on the toxicity of TiO2 and ZnO NPs that highlight both
their lack of toxicity and their associated geno- and cytotoxicity in vitro and in vivo. This
inconclusiveness can be related to missing guidelines for skin toxicity, sensitization, and
corrosion, as well as to the use of different testing protocols, cell lines, and unrealistic dose
exposure [239-242].
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2.5.2.1 Reported Lack of Toxicity
In vitro and in vivo studies have shown that neither TiO2 nor ZnO is toxic, both on
the micro- and on the nanoscale [243, 244]. TiO2 NPs (20 nm) did not exhibit any
cytotoxicity, genotoxicity, photocytotoxicity, or photogenotoxicity in rat liver epithelial
cells when exposed to UVA irradiation [245]. Therefore, the Therapeutic Goods
Administration (TGA) concluded in 2016 that no risk is posed by these inorganic UV filters
[196]. ZnO NPs have been shown to display a higher cytotoxicity against cancer cells than
normal cells, making these particles potentially interesting for cancer treatment [246].
2.5.2.2 Reported Toxicity
TiO2 has been classified by the International Agency for Research on Cancer (IARC)
as a group 2B carcinogen [247]. According to IARC, these carcinogens are ‘possibly
carcinogenic to humans’, since pigment-grade ultrafine TiO2 dust has been linked to the
formation of respiratory cancer in rats [11, 247]. On the other hand, the FDA classified ZnO
as generally safe, when used as directed following cosmetics directives [248].
In the absence of UV irradiation
The toxicity of TiO2 and ZnO NPs has been assessed in human fibroblasts in the
absence of UV light [249-253]. ZnO (50 – 70 nm) and TiO2 (< 150 nm) NPs have been
shown to cause reduced viability after exposure for 4 h and 24 h on skin fibroblasts,
leading to a half maximum inhibitory concentration (IC50) of 49.56 ± 12.89 ppm (Figure
2.30(a)) and 2696 ± 667 ppm (Figure 2.30(b)) for ZnO and TiO2, respectively [249]. The
increased toxicity of ZnO NPs has been linked to the formation of Zn2+ ions and the
generation of ROS [110, 111, 211].
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Figure 2.30. Dose-dependent cell viability curves of (a) ZnO nanoparticles and (b) TiO2
nanoparticles following exposures of 4 h and 24 h on human skin fibroblasts [249].
In the presence of UV irradiation
TiO2 and ZnO NPs have been widely associated with potential DNA damage, which
can also be linked to their photocatalytic activity [11]. ZnO NPs (< 200 nm) with
concentrations of 105 – 320 µg/mL displayed a noticeable increase in genotoxicity during
in vitro investigations using Chinese hamster ovary (CHO) cells under exposure to UV
radiation at > 290 nm and doses of 0.35 and 0.7 J/cm2 [254]. TiO2 specimens, which were
extracted from sunscreen products, after UV irradiation at 300 – 400 nm and 12 W/cm2,
caused single-strand and double-strand breaks on DNA plasmids and nuclei of human skin
cells [255]. It was also shown that ultrafine TiO2 NPs (< 30 nm) caused lipid peroxidation
and production of H2O2 in rat lung alveolar macrophages [255]. Besides the formation of
H2O2, superoxide anion radicals, hydroxyl radicals, and singlet oxygen, which are wellknown to be cytotoxic and/or genotoxic, are often formed [108, 187, 255]. Interestingly,
TiO2 NPs do not show any significant DNA damage under dark conditions. Only after
irradiation with UV rays, does TiO2 cause genotoxicity [256].
Of particular importance is the study of the toxic effects of TiO2 and ZnO when
exposed to repeated UV radiation over long periods of time. ZnO NPs showed the
formation of ROS inside keratinocytes and a decrease in their viability at a concentration of
15 µg/mL, while TiO2 did not show any noticeable generation of ROS or toxicity [250].
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More interestingly, it was discovered that after 3 months, both types of NPs accumulated in
the form of aggregates within the cytoplasma, which resulted in reductions in
mitochondrial function and changes in cellular morphology [250].
Importance of crystal structure of TiO2
Although anatase TiO2 is considered to be photocatalytically active, X-ray
diffraction (XRD) analysis of the inorganic components that were separated from
commercially available sunscreens identified either rutile TiO2 or a combination of rutile
and anatase TiO2 as the active ingredient [206, 236]. In particular, the composition of
commercial Aeroxide® (P25, Degussa) has been identified, which contains approximately
80% anatase and 20% rutile TiO2 [228, 257]. Upon UV irradiation, the production of
reactive hydroxyl radicals was shown to be significantly increased for anatase TiO 2
compared to rutile TiO2 [258]. More importantly, the ROS production of P25 is
considerably increased compared to anatase TiO2 alone [259].
TiO2 NPs have been studied in vitro in their pure phases (anatase, rutile) and their
mixed form, in particular in form of P25 [249, 252, 253]. One study reported that no
toxicity could be observed in HaCaT cells following exposure to TiO2 in the form of rutile
with a particle size of 100 nm (R100), anatase with an average particle size of 25 and 325
nm (A25, A325), and P25 (35 nm, 86:14 anatase:rutile) alone [252]. When irradiated with
UVA at 340 nm, however, subsequent dose- and concentration-dependent toxicity was
caused by the anatase and P25 samples, which was related to the production of ROS, while
the rutile sample showed very low toxicity (Figure 2.31) [252]. These results have been
confirmed by the authors of [253], who observed an 1.8 fold increase in the accumulation
of intracellular ROS levels in HaCaT cells after exposure to 200 µg/mL of P25 (21 nm;
75:25 anatase:rutile) for 24 h and subsequent irradiation with UVA at 365 nm.
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Figure 2.31. (a) Effect of TiO2 at a concentration of 100 μg/mL on the metabolic activity of
HaCaT cells as a function of irradiation dosage. (b) Generation of hydroxyl radicals from
TiO2 under irradiation with ultraviolet A light (340 nm). The electron spin resonance
spectra were recorded at room temperature in the presence of 5-tert-butoxycarbonyl 5methyl-1-pyrroline N-oxide and TiO2 at a concentration of 0.1 mg/mL. Adapted from [252].
2.5.3 Photostability and Efficiency
Besides the penetration of NPs into deep skin layers, their photoactivity and
associated toxicity, the photostability of the formulation has a substantial impact on the
overall performance of the sunscreen product. Three pathways exist for a molecule that
absorbs UV radiation to convert or scatter the absorbed energy [187]:


Radiative decay (emission),



Non-radiative decay (heat), and



Photochemical reactions.

Chemical UV filters
The photoinstability of chemical UV filters is commonly known, causing not only
the degradation of organic compounds into by-products with unknown toxicity, but also
the reduction of UV attenuation, which lowers the actual UVA/UVB protection [187, 236,
237]. Sunscreens based on avobenzone, for instance, were shown to have lost almost 50%
of their advertised protection after an UV irradiation at 295 – 400 nm and 27 mW/cm2 for
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only 2 h [260]. This organic UV filter can even exhibit photooxidizing properties, and in
combination with other chemical organic UV filters, the photoinstability can be enhanced
[187]. The generated free radicals even persisted after the exposure to UV radiation had
ended [261].
Inorganic UV filters
Another study investigated the photostability of commercially available sunscreen
products containing inorganic UV filters [237]. The study showed that after a 2 h exposure
of the sunscreens to simulated sunlight at wavelengths > 290 nm and 48 W/m2, significant
changes in attenuation occurred. Photodegradation of a sunscreen lotion with SPF 25
containing the UVA absorbers avobenzone and terephthalydenedicamphor sulfonic acid, a
camphor derivative as UVB filter, and the inorganic UV filter TiO2 led to a 10% decrease in
attenuation at 300 and 360 nm, and the formation of new photoproduct(s) at wavelengths
< 290 nm [237]. A sunscreen lotion with SPF 15 containing octyl methoxycinnamate, octyl
salicylate, and TiO2 showed a 40% drop in attenuation at 300 nm. More interestingly, a
sunscreen lotion based on inorganic TiO2 and ZnO and unknown organic ingredients with
SPF 25 exhibited a decrease in attenuation of almost 95% at a wavelength of 315 nm
within the 2 h exposure to simulated sunlight [237].
It was further shown that the organic UV filter oxybenzone showed significantly
greater photoinstability in combination with TiO2 compared to a combination of
oxybenzone and octyl methoxycinnamate, which further underlines the photoactivity and
associated problems of TiO2 [237]. The photocatalytic activity of inorganic NPs can cause
the generation of ROS and ultimately the degradation of sunscreen ingredients and a
decrease in SPF (see section 2.4.3) [262].
Consequences for the end-user
Since the SPF only accounts for UVB protection, its decrease is not the only
concern. More importantly, a study published in 2000 showed that only 10 % of the
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studied 59 commercially available sunscreen products provide broad spectrum protection
with a critical wavelength ≥ 370 nm (see section 2.4.2) [200].
The majority of end-users are unaware of the lack of broad spectrum protection
and the loss of UV attenuation of commercial sunscreens over time. As such, the general
rate of re-application of sunscreen is low, together with a lack of generous coverage of all
body parts with sunscreen lotion [187]. In a long-term study running over 5 years, over
1600 residents of Nambour, Queensland, Australia, were given either sunscreens or
betacarotene as a placebo. The study showed that there was no detectable difference in
basal-cell and squamous-cell carcinoma incident rates [263].
Of particular concern is also the fact that the exact sunscreen formulations are
mostly unknown, although they are commonly available and used by a large number of
people. This significantly complicates the determination of sunscreen safety and possible
side effects that might arise with the use of photocatalytically active ingredients.
2.5.4 Improvement of Existing Inorganic Ultraviolet Filters
The concerns that have been raised regarding both organic and inorganic UV
filtering additives have led to increasing research on sunscreen stability, safety, including
that of inorganic NPs and organic UV filters, photoactivity, and efficiency. The main goal is
to improve commercially available sunscreen formulations by improving the properties of
their organic and inorganic ingredients.
2.5.4.1 Stability of Emulsions
Sunscreen formulations are based on emulsions that might break down once
applied onto the skin, which can potentially increase the skin permeability for NPs [11]. It
has been shown that the penetration levels of TiO2 were higher for an oily dispersion in
comparison to an aqueous dispersion [264]. It is therefore advantageous to stabilize the
emulsion with the focus on an aqueous dispersion.
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The addition of microsponge delivery systems to a modern sunscreen formulation,
for instance, has improved its stability and cost-efficiency [265]. Once incorporated with
active UV filtering materials, the microsponge systems release these only when the
sunscreen is applied on the skin [265].
2.5.4.2 Broad Ultraviolet A/Ultraviolet B Protection
One problem with the use of nanosized TiO2 and ZnO is their shift of the absorption
threshold to shorter wavelengths, leading to more UVB absorption and an imbalance in the
recommended UVA/UVB protection. The absorption of TiO2 NPs in particular shifts to UVB
only, so that broad spectrum protection is not achieved anymore. A possible solution to
this problem is the addition of both nanosized and microsized ZnO to maintain UVA
protection and transparency at the same time [11]. A study suggested that ZnO with a
particle size of 130 nm had a more severe effect on UVA protection than ZnO particles with
a size of only 20 nm [266].
2.5.4.3 Reduction of Photoactivity
The Scientific Committee on Consumer Safety (SCCS) has declared that sunscreens
that contain TiO2 as active ingredient should be composed of the less photocatalytically
active rutile TiO2 with a maximum of 5% anatase TiO2 [267].
Surface modifications
In addition, there have been a number of attempts to reduce the photocatalytic
activity of inorganic UV filters. For instance, the surface of TiO2 was modified using a
thermally assisted method, which resulted in a deactivation of the photocatalytic activity
and further prevented DNA damage to human keratinocyte skin cells [268]. Saccharomyces
Cerevisiae yeast cells showed greater survival rates with the inactivated TiO2 NPs under
UV radiation in comparison to azabenzone (Figure 2.32), and the inactivated NPs still
exhibited their characteristic UVA/UVB attenuation [268].
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Figure 2.32. Survival of Saccharomyces Cerevisiae yeast cells after ultraviolet irradiation
for 0 – 40 min. The yeast cells were treated without an ultraviolet filter (left image), with
modified TiO2 (centre image), and with azobenzone (right image). The number of yeast
cells on the left was twofold greater than the number of cells on the right [268].
Surface coatings
Typically, the formation of hydroxyl radicals, or other relevant ROS, takes place on
the surface of the NPs, after the electron-hole pair has been formed [11]. By modifying the
surface properties of these NPs, such as by applying coatings or ROS scavenging materials
on their surfaces, their photocatalytic activity can be altered. The coated NP is entirely
isolated from the surrounding medium (skin, water, and oxygen), preventing the
generation of ROS [11]. Alternatively, the coatings can also actively scavenge the
photogenerated ROS [11].
For a surface coating to be suitable, it needs to be non-toxic, highly biocompatible,
photostable, and more importantly, it cannot influence the UV attenuation of the NPs. Such
coatings are typically based on silica (SiO2), aluminium oxide (Al2O3), aluminium hydroxide
(Al(OH)3), methicone , and poly(methacrylic acid) [11, 269].
The composition of the nanocomposites is of particular importance, since materials
such as TiO2/SiO2 and TiO2/Al2O3 can also display enhanced photocatalytic activity [270]. A
comprehensive study investigating the generation of ROS by uncoated and coated TiO2
NPs, either in the form of pure rutile or in a mixture of 80% anatase and 20% rutile (P25)
was conducted by the authors of [228]. Table 2.6 gives an overview of the tested materials.
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Table 2.6. Physico-chemical properties of selected commercially available coated TiO2
nanoparticles [228].
Trade name

Composition (%)

Crystal phase

Particle size

(%)

(nm)

Rutile, 100

100

TiO2, 75
Maxlight™ F-TS20
SiO2, 22
TiO2
Eusolex® T-AVO

< 200
Rutile, 100

SiO2

(needle-like)

TiO2, 84
30 – 60 x 10
T-Lite® SF

Al(OH)3, 7

Rutile, 100
(needle-like)

Dimethicone, 4.5
TiO2, 78
SiO2, 7.5

30 – 60 x 10
Rutile, 100

T-Lite® SF-S

Dimethicone, 5.5

(needle-like)

Al(OH)3, 3.5
TiO2, > 50
Anatase, 80
TEGO® Sun TS Plus

SiO2, 10 – 25

28 – 32
Rutile, 20

Trimethoxycaprylylsilane, 4.5
TiO2, > 90
Anatase, 80
PW Covasil S

Trimethoxycaprylylsilane, < 5

28 – 32
Rutile, 20

Polymethyl methacrylate, 5
TiO2, > 95

Anatase, 80

Trimethoxycaprylylsilane, < 5

Rutile, 20

TiO2, 100

Anatase, 80

PW Covasil S-1

28 – 32

Aeroxide®

28 – 32
Rutile, 20

The lipid peroxidation was determined in porcine skin under UV irradiation at a
wavelength of 250 – 800 nm and compared to control samples without TiO2 [228]. PW
74

Chapter 2 – Literature Review

Covasil S, PW Covasil S-1, T-Lite® SF, and standard Aeroxide® induced substantial lipid
peroxidation, while the use of Maxlight™ F-TS20, TEGO® Sun TS Plus, and T-Lite® SF-S
resulted in reduced lipid peroxidation [228]. The obtained results suggest that, besides the
phase of TiO2, the type of surface material has an impact on the overall capacity to reduce
photoactivity, with silica coatings being the most promising.
Similar tests with the focus on cytotoxicity and genotoxicity were performed with
uncoated and coated ZnO NPs (30 nm) [271]. The results indicate that the NPs that were
coated with poly(methacrylic acid) or oleic acid exhibited reduced cytotoxicity in
comparison with uncoated ZnO NPs. The ZnO NPs coated with poly(methacrylic acid),
however, showed the highest genotoxicity [271].
Addition of photostabilizers and antioxidants
Besides the use of surface coatings, the degradation of active organic ingredients
can be reduced by the addition of photostabilizers such as octocrylene, 4methylbenzylidene camphor, butyloctyl salicylate, hexadecyl benzoate, butyloctyl
benzoate, and polycrylene to sunscreen formulations [272].
Furthermore antioxidants, such as vitamins, are added to sunscreens to provide
protection from DNA inactivation or cell damage [273, 274]. Although these organic
additives may offer benefits, they are potential allergens and typically have lower
photostability than inorganic components (see section 2.5.3) [237].
2.5.5 New Class of Nanoparticles for Sunscreen Formulations
Besides the improvement of existing UV filters, research is also focused on the
development of new UV filters. Particular interest is paid to their photocatalytic activity,
which cannot be completely prevented with surface coatings in the case of inorganic UV
filters [11]. Besides having high physical and chemical stability, once added into the base
emulsion, the optimum UV filter should ideally fulfil the following requirements [187]:
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Transparency,



High photostability and low photocatalytic activity,



High biocompatibility, low cytotoxicity, and low genotoxicity,



Non-permeability into skin,



Broad spectrum UVA/UVB protection, high UV attenuation, and high SPF.

2.5.5.1 Inorganic Nanoparticles
Since it is assumed that the generation of ROS is also related to NP toxicity in the
absence of UV radiation, an optimal NP-based UV filtering component does not show any
generation of ROS – neither in presence nor the absence of UV radiation [108-111]. In
contrast, by introducing ROS scavenging properties into the NP system, the
biocompatibility of the inorganic UV filter can be improved, and at the same time, the
decomposition of organic sunscreen components can be reduced.
Materials of interest include pure CeO2 [113-115] and rare earth- [113], alkaline
earth- [113, 275], and transition metal [276] doped CeO2. The absorbance curves of pure
and Ca-doped CeO2 NPs are shown in Figure 2.33. CeO2 NPs provide selective absorbance
in the UV range and it has been shown that sunscreen emulsions prepared with TiO2/CeO2
yielded in an increase of 27% in their SPF compared to a formulation containing the
classical combination of TiO2/ZnO [119]. More importantly, CeO2 NPs show high
biocompatibility and can scavenge free radicals (see section 2.3.4.4) [120, 121].
Nevertheless, these nanomaterials have a relatively high cost in comparison to
TiO2 NPs, making latter ones still preferable. Therefore, cheaper materials have been
investigated, such as α-Fe2O3 [277], Ce-doped α-Fe2O3 [278], and Fe2O3/CeO2 nanocomposites
[238], which showed scavenging of photogenerated hydroxyl radicals as well as improved UV
absorbance. More recently, Ti-doped SnO2 NPs have been synthesized that exhibit reduced
photocatalytic activity compared with TiO2 and ZnO NPs [279].
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Figure 2.33. Absorbance curves of pure (black curve), 20 mol.% (red curve), and 40 mol.%
(blue curve) CeO2 nanoparticles. Adapted from [275].
2.5.5.2 Organic Nanoparticles
Besides the development of new inorganic NPs as UV filters, the investigation of
organic NPs as potential sunscreen ingredients has aroused research interest. For instance,
organic NPs were isolated from English ivy (Hedera helix) and exhibited greater UV
blocking properties than TiO2 NPs [280]. The biodegradable ivy NPs also showed greater
biocompatibility and decreased cell toxicity in human epithelial HeLa cells compared with
TiO2 NPs. Mathematical models suggested that they have limited potential to penetrate the
skin [280]. It is, however, necessary to establish the photostability of those types of NPs.
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3.1 Synthesis of Nanomaterials
3.1.1 Materials
Bismuth(III) nitrate pentahydrate (Bi(NO3)3∙5H2O, 98%), ammonium hydroxide
(NH4OH, 28–30%), tantalum ethoxide ((CH3CH2O)5Ta, ≥ 99.98%), acrylic acid (AA, 99%),
methanol (≥ 99.8%), hydrochloric acid (HCl, 37%), 2-propanol (99.5%), and denatured
ethanol were purchased from Sigma-Aldrich. Nitric acid (HNO3, 69%) was purchased from
Merck and chloroform (1% ethanol) was purchased from Chem Supply.
TiO2 (Aeroxide®, P25) and ZnO nanoparticles (NPs, < 100 nm) were obtained from
Sigma-Aldrich. Commercial poly(acrylic acid) (PAA) with a molecular weight (MW) of
450,000 was purchased from Polysciences Inc. All commercial materials were used
without further purification.
3.1.2 Synthesis of Bi(OH)3 Nanoparticles
Bi(OH)3 NPs were synthesized via a classical precipitation route. First, 4 g of
Bi(NO3)3∙5H2O (8.25 mmol) was dissolved in 40 mL of 69% HNO3. Then, 30% NH4OH was
added dropwise until a white precipitate was formed. The precipitate was filtered via
centrifugation (Eppendorf, 5 min, 3920 g), washed eight times with deionized (DI) water,
resuspended in 150 mL of DI water, and heated under stirring at 80 – 100°C for 5.5 h. The
precipitate was then filtered (5 min, 3920 g), washed eight times with DI water (10 min,
3920 g), and dried in vacuum at 60ᵒC for 48 h.
3.1.3 Synthesis of α-Bi2O3 Nanoparticles
To obtain α-Bi2O3 NPs, Bi(OH)3 NPs, which were obtained through the classical
precipitation method described above [1], were annealed in a horizontal tube furnace
(LABEC) at 525°C and a heating rate of 10ᵒC/min for 4 h under air atmosphere. After
annealing, a yellow powder was obtained.
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3.1.4 Preparation of Nanocomposites of TiO2 and (BiO)2CO3
TiO2/(BiO)2CO3 nanocomposites were synthesized via a precipitation method. First,
600 mg (7.51 mmol) of TiO2 NPs was suspended in 110 mL of DI water and sonicated for 1
h using a sonication bath (Branson 3800, Ultrasonics Corp). Then, according to the atomic
ratio of Bi/Ti, Bi(NO3)3∙5H2O was dissolved in 0.75 – 2.95 mL (17.98 – 70.70 mmol) of 69%
HNO3. The acid was 50% neutralized with the dropwise addition of 30% NH4OH. Then, the
reaction mixture was added to the suspension of TiO2 and stirred for 2 min. Further
NH4OH was added dropwise until the pH reached a value of 8. The precipitate was filtered
via centrifugation (Eppendorf, 5 min, 157 g), washed eight times with DI water (5 min, 157
g), suspended in 35 – 50 mL DI water, and heated under stirring at 80 – 100ᵒC for 5.5 h.
The composites were filtered (5 min, 157 g) and washed eight times with DI water, and the
white powder was dried in vacuum at 60ᵒC for 48 h. The samples were denoted as Bi/Ti 2
at.%, Bi/Ti 4 at.%, and Bi/Ti 8 at.% for the composites with Bi:Ti atomic ratios of 0.02,
0.04, and 0.08, respectively.
3.1.5 Synthesis of δ-Ta2O5 Nanoparticles
δ-Ta2O5 NPs were synthesized using a classical precipitation route. First, 10 g
(24.62 mmol) of (CH3CH2O)5Ta was transferred carefully with exclusion of water into
200 mL of ethanol. The solution was stirred at room temperature, and then 60 mL of DI
water was added quickly to the reaction mixture, which resulted in the formation of a
white precipitate. The precipitate was filtered via centrifugation (Eppendorf, 10 min,
1656 g, room temperature), washed twice with DI water (10 min, 1656 g, room
temperature), and dried at 90ᵒC overnight. Then, the precipitate was annealed in a tube
furnace (LABEC) at 730ᵒC at a heating rate of 5ᵒC/min for 30 min under air atmosphere.
3.1.6 Coating of δ-Ta2O5 Nanoparticles with Poly(acrylic acid)
To obtain structurally stable NP-polymer composite materials, the polymer is
usually grafted onto the NP surfaces. If the surface of the substrate is activated via prior
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etching, the number of hydroxyl groups increases, which also results in an increase in
physical adsorption of AA monomers [2].
For instance, gold-coated silicon structures were formed following plasma etching
treatment [2]. In another study, silicon NPs were first treated with a mixture of
hydrofluoric acid and nitric acid, and then were grafted with PAA [3]. The etching of the
NPs has been shown to increase the binding affinity of proteins, which can interact with a
wider range of orientations [4]. Other approaches include ultraviolet-ozone soft etching of
ceramic NPs before the polymer is grafted onto their surfaces [5]. Following this approach,
the polymer chains grow around each individual ceramic particle, avoiding the wrapping of
clusters of substrate NPs [6, 7].
The coating of δ-Ta2O5 NPs with PAA was performed in three steps:


First step: surface activation using methanol to increase the number of
hydroxyl groups on the NP surface.



Second step: acidic etching using concentrated HCl to increase the physical
adsorption of AA monomers.



Third step: thermal induced organic polymerization in emulsion of
acrylate chains of AA leading to PAA-coated NPs.

First, 330 mg (0.75 mmol) of δ-Ta2O5 NPs was added into a centrifuge tube
containing 25 mL of methanol. The centrifuge tube was placed in a sonication bath
(Branson 3800, Ultrasonics Corp) and sonicated for 25 min. The suspension was then
centrifuged at room temperature (Eppendorf, 7 min, 980 g), the NPs were resuspended in
20 mL of concentrated HCl, and the suspension was stirred gently under nitrogen (N2) flow
for 25 min. The suspension was centrifuged at room temperature (5 min, 794 g), and the
NPs were resuspended in 20 mL of AA (291.42 mmol) and placed back under N2-flow. The
suspension was stirred for a total of 1, 2.5, and 5 h, respectively, at a temperature of 83 ±
1 °C. After the desired amount of time, 10 mL of chloroform was added to the reaction
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mixture to stop the polymerization process. The suspension was then centrifuged at room
temperature (3 min, 157 g), washed three times with chloroform (3 min, 157 g, room
temperature), and the PAA-coated NPs were dried at room temperature for 48 h. The
coating procedure is schematically shown in Figure 3.1.

Figure 3.1. Schematic illustration of the coating procedure involving the reaction of δTa2O5 nanoparticles and acrylic acid (AA).
To determine the surface properties of δ-Ta2O5 after treatment with HCl via X-ray
photoelectron spectroscopy (see section 3.2.3), an aliquot was taken before resuspension
in AA, followed by washing three times with methanol (3 min, 157 g, room temperature),
and drying at room temperature for 48 h.

3.2 Physical and Chemical Characterization of Nanomaterials
3.2.1 Materials
Phosphate buffered saline (PBS), denaturated ethanol, sodium acetate (≥ 99.0%),
sodium carbonate decahydrate (≥ 99.99%), acetic acid (≥ 99.7%), and sodium bicarbonate
(≥ 99.7%) were purchased from Sigma-Aldrich.
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3.2.2 Specific Surface Area (Brunauer-Emmett-Teller)
The Brunauer-Emmett-Teller (BET) method for the determination of the specific
surface area of nanopowders is based on the adsorption of gas molecules onto the surface
of a material. It assumes that the adsorbate forms a weakly bonded monolayer, and the
volume of gas is correlated with the surface area of the tested material [11].
This method makes it possible to experimentally determine the adsorbed and
desorbed volume of an inert gas, usually nitrogen, at various relative pressures and at a
constant temperature, which is then used to calculate the specific surface area [11, 12]. The
BET model includes multilayer adsorption, where the first layer describes the heat of
adsorption. Equation (3.1) describes the BET adsorption isotherm [11, 12]:

(
where
(Pa),

) (

)

(3.1)

is the adsorbed gas volume of a monolayer (m3), p is the equilibrium pressure
is the saturation vapour pressure (Pa), and

is the BET constant. The BET

constant can be described by Equation (3.2) [11]:
(3.2)
where

is the heat of adsorption for the first layer (J),

is the heat of adsorption for the

second and higher layers (J), Rgas is the ideal gas constant (8.314 J ∙ mol-1 ∙ K-1), and T is the
temperature (K). The BET surface area SBET (m2 ∙ g-1) is defined by Equation (3.3) [11]:
(3.3)
where

is the Avogadro’s number (6.022 × 1023 mol-1), s is the adsorption cross-

section of the adsorbing gas (m2),

is the molar volume of adsorbed gas (m3 ∙ mol-1), and

is the mass of adsorbent (g).
The BET surface area of all materials was measured using a Nova 1000 high speed
gas sorption analyser from Quantachrome. The adsorption of N2 at the temperature of
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liquid nitrogen was determined, and prior to measuring, the samples were degassed at
60°C for 15 h in vacuum.
3.2.3 X-Ray Diffraction (XRD)
XRD is widely used to identify crystal structures, which provide a diffraction
grating for electromagnetic radiation such as X-rays with a wavelength in the range of the
lattice plane distances, as shown in Figure 3.2.

Figure 3.2. Schematic principle of X-ray diffraction by a crystalline sample with the angle θ
of the incident beam on lattice planes with spacing d.
X-rays that are directed through the atoms in the crystalline structure are scattered
through the electron shell of the radiated atom. The radiation caused by constructive
interference is recorded by a detector with a deflection angle of 2θ and results in visible
reflections in the XRD pattern. In contrast, destructive interference does not yield visible
reflections. The conditions that need to be present for constructive interference are
summarized in the Bragg equation (Equation (3.4) [8, 9]:
( )

(3.4)

where d is the spacing between diffraction planes (nm), θ is the incident angle (rad),
is the diffraction order, any integer, and λ is the wavelength of the beam (nm).
In general, Cu Kα radiation is used with a wavelength of 0.1542 nm.
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By assigning the Miller indices hkl to the particular diffraction angles, the lattice
plane difference can be calculated. If the crystal lattice structure is known, the lattice
parameters of the unit cell (a, b, and c) can be determined, according to Equation (3.5) [9]:
( )

( )

(3.5)

( )

If the crystals are very small in size (100 – 200 nm), a broadening of the reflections
occurs, which can be described by the Scherrer equation. The mean crystallite size can be
calculated by the following Equation (3.6)) [10]:
(3.6)

( )
where

is the average crystallite size (nm),

the particles are spherical,

is a form constant (assuming that

= 0.89), λ is the wavelength of the X-ray radiation (nm), β is

the full width at half maximum (rad), and θ is the Bragg angle of diffraction (rad).
The phases of all produced and as-received materials were characterized via an
Enhanced Mini-Materials Analyzer X-Ray Diffractometer (GBC Scientific) and a Mac Science
M03XHF22 diffractometer with Cu Kα radiation at 40 kV and 25 mA. Lattice parameters
were obtained via Rietveld refinement using the Marquardt least square method.
3.2.4 X-Ray Photoelectron Spectroscopy (XPS)
XPS is a surface-sensitive quantitative spectroscopic technique that gives
information about the elemental composition of a sample and the chemical and electronic
states of elements on the surface [13].
A sample is irradiated using a beam of X-rays, which penetrate the first 0 – 10 nm
of the material [13]. The kinetic energy and emitted electrons are collected by a detector,
as displayed in Figure 3.3. To minimize the loss of photoemitted electrons due to inelastic
collisions or recombination, ultra-high vacuum (< 10-9 mbar) is needed. By counting the
ejected electrons over the range of kinetic energies, the photoelectron spectrum is
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recorded. The energies and intensities of the photoelectron peaks are characteristic of each
element and allow their identification, except for hydrogen [13].

Figure 3.3. Working principle of X-ray photoelectron spectroscopy.
XPS was conducted using a SPECS PHOIBOS 100 Analyzer installed in a high
vacuum chamber with base pressure below 10−8 mbar. X-ray excitation was provided by Al
Kα radiation with a photon energy of 1486.6 eV at a voltage of 12 kV and power of 120 W.
The XPS binding energy spectra were recorded with pass energy of 20 eV in fixed analyser
transmission mode. Analysis of the XPS data was carried out using CasaXPS 2.3.15
software.
3.2.5 Fourier-Transform Infrared Spectroscopy (FTIR)
Infrared (IR) spectroscopy is used to identify organic compounds [14, 15].
Typically, a FTIR spectrometer consists of an IR source and an interferometer, which splits
one beam of light into two (Figure 3.4). After the beams are recombined at the
beamsplitter, constructive and destructive interference is generated, yielding an
interferogram [16]. The combined beam passes through the sample, which absorbs all
wavelengths characteristic of its spectrum, ultimately changing the interferogram. The
detector measures these changes, and a computer transfers the digitized signal using the
Fourier transform [16].
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Figure 3.4. Working principle of a Fourier transform infrared spectrometer, adapted from
[17].
When IR radiation hits the sample, energy is absorbed by the individual molecules,
which causes a change in the dipole moment and ultimately, the formation of different
stretching and bending vibrations. The number of degrees of vibrational freedom of the
molecule is directly linked to the number of absorption peaks in the FTIR spectrum, while
the intensity of the peaks corresponds to the change of dipole moment [15, 16]. Not all
fundamental vibrations, however, are visible in the FTIR spectrum, since certain modes are
IR inactive if there is no change in the dipole moment, or they might have the same
frequency. Furthermore, more bands can be generated due to overtones or combinations
of fundamental frequencies [14].
FTIR spectra were recorded on an IR Prestige 21 Spectrometer from Shimadzu
Corporation over the range of 4000 – 500 cm-1 (64 scans, resolution of 4 cm-1) via
attenuated total reflectance (ATR) using the MIRacle attachment. The ATR method is based
on a crystal with high refractive index, such as diamond, through which a beam of IR light
is passed at a certain angle. An evanescent wave is generated, which, due to total internal
reflection, extends beyond the surface of the crystal into the sample [18].
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3.2.6 Raman Spectroscopy
Similar to IR spectroscopy, Raman spectroscopy provides information about
vibrational, rotational, and other low-frequency modes in a molecule. A laser is used as the
source of monochromatic light in the visible, near infrared, or near ultraviolet range, which
hits the sample and can be reflected, absorbed, or scattered [19].
When analysing samples that have a change in polarizability, the frequency of the
scattered radiation shows, besides the incident radiation (Rayleigh scattering), also
radiation that is scattered at different wavelengths (Stokes and Anti-Stokes Raman
scattering), as pictured in Figure 3.5 [19]. This change in wavelength of the scattered
photons can be used to identify chemical structures.

Figure 3.5. Rayleigh and Raman scattering (Stokes and Anti-Stokes).
Raman spectra were recorded on a Raman Jobin Yvon HR800 Spectrometer using
×50 LWD and ×100 LWD objectives over the range of 50 – 3500 cm-1.
3.2.7 Ultraviolet-Visible (UV-Vis) Spectroscopy
UV-vis spectroscopy is used to determine the UV-vis absorption properties of
samples, or, in the case of semiconducting materials, their band gap [20].
Typically, an UV-vis spectrometer consists of a UV-vis source and a beam splitter
that separates the light beam into two equal intensity beams. One beam passes through a
cuvette containing the sample and a solvent/dispersant, while the other beam passes
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through a cuvette filled with only the solvent/dispersant (= reference) (Figure 3.6) [21].
Detectors measure the intensity of both light beams, where the intensity of the sample
beam is defined as I and the intensity of the reference is defined as I0 [21].

Figure 3.6. Working principle of an ultraviolet-visible spectrometer.
The concentration c of the sample (mol ∙ L-1) can be calculated via the LambertBeer law as shown in Equation (3.7) [22]:
(3.7)

( )

where A is the absorbance, ɛ is the extinction coefficient (m2 ∙ g-1), l is the path length
through the sample (m), and α is the absorption coefficient (m-1).
UV-vis light can either be reflected or absorbed by a molecule [21, 23]. If the energy
is high enough, the molecules can undergo electronic transitions from the ground state to
the excited state or from the valence band to the conduction band. For a superconductor,
the optical absorption behaviour near the band edge follows Equation (3.8) [20]:
(

)

(

)

(3.8)

where α is the absorption coefficient, h is the Planck constant (6.626 × 10-34 (m2 ∙ kg ∙ s-1), ν
is the light frequency (s-1), B is a constant, and

is the band gap (eV). The value of m

depends on the type of optical transition (i.e. m = 2 for a direct transition and m = 0.5 for an
indirect transition) [20].
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UV-vis measurements of suspended NPs
Suspensions were prepared in DI water at a concentration of 1 mg/mL and were
sonicated for 2 h using a sonication bath (Branson 3800, Ultrasonics Corp). Dilutions were
prepared at concentrations of 25 – 50 µg/mL to yield an absorbance close to 1.0. The
absorbance was recorded on an UV-3600 spectrophotometer from Shimadzu Corporation
over the range of 800 – 200 nm by using 1.4 mL quartz cuvettes with a path length of 1 cm.
UV-vis measurements of solutions
The UV-vis absorbance of solutions was measured directly, as described above,
without sonication. For the calibration curve of methotrexate (MTX) and the drug release
experiments, the supernatant of each sample was directly measured, and the quantity of
MTX was calculated from the absorbance maximum at 303 nm (see section 3.6.8.2).
3.2.8 Dynamic Light Scattering (DLS)
DLS is used to determine the geometric size distribution profile of small particles
(down to 1 nm in diameter) in suspension [24]. These particles include NPs, colloids,
proteins, polymers, or emulsions. When in suspension with an aqueous dispersant, a
hydration layer is typically formed surrounding the particle or molecule. The measured
particle size is therefore given as a hydrodynamic diameter [24].
During the DLS measurement, a laser beam is focused on the sample and the
fluctuations of scattered light are detected at a known scattering angle by a fast photon
detector [25]. The fluctuations are caused by Brownian motion, which differs for small and
large particles: while smaller particles show faster dynamics, larger particles tend to
diffuse more slowly in suspension (Figure 3.7). The Stokes-Einstein equation shows the
relation of the diffusion coefficient

(m2/s) and hydrodynamic radius

(nm) of the particles (Equation (3.9)) [24]:
(3.9)
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where

is the Boltzmann constant (1.38 × 10-23 m2 ∙ kg ∙ s-2 ∙ K-1), T is the temperature (K),

and is the viscosity (Pa ∙ s).

Figure 3.7. Scheme of Brownian motion of (a) small and (b) large particles [26].
The hydrodynamic diameter of the nanomaterials suspended in PBS at a
concentration of 50 µg/mL was determined using a Malvern – Zetasizer APS2000. The light
scattering experiments were conducted using an 830 nm laser in three independent
measurements at room temperature. An autocorrelation function for the scattered light
from the suspension was used to obtain the size distribution, utilizing the Malvern –
Zetasizer 7.03 software.
3.2.9 Thermogravimetric Analysis (TGA)
TGA is typically used to investigate changes in the mass of a material during
heating and provides information about the composition of a sample, and its stability and
degradation. The sample is typically placed in a crucible that is made of an inert and hightemperature-resistant material such as platinum or aluminium oxide, which is then placed
in a precisely controlled furnace, as shown in Figure 3.8. A heating program in different
atmospheres, such as argon, nitrogen, air, or oxygen, with final temperatures of up to
1200ᵒC is applied, and a highly sensitive balance registers any mass changes [27]. A loss of
mass is typically related to certain processes, such as evaporation, sublimation, or the
generation of volatile products, while a gain of mass can be caused by oxidation [27].
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Figure 3.8. Schematic diagram of a thermogravimetric analyser.
The stability of the synthesized and as-received materials and the quantity of
organics were investigated using a Metter Toledo TGA/DSC 1 STARe system. Each sample
was placed in an aluminium oxide cup and heated from 50 - 800ᵒC at a heating rate of
5ᵒC/min in air atmosphere.
3.2.10 Computed Tomography
The principle of CT, including the set-up of a CT scanner and the use of CT contrast
enhancing agents, is discussed in section 2.3.7.1.
The anatomical contrast enhancement capability of α-Bi2O3, Bi(OH)3, and δ-Ta2O5
NPs, and composites of δ-Ta2O5 and PAA were demonstrated using CT. Suspensions with
concentrations of Bi and Ta ranging from 0 to 8 mg/mL in PBS were prepared in 1.5 mL
vials and sonicated for 2 h. Then, the vials were imaged together using a Toshiba Asteion
TSX-021A whole body X-ray CT scanner with a tube voltage of 100, 120, and 135 kV, as
shown in Figure 3.9. The CT images were obtained using the standard patient image
reconstruction algorithms included with the scanner.
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Figure 3.9. (a) Toshiba Asteion TSX-021A computed tomography scanner. (b) 1.5 mL vials
with α-Bi2O3 (top) and δ-Ta2O5 (bottom) nanoparticles suspended in phosphate buffered
saline.
CT numbers (HU) were calculated using ImageJ by normalizing the obtained grey
scale (tissue) against the control (water). The CT number is directly linked to the image
pixel and the tissue voxel via the attenuation coefficient µ (cm2 ∙ g-1), as shown in Equation
(3.10) [28]:
(3.10)

3.2.11 Polymer Swelling Studies
PAA as a hydrogel is able to hold large amounts of water and to deswell reversibly
[29]. The swelling studies of nanocomposites based on δ-Ta2O5 and PAA were conducted in
buffer solutions with a pH of 3.6, 5.4, 7.4, and 9.4 at 37ᵒC, as it was shown that the
shrinking and expansion of PAA depends on the pH value (see section 5.1.2) [30].
Preparation of buffer solutions
Four different pH buffer solutions were prepared to yield a pH of 3.6, 5.4, 7.4, and
9.4, respectively, at 20°C. The acetate buffer with pH 3.6 was prepared by combining 92.5
vol. % of 0.1 M acetic acid with 7.5 vol. % of 0.1 M sodium acetate. To yield a pH of 5.4, 85.5
vol. % of 0.1 M sodium acetate was combined with 14.5 vol. % of 0.1 M acetic acid. For
experiments that require a buffer with pH 7.4, PBS was used. The carbonate-bicarbonate
buffer with a pH 9.4 was prepared by combining 70 vol. % of 0.1 M sodium bicarbonate
with 30 vol. % of 0.1 M sodium carbonate.
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Swelling of PAA
First, the desired weight of the NPs (

; g) was added into the buffer solution with

the desired pH value. At predetermined time intervals, the NPs were removed from the
swelling medium, blotted with filter paper to remove excess buffer solution from the NP
surfaces, and the weight of the swollen composite (

; g) was determined. The swelling

behaviour of the NPs was observed for a total of 48 h, and the swelling ratio (SR) was
calculated, as shown in Equation (3.11) [31]:
(

)

(3.11)

3.3 Morphological Characterization of Nanomaterials
Electron microscopy is mainly divided into scanning electron microscopy (SEM)
and transmission electron microscopy (TEM), although there are also modes in between,
such as scanning transmission electron microscopy (STEM). These techniques are based on
an electron beam that is focussed on a specimen and interacts with its atoms, as shown in
Figure 3.10. The generated signals can be used to obtain information about the particle
morphology and size. The elemental composition of a specimen can be determined via
electron energy loss spectroscopy (EELS) or energy dispersive X-ray spectroscopy (EDS).
In this thesis, SEM, STEM, and TEM images and EDS mappings were acquired using
a JSM7500FA cold field emission gun scanning electron microscope (FEGSEM, JEOL), a
JEOL JEM-2010 transmission electron microscope, and a JEOL JEM-ARM200F atomic
resolution microscope.
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Figure 3.10. (a) Signals generated during the interaction of an electron beam with a
specimen. (b) Interaction volumes in the depth range of an electron beam and a specimen.
Sample preparation
The nanomaterials were suspended in denaturated ethanol (Sigma-Aldrich) or 2propanol (99.5%, Sigma-Aldrich) and sonicated for 0.5 – 2 h using a sonication bath
(Branson 3800, Ultrasonics Corp). A drop was then placed onto a 200 mesh carbon coated
copper grid, which was dried at room temperature. Specimens for EDS bulk analysis were
directly placed on carbon film and mounted to the specimen holder. All prepared specimen
were stored inside a desiccator.
3.3.1 Scanning Electron Microscopy
SEM is used to obtain indirect images of the specimen surface by scanning it with a
very fine electron probe with energies ranging from 0.2 to 40 keV [32]. The position of the
electron beam on the sample directly corresponds to a position in the image, so that
information about the topography of the sample can be obtained.
The most common imaging modes are based on the emission of secondary
electrons (SE) with energies < 50 eV and back scattered electrons (BSE) with energies > 50
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eV [32]. Depending on the angle between the surface and the beam, more or less SE are
emitted and detected, resulting in an image showing the tilt of the surface [32]. To
minimize the recombination and collision of electrons, ultra-high vacuum (10-3 Pa) is
necessary. A schematic illustration of a SEM is shown in Figure 3.11.

Figure 3.11. Adapted schematic illustration of a scanning electron microscope [33].
SEM images were obtained using a JSM7500FA cold field emission gun scanning
electron microscope with an accelerating voltage of 15 kV. STEM images were acquired at
an accelerating voltage of 30 kV.
3.3.2 Transmission Electron Microscopy
In the TEM mode, a beam of electrons passes through a very thin specimen (≤ 100
nm thick), allowing the transmission of electrons, which ultimately results in the formation
of an image [32]. A schematic illustration of a TEM is shown in Figure 3.12.
Due to the smaller de Broglie wavelength of electrons, the resolution of a
transmission electron microscope is significantly increased in comparison to light
microscopes (Equation (3.12)) [34]:
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(3.12)
where λ is the wavelength (m), h is the Planck constant (6.626 × 10-34 (m2 ∙ kg ∙ s-1),
is the mass of the electron (kg), and

the electron velocity (m ∙ s-1).

According to de Broglie, an increase in the accelerating voltage results in an increase in the
electron velocity and ultimately an increase in resolution. Thus, high-end transmission
electron microscopes are capable of imaging single columns of atoms.

Figure 3.12. Adapted schematic illustration of a transmission electron microscope [33].
TEM images were obtained using a JEOL JEM-2010 transmission electron
microscope with an accelerating voltage of 200 kV. High-resolution TEM images were
obtained using a JEM-ARM200F atomic resolution microscope. The image processing was
performed using Gatan Digital Micrograph, and particle size distributions were determined
using ImageJ.
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3.3.3 Energy-Dispersive X-Ray Spectroscopy
EDS units are typically connected to SEM and TEM microscopes and can be used to
determine the elemental composition of a specimen. Upon exposure of a specimen to a
high-energy electron beam, an electron in an inner shell can be excited and ejected, which
results in the formation of an electron hole, as shown in Figure 3.13 [32]. Electrons from
outer shells with higher energy can fill this hole, releasing energy in the form of X-rays,
which are collected by a detector. The energy levels of the electron shells are characteristic
of each atom, so that distinctive spectra are obtained [32].

Figure 3.13. Principle of energy-dispersive X-ray spectroscopy.
EDS bulk analysis and EDS mappings were performed with a JSM7500FA cold field
emission gun scanning electron microscope equipped with an X-Flash 4010 10 mm2, 127
eV SDD energy dispersive X-ray detector (Bruker, Massachusettes, USA). An accelerating
voltage of 20 kV was used to obtain X-ray spectra of photons between 0 – 20 keV with a
real time acquisition period of at least 120 s.
High-resolution EDS mappings were acquired using a JEM-ARM200F atomic
resolution microscope fitted with a Centrino SDD 100 mm2 detector (JEOL, Akishima, Tokyo,
Japan). The EDS spectral imaging acquisition was performed using Thermo Scientific
COMPASS software for the NORAN System 7 X-ray Microanalysis System.
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3.4 Photocatalytic Activity and Ultraviolet-Blocking Properties of
Sunscreen Formulations
3.4.1 Materials
Crystal violet (≥ 90%), hexane (≥ 95%), and denatured ethanol were obtained from
Sigma-Aldrich. TiO2 (Aeroxide®, P25) and ZnO NPs (≤ 100 nm) were purchased from
Sigma-Aldrich. ZnO NPs coated with triethoxycaprylylsilane (Z-COTE® HP1) were
obtained from BASF. Eusolex® T-S TiO2 NPs are coated with stearic acid and were obtained
from Merck KGaA. All commercial nanopowders were used without further purification.
Four commercially available sunscreen products were purchased, including Nivea ®
(SPF 50) and Nivea® anti-age (SPF 30), which have inorganic ingredients (i.e. TiO2 NPs).
These sunscreens were tested for their photostability and photocatalytic activity. OMBRA®
(SPF 50) and Auscreen® (SPF 50) are organic-based sunscreens and were used for
rheological measurements.
3.4.2 Preparation of Sunscreen Formulations
A water-in-oil emulsion was prepared containing 25 wt.% organic filters and 5
wt.% commercially available TiO2 (Eusolex® T-S) NPs. In order to test the performance of
commercial ZnO and synthesized Bi(OH)3 NPs, the emulsions were supplemented with
either type of NP for a final concentration of 3 wt.% (Figure 3.14(a)).
3.4.3 Separation of Inorganic Sunscreen Components
The photostability of sunscreen formulations is related to the phase of the TiO2 NPs
present in the formulations, with anatase TiO2 being photocatalytically more active than
rutile TiO2 [35, 36]. The separation of commercial sunscreen ingredients and the XRD
analysis of the inorganic components identified either the rutile phase or a combination of
rutile and anatase TiO2 [35, 37].
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To extract the inorganic components from the commercial sunscreens used for the
sun exposure tests (see section 3.4.5) and the TiO2-based emulsions (see section 3.4.2), 1 –
2 g of sunscreen formulation was placed in a centrifuge tube, as described in the literature
[37]. After 30 mL of hexane was added, the mixture was shaken to remove the active
organic components, and centrifuged at room temperature (Eppendorf, 5 min, 1411 g). The
supernatant was discarded, and 30 mL of ethanol was added to the residue to remove the
remaining organics. After centrifugation (5 min, 1411 g, room temperature), the
supernatant was discarded, and 30 mL of DI water was added to the residue to remove the
surfactants from the inorganic components. The mixture was shaken, centrifuged at room
temperature (5 min, 1411 g), and the remaining inorganic components were washed
several times with ethanol (5 min, 1411 g, room temperature). The inorganic components
were dried overnight, and the crystalline phase was determined via XRD. The extracted
inorganic components are shown in Figure 3.14.

Figure 3.14. Separation of inorganic sunscreen components of (a) sunscreen emulsion
containing TiO2 and Bi(OH)3 NPs (left) and commercial sunscreen formulations of (b)
Nivea® anti-age (SPF 30), and (c) Nivea® (SPF 50). On each watch glass, the left side shows
the sunscreen and the right side shows the obtained inorganic components after
extraction.
3.4.4 Photocatalytic Activity
The degradation of crystal violet is used as an indicator to investigate the presence
of hydroxyl radicals in NP suspensions upon exposure to UV-vis light. Hydroxyl radicals
typically react with crystal violet, resulting in multiple by-products and a concomitant loss
of colour, which can be monitored by UV-vis spectrometry [38].
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Suspensions of Bi(OH)3, TiO2, and ZnO NPs, and combinations of these
nanomaterials were prepared in DI water and sonicated for 2 h using a sonication bath
(Branson 3800, Ultrasonics Corp). The concentration of TiO2 and ZnO remained constant at
5 mg/L, while the concentration of Bi(OH)3 was varied between 1 – 5 mg/L. Crystal violet
dye at an initial concentration of 12 µmol/L was added to the NP suspensions, which were
equilibrated by stirring in the dark for 60 min, as indicated in Figure 3.15. An aliquot was
taken prior to irradiation and the absorbance was measured at 590 nm using an UV-3600
spectrophotometer from Shimadzu. In a typical run, the aliquot was firstly centrifuged to
remove the photocatalyst (Eppendorf, 1 min, 157 g, room temperature), and after UV-vis
measurement, the aliquot was resuspended and returned to the reaction mixture.

Figure 3.15. Schematic procedure for assessment of photocatalytic activity of
nanomaterials using crystal violet.
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Exposure to UVA/UVB
After determination of the initial absorbance, the reaction mixture was placed in a
RPR-200 photochemical reactor (Rayonet, Branford, CT, USA), equipped with 300 nm and
350 nm lamps. Upon exposure to UV light, aliquots were withdrawn every 5 min for a total
of 30 min, and the absorbance was measured.
Exposure to simulated sunlight
For the sun simulation experiments, a halogen lamp (50 W power) was used, and
the degradation of crystal violet was investigated under illumination of global (G) air mass
(AM) 1.5 G one sun (100 mW/cm2). The irradiation time ranged from 0 – 6 h, and the
absorbance was measured in intervals of 30 min.
The kinetics of the dye degradation was investigated using a first-order reaction.
The apparent rate constant k (min-1) was calculated according to Equation (3.13) [32]:
(3.13)
where c is the concentration (mol ∙ L-1) as the reaction progresses,

is the initial

concentration (mol ∙ L-1), and t is the time (min).
3.4.5 Sun Exposure of Sunscreen Formulations
Another cheap and reliable method for evaluating potential photocatalytic
sunscreen activity has been described by [37] and a similar protocol was employed here.
Flat panels (250mm × 150mm) of pre-painted steel product were obtained from a
production run of a coil-coating paintline in Port Kembla NSW. The steel panels were
painted with five different sunscreen formulations: three prepared emulsions (see section
3.4.2) and two commercial sunscreens (Nivea® (SPF 50) and Nivea® anti-age (SPF 30))
were tested.
The sunscreen formulations were applied to the steel panels using a #10
drawdown bar, which gives a uniform applied wet-film thickness of ~13µm. Typically, 3 g
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of the emulsion was placed halfway along the length of the test panel and was drawn down,
thus covering half the panel. The top half of the panel remained uncovered and was used as
a negative control for comparison. The panels were then mounted lengthwise on an open,
fence-type, exterior exposure rack facing north at 45°, at a latitude of ~34.5ᵒS
(Wollongong, NSW) for a total of twelve weeks, as shown in Figure 3.16. The exposure time
of twelve weeks was chosen since significant differentiation after this particular time can
be expected if photocatalytic components are present in the formulation under test [37].

Figure 3.16. Sun exposure of steel panels painted with different sunscreen formulations.
(a) Front view of the exposure rack. (b) View of the exposure rack facing north at 45°.
3.4.5.1 Gloss Readings of the Test Panels
A 30 mm wide test strip was cut of each panel after six and twelve weeks of sun
exposure, and prepared for gloss readings. Firstly, the cut strips were cleaned, particularly
to reduce any residues of the weathered emulsions. A soft brush was used to clean the
lower parts of the strips under running water with a temperature of 40°C. Then, a solution
of diluted detergent was placed on a soft paper towel, which was carefully used to rub the
surface of the strips. After 1 min of rubbing, the strip was rinsed under running water
(40°C), and then dried at room temperature. With the help of a 60° gloss meter (BykGardner), the gloss of each sample was determined.
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3.4.5.2 Scanning Electron Microscopy Imaging of the Test Panels
Changes in the surface roughness were monitored over time using SEM. A 4.5 cm ×
2.0 cm area was cut from each panel after twelve weeks exposure and cleaned of debris
under warm running water with a fine hair paint brush. The test strip was then coated
with a thin layer of platinum, and the surface roughness was examined using a JEOL JSM7001F scanning electron microscope. SEM images were acquired at an accelerating voltage
of 5 kV.
3.4.6 Rheological Properties
Rheological properties were determined for TiO2/ZnO and TiO2/Bi(OH)3
emulsions and two sunscreen formulations commercially available in Australia: OMBRA®
(SPF 50) is a viscous cream dispensed from a bottle, while Auscreen® (SPF 50) is applied
through a spray dispenser. These two commercial products were chosen in order to
compare their viscosity and ease of topical application to those of the prepared emulsions.
For a typical measurement, a small amount of emulsion was placed on the base
plate of a Physica MCR 301 (Anton Paar, Graz, Austria) rheometer, and the viscosity was
measured at room temperature with a test gap of 0.3 mm over a range of rotational shear
rates, which were increased from 0.01 to 1000 s-1. The viscosity was recorded every 5 s for
a total of 50 measurement points. The obtained rheograms were analyzed, and the flow
index

was calculated using Equation (3.14) [39]:
(3.14)

where τ is the shear stress (dyne ∙ cm-2), r is the shear rate (s-1), and K is the consistency
index.
3.4.7 Photoprotection Efficiency
In-vitro SPF and UVA protection factor (UVA-PF) measurements of the prepared
emulsions were performed using a Labsphere UV2000S in accordance with ISO
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24,443:2012, in order to evaluate the photoprotection efficiency in the UVA and UVB
ranges.
30 mg of emulsion was placed on the surface of a standard poly(methyl
methacrylate) (PMMA) plate (Europlast, Aubervilliers, France) and spread homogeneously
across its surface by finger. After spreading, 15 ± 0.5 mg of emulsion remained on the
PPMA plate, which was left to dry under ambient conditions. Four plates were prepared for
each emulsion and the transmission was measured between 290 and 400 nm at six
different locations on the PMMA plate. The SPF was calculated using Equation (3.15) [40]:
∫

(3.15)

∫

where Eλ is the erythemal spectral effectiveness (W ∙ m-2), Sλ is the solar spectral
irradiance (W ∙ m-2 ∙ nm-1), and Tλ is the spectral transmittance of the emulsion.
The UVA-PF was also calculated from the obtained measurements, according to
Equation (3.16) [40]:
∫

(3.16)

∫

The critical wavelength is typically used to evaluate the efficiency of protection in
the UVA region and was determined by using the first value of wavelength for which the
following ratio, R, in Equation (3.17) is ≥ 0.9 [41]:
∫

(3.17)

∫
where Aλ is the absorbance.

127

Chapter 3 – Materials and Methodology

3.5 In Vitro Cell Culture Methods
3.5.1 Materials
Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS), penicillin,
streptomycin, Dulbecco’s Phosphate Buffered Saline (DPBS, with/without Ca2+ and Mg2+),
PBS (without Ca2+ and Mg2+), and trypsin ethylenediaminetetracacetic acid (trypsin–EDTA,
0.05%) were purchased from Life Technologies. DMEM was supplemented with phenol
red, glucose (4.5 g/L), and L-glutamine. Dimethyl sulfoxide (DMSO, ≥99.9%), Trypan blue
solution (0.4%), and denaturated ethanol were purchased from Sigma-Aldrich.
All in vitro cell culture methods were conducted inside a Euroclone – Safemate 1.2
ABC Class II biological safety cabinet.
3.5.2 Cell Lines
Four different cell lines were available for the investigation of biological activity of
selected nanomaterials: two normal cell lines, and two malignant cell lines. The cells were
purchased from the European Collection of Cell Cultures (ECACC) and the American Type
Culture Collection (ATCC).
The four cell lines allow the use of the same growth medium, which results in a
better comparison of biological interactions of the nanomaterials with different cell types,
reducing side effects that may arise due to the use of different medium formulations.
3.5.2.1 Human HaCaT Skin Cells
HaCaT human skin cells are transformed keratinocytes derived from histologically
normal adult skin [42]. The skin cells were used to investigate the biocompatibility of the
materials for sunscreen applications. Information on HaCaT cells is displayed in Table 3.1,
and the cell morphology is shown in Figure 3.17.

128

Chapter 3 – Materials and Methodology

Table 3.1. Information on HaCaT human skin
cells [42].
Species

Human

Origin

Skin

Disease

–

Growth mode

Adherent

Morphology

Fibroblast

200 μm

95% (v/v) growth medium

Freezing

Figure 3.17. Microscopic image of normal

medium

+ 5% (v/v) DMSO

HaCaT human skin cells.

Abbreviation: dimethyl sulfoxide (DMSO)
3.5.2.2 Madin-Darby Canine Kidney (MDCK) Cells
As a second non-malignant cell line, MDCK cells were used, which were derived
from an adult female cocker spaniel [42]. Information on MDCK cells is displayed in Table
3.2, and the cell morphology is shown in Figure 3.18.
Table 3.2. Information on Madin-Darby
canine kidney cells [42].
Species

Dog

Origin

Kidney

Disease

–

Growth mode

Adherent

Morphology

Epithelial

Freezing
medium

200 μm

90% (v/v) growth medium
Figure 3.18. Microscopic image of normal
+ 10% (v/v) DMSO

Madin-Darby canine kidney cells.

Abbreviation: dimethyl sulfoxide (DMSO)
3.5.2.3 9L Rat Brain Tumour Cells
To study the potential selectivity of the tested bioactive NP systems, the
nanomaterials were tested on 9L rat brain tumour cells, which were derived from an N129
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nitrosomethylurea-induced tumour and are known to exhibit extremely high resistance to
both chemotherapy and radiotherapy [42, 43]. Information on 9L cells is displayed in Table
3.3, and the cell morphology is shown in Figure 3.19.
Table 3.3. Information on 9L rat brain tumour
cells [42].
Species

Rat

Origin

Brain

Disease

Glioma

Growth mode

Adherent

Morphology

Fibroblast

200 μm

90% (v/v) growth medium

Freezing

Figure 3.19. Microscopic image of 9L rat

medium

+ 10% (v/v) DMSO

brain tumour cells.

Abbreviation: dimethyl sulfoxide (DMSO)
3.5.2.4 Human MCF-7 Breast Cancer Cells
MCF-7 cells are radiosensitive breast adenocarcinoma cells, which were
established from a 69-year old female [42]. Information on MCF-7 cells is displayed in
Table 3.4, and the cell morphology is shown in Figure 3.20.
Table 3.4. Information on MCF-7 human
breast cancer cells [42].
Species

Human

Origin

Breast

Disease

Adenocarcinoma

Growth mode

Adherent

Morphology

Epithelial

Freezing
medium

200 μm

95% (v/v) growth medium
Figure 3.20. Microscopic image of MCF-7
+ 5% (v/v) DMSO

human breast cancer cells.

Abbreviation: dimethyl sulfoxide (DMSO)
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3.5.3 Subculture of Cells
The cells were routinely maintained in the exponential growth phase in T75 cm 2
cell culture flasks with a vented screw cap (Greiner Bio-one) containing DMEM with phenol
red,

L-glutamine,

and

glucose,

supplemented

with

FBS

(10%

(v/v))

and

penicillin/streptomycin (1% (v/v)). All cell cultures were maintained at 37ᵒC and 5% (v/v)
CO2 in a cell culture incubator (Heracell 150i). The cell concentration ranged between
2 – 4 × 104 cells/cm2, and the cells were passaged after confluence was reached for up to
30 passages.
During a subculture, the growth medium was discarded and the monolayer of cells
was washed twice with 10 mL of pre-warmed DPBS (without Ca2+ and Mg2+). Then, 0.05%
trypsin-EDTA was added and the cells were incubated for 5 – 10 min at 37ᵒC and 5% (v/v)
CO2. After detachment, the trypsin-EDTA was neutralized with pre-warmed complete
growth medium, and an aliquot was taken for a cell count. The desired volume of cell
suspension was then transferred into a new T75 cm2 flask containing 25 mL of fresh
growth medium. All maintained cell cultures were routinely tested for mycoplasma
contamination.
3.5.4 Cell Counting
The concentration of cells in suspension was determined using a Neubauer
haemocytometer. Typically, an equal volume of cell suspension was mixed with a solution
of 0.4% Trypan blue. Then, 10 µL of the mixture was placed inside the counting chamber
and the amount of viable cells was determined (Figure 3.21). Trypan blue is a dye that can
enter dead cells and stains them blue, while viable cells are impermeable and remain clear.
The cell concentration was calculated by only counting the viable cells.
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Figure 3.21. Cell counting using a Neubauer haemocytometer. Adapted from [44].
3.5.5 Cryopreservation of Cells
The cryopreservation of cells includes the freezing and thawing of cells, as further
described below.
3.5.5.1 Freezing of Cells
Prior to freezing, 4 – 6 T75 cm2 flasks were seeded for confluence on the day of
freezing, and their growth medium was replaced 24 h before freezing.
On the day of freezing, the cells, which were in the exponential growth phase, were
washed and trypsinized, as described for the standard subculture. After successful cell
detachment, pre-warmed growth medium was added and the cell concentration was
determined. Meanwhile, the cell suspension was placed on ice, and the cells were
centrifuged at 4°C (Eppendorf, 5 min, 300 – 469 g) to obtain the cell pellet. The
supernatant was discarded and the cell pellet was resuspended in ice-cold freezing
medium (see section 3.5.2) to reach a concentration of 2 – 4 × 106 cells/mL. The freezing
suspension was then transferred into 2 mL Nalgene® cryogenic vials and placed in a
Nalgene® Mr. Frosty freezing container with 250 mL of isopropanol, allowing the cells to
freeze at a cooling rate of 1 – 3°C/min once they were placed in a freezer (-80°C).
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On the next day, the frozen vials were transferred to a permanent gas phase liquid
nitrogen storage vessel. These vials were denoted as the ‘master stock’. To confirm
successful freezing of the cells, a frozen vial of the ‘master stock’ was taken after 24 h
storage inside the liquid nitrogen vessel and thawed. Once viability was confirmed, the
thawed cells represented the ‘working stock’ and were maintained for 30 passages.
3.5.5.2 Thawing of Cells
First, the frozen cryogenic vial was removed from the liquid nitrogen storage vessel
and placed in a 50 mL tube containing pre-warmed 70% ethanol. The tube was then placed
in a water bath at 37°C, where it was left just until the cell suspension was thawed. The
cells were transferred into a new T75 cm2 flask, and pre-warmed, fresh growth medium
was added dropwise to equilibrate the cells to the medium. The cell suspension was gently
mixed and an aliquot was taken for a cell count. The flask was maintained at 37ᵒC and 5%
(v/v) CO2.
On the next day, after the cells had attached to the flask and expelled the DMSO, the
old growth medium was replaced with fresh pre-warmed growth medium. The cell growth
was monitored until a confluence of 80 – 90% was reached, and the cells were passaged.

3.6 In Vitro Biological Characterization
3.6.1 Materials
Hoechst 33342 nucleic acid stain (≥ 98%), propidium iodide (PI, ≥ 94%),
methotrexate hydrate (≥98%), crystal violet solution (2.3% crystal violet, 0.1% ammonium
oxalate, 20% ethyl alcohol), 2’,7’-dichlorodihydrofluorescein diacetate (DCFH2-DA, ≥ 97%),
PBS sachets (pH 7.4), ribonuclease A (RNAse A), Trypan blue solution (0.4%), 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 98%), sodium bicarbonate
(≥ 99.7%), acetic acid (≥ 99.7%), sodium hydroxide (NaOH, 99.99%), methanol (≥ 99.8%),
sodium acetate (≥ 99.0%), sodium carbonate decahydrate (≥ 99.99%), DMSO (≥99.9%),
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and denatured ethanol were purchased from Sigma-Aldrich. DMEM, FBS, penicillin,
streptomycin, DPBS (with/without Ca2+ and Mg2+), PBS (without Ca2+ and Mg2+), and
trypsin–EDTA, 0.05% were purchased from Life Technologies. DMEM was supplemented
with phenol red, glucose (4.5 g/L), and L-glutamine.
TiO2 (Aeroxide®, P25) and ZnO NPs (≤ 100 nm) were obtained from Sigma-Aldrich
and

used

without

further

purification.

Bi(OH)3,

α-Bi2O3,

and

TiO2/(BiO)2CO3

nanocomposites were synthesized (see section 3.1.2, 3.1.3, and 3.1.4).
Stock solutions
Hoechst 33342 (10 mg/mL) and RNAse A (1 mg/mL) were dissolved in DI water;
PI (1 mg/mL) was dissolved in PBS; DCFH2-DA (125 µg/mL) was dissolved in denatured
ethanol. MTT (5 mg/mL) was dissolved in PBS. MTX was dissolved in bicarbonatecarbonate buffer.
3.6.2 Statistical Analysis
Data are presented as means ± standard deviation (SD). Significant differences
between the treatments and the control were evaluated using the one-way analysis of
variances (ANOVA) and Tukey’s multiple comparison test. With P being the probability, a
value of P < 0.05 was considered statistically significant.
3.6.3 Preparation of Nanoparticle Suspensions
All nanomaterials that were used for in vitro biological characterization, were
firstly autoclaved (Getinge, H5 5510 EC1) at 121°C and 15 psi, and then suspended in PBS
(without Ca2+ and Mg2+) at a concentration of 1 mg/mL. The suspensions were sonicated
for 2 h using a sonication bath (Branson 3800, Ultrasonics Corp) and added to the growth
medium to yield concentrations of 6.25 – 500 µg/mL.

134

Chapter 3 – Materials and Methodology

3.6.4 Live Cell Imaging
Live cells were imaged using confocal microscopy and the InuCyte ZOOM system.
While the former one allows high resolution imaging and can give information about the
cellular uptake of NPs, the latter method is used to observe cell growth over time.
Furthermore, both methods allow the use of staining agents such as PI to identify apoptotic
cells [45].
3.6.4.1 Confocal Microscopy
Confocal microscopy is widely used for biological specimens and materials science,
as it offers control of the depth of field, reduced background noise, and the ability to obtain
three-dimensional images. The specimen preparation is similar to that for conventional
fluorescence microscopes and allows imaging of both fixed and living cells and tissues with
multiple thicknesses.
In a traditional wide-field fluorescence microscope, an incoherent mercury or
xenon lamp illuminates the entire specimen, which leads to the excitation of different
optical paths at the same time. The photodetector then detects a large part of the
unfocused background noise, reducing the overall optical resolution, especially in thicker
specimens (> 2 µm). In contrast, the confocal microscope (Figure 3.22) uses point
illumination from a laser, which is reflected by a dichroic mirror, and a spatial pinhole that
blocks out-of-focus light in the image formation process [46, 47]. By using this setup, the
specimen is excited by the light source at one depth at a time, and only photons that are
close to the focal plane are detected, which ultimately results in increased optical
resolution [48].
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Figure 3.22. Working principle of a confocal microscope, adapted from [49].
Live cell images of 9L, MCF-7, and MDCK cells were collected with the confocal
microscope after exposure to the NPs using a Leica – TCS SP5 Advanced System with Live
Cell Imaging (CO2 chamber).
3.6.4.2 Staining with Propidium Iodide
PI is a fluorescent dye that is widely used in fluorescence microscopy, confocal
microscopy, flow cytometry, and fluorometry [45].
PI is membrane-impermeant and reaches the nucleus either by permeabilization of
the cells, or by passing through disordered areas of cell membranes, as shown in Figure
3.23 [50]. Once PI gains access to nucleic acids and intercalates between the base pairs of
the double stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), its
fluorescence is enhanced 20- to 30-fold, which is used to identify dead cells in a cell
population [45, 51].
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Figure 3.23. Working principle of cell staining with propidium iodide.
9L, MCF-7, and MDCK cells were seeded on NuncTM Lab-TekTM Chambered
Coverglass, and Bi(OH)3 and α-Bi2O3 NPs were added at a concentration of 50 μg/mL. The
cells were imaged every 2 – 4 h using confocal microscopy (see section 3.6.4.1) to
investigate when cellular uptake of the NPs begins. The cell viability was determined after
a total exposure time of 24 h was reached by the addition of 10 µM PI 5 min prior to
imaging. The emission images were recorded using Leica LAS X software.
3.6.4.3 IncuCyte ZOOM System
The IncuCyte Zoom system offers real-time and non-invasive imaging of live cells
and can be used to monitor cell growth and workflow, and perform live cell assays [52].
Typically, the cells are seeded and maintained either in microplates, or T25 cm2 or T75 cm2
flasks and placed in the IncuCyte system inside a cell culture incubator at 37°C and 5%
(v/v) CO2. Different objectives are installed underneath the cells, allowing the capture of
bright-field and fluorescence images in a chosen time interval.
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The cell growth was observed for all cell lines using an Essen Bioscience – IncuCyte
ZOOM system with three different approaches: imaging of the separate cultures, the
exchange of growth medium, and co-culturing.
Separate cell cultures
9L, MCF-7, MDCK, and HaCaT cells were seeded in T25 cm2 flasks (Falcon) allowing
for attachment, and suspensions of Bi(OH)3, α-Bi2O3, TiO2, and TiO2/(BiO)2CO3 were added
at a concentration of 50 µg/mL. Upon NP addition, the flasks were instantly placed inside
the IncuCyte system, and live cell images were obtained every 4 h for a total of up to 48 h.
Growth medium exchange
9L cells were first seeded on T25 cm2 flasks and treated with the different NPs for
24 h. Then, the growth medium was removed from the cell culture, centrifuged at 469 g at
room temperature for 5 min, and added to healthy cultures of 9L and MDCK cells, whose
growth medium had been removed in advance. The cell viability was imaged for 24 h.
Co-culture
For the co-culture of 9L and MDCK cells, 9L cells were seeded on T25 cm2 flasks 24
h before the MDCK cells were seeded in the same flask. After another 24 h, the NPs were
added to the culture flask, and the cell viability was imaged for 24 h.
3.6.5 Flow Cytometry
Flow cytometry measures the physical and biochemical characteristics of cells or
particles in suspension and is used for cell counting and cell sorting [53, 54]. Furthermore,
the technique allows the detection of proteins or other biomolecules that bind to specific
cell compartments, such as DNA. With the obtained results, information can be gained
regarding cell cycle kinetics and DNA damage (cell cycle population) [55].
Typically, a flow cytometer consists of three systems: fluidics, optics, and electronic
systems. The sheath fluid (= fluidics system) separates the cells, so that only one cell at a
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time reaches the laser (= optics system), where two observations can be made: first, if the
cells or particles were stained prior to their introduction into the flow cytometer, the
emission of fluorescence can be detected [56, 57] (Figure 3.24). The second detection is the
forward angle scatter (FSC) and side angle scatter (SSC) of light when it hits the cell [54].
The electronic system converts the detected signals into digital data.

Figure 3.24. Schematic illustration of a flow cytometer. Adapted from [58].
The internalization of NPs and the cell cycle population were investigated using a
Becton Dickinson fluorescence-activated cell sorting (FACS) flow cytometer (BD LSR II; BD
Biosciences, USA).
3.6.5.1 Detection of Forward and Side Scatter
When a cell or particle is hit by a focused laser beam, the laser light is scattered in
all directions, as shown in Figure 3.25. While the intensity of the FSC light is proportional
to the size of the cell and does not change with the degree of internalisation, the SSC light is
proportional to the cell granularity and can be used to examine the cellular uptake [59].
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Figure 3.25. Forward and side scatter of radiation hitting a single cell.
9L and MDCK cells were seeded on T12.5 cm2 flasks (Falcon), and suspensions of
Bi(OH)3 and α-Bi2O3 NPs were added at concentrations of 0, 6.25, 12.5, 25, and 50 µg/mL.
After 24 h of NP exposure, the cells were trypsinized, and the cell concentration was
determined. Around 2 × 106 cells were centrifuged at 300 – 469 g at room temperature for
5 min, and the obtained cell pellet was washed twice with PBS (without Ca2+ and Mg2+). The
cell pellet was resuspended in 500 μL PBS, transferred into 5 mL polystyrene flow tubes,
and analyzed with a flow rate of 60 mL/min until 10,000 events were recorded. The degree
of internalization of the NPs was determined with FACSDiva software, where cell doublets
and aggregates were gated out.
3.6.5.2 Cell Cycle Population
The cell cycle population was determined via an assay utilizing cell staining with
the fluorescent dye PI, as further described in section 3.6.4.2. The assay generates a cell
population histogram in respect to the fluorescent intensity of PI, which is correlated with
the amount of DNA within each cell: cells that are in the G0/G1 phase will have half the DNA
of G2 cells or cells in the mitosis stage [60].
In Figure 3.26, the G0/G1 phase is indicated as diploid (2N, with N being the haploid
complement of chromosomes), while the G2/M phase has a tetraploid (4N) DNA content
[60]. Since the cells in the S-phase are replicating, they will have events that are in between
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the G1 and the G2/M phase [60]. The sub G1 level indicates apoptotic cells, since DNA exits
cells after the membrane is made permeable, leading to a decrease in the intracellular
content [61].

Figure 3.26. Schematic illustration of the cell cycle, showing the flow cytometric
components of each phase. Adapted from [60].
The cell cycle population was investigated using a method described in [62]. 9L and
MDCK cells were seeded on T12.5 cm2 flasks and suspensions of Bi(OH)3 and α-Bi2O3 NPs
were added at a concentration of 50 µg/mL. After 24 h of NP exposure, the cells were
trypsinized, and the cell concentration was determined. Around 2 × 106 cells were
centrifuged at 300 – 469 g and 4°C for 5 min and washed twice with ice-cold PBS (without
Ca2+ and Mg2+). The cells were fixed with dropwise addition of 1 mL ice-cold 70% ethanol
and stored at -20ᵒC. After 48 h, the cell suspension was centrifuged and washed twice with
ice-cold PBS. The cell pellet was resuspended in 200 μL of ice-cold PI solution (8 μL of PI
stock solution, 20 μL of RNAse stock solution, and 172 μL of PBS) and transferred into 5
mL polystyrene flow tubes. The flow tubes were incubated for 60 min at 37ᵒC and 5%
(v/v) CO2, and the stained cells were analyzed using a flow rate of 60 mL/min until 10,000
events were recorded. The stained nuclei were analyzed for DNA-PI fluorescence, and the
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population of cells in all phases of the cell cycle (G0/G1, S, and G2/M) was determined with
FACSDiva software.
3.6.6 Cell Survival and Proliferation
Cell survival and proliferation was investigated using the clonogenic assay and the
MTT assay. The clonogenic assay is widely used to evaluate cell survival and proliferation,
since the results have a certain degree of correlation with the clinical response [63]. This
assay is associated with a slow turn-around time, however, and low efficiency, leading to
investigations to find faster and simpler methods to assess drug sensitivity.
The MTT assay is an alternative, which is fast, easy to handle, and widely used in
cell biology [64]. The drug sensitivity was evaluated in five human lung cancer cell lines
using both methods, and it was shown that the correlation coefficient between the results
obtained through the clonogenic assay and MTT assay depend on the tested treatment
[63]. While the correlation coefficient

was high for platinum analogues

(

= 0.939), the correlation decreased for anthracyclines/anthracenedione

(

= 0.611) [63].
In this doctoral thesis, clonogenic assays were used to evaluate cell survival of 9L,

MCF-7, and MDCK cells when exposed to Bi(OH)3 and α-Bi2O3 NPs. The MTT assay was
used to investigate the biocompatibility of TiO2, TiO2/(BiO)2CO3, ZnO, and Bi(OH)3 NPs for
potential sunscreen application in normal HaCaT and MDCK cells. Furthermore, the MTT
assay was utilized in combination with irradiation by simulated sunlight.
3.6.6.1 Clonogenic Survival Assay
The clonogenic survival assay is an in vitro method and based on the ability of a
single cell to form a colony, which is made up of at least 50 cells. Also referred to as the
colony formation assay, this assay is regarded as the gold standard sensitivity assay, which
evaluates every single cell and its capability to theoretically go through unlimited cell
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division [65, 66]. It is the method of choice for investigation of the effects of drugs,
cytotoxic agents, or ionizing radiation on the survival and proliferation of cells [65, 67].
Typically, the clonogenic assay consists of four steps, including the seeding of cells,
their exposure to drugs, cytotoxic agents, or ionizing radiation (for the control = no
exposure), and the incubation of plated cells for fifteen doubling times to allow the growth
of colonies, which, in the last step, are fixed, stained, and counted under a microscope
(Figure 3.27).

Figure 3.27. Schematic procedure of the clonogenic survival assay.
The number of cell colonies is used to determine the surviving fraction (SF in %) of
the cells, which is the ratio of the plating efficiency of the treatment (
efficiency of the control (

), as shown in Equation (3.18) [68]:
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(3.18)

The plating efficiency (PE) is the ratio of counted cell colonies (
initial seeding number (

) to the

), as displayed in Equation (3.19):
(3.19)

Determination of optimum seeding density
To determine the optimum seeding density of cells that yields approximately 100
cell colonies after the incubation for fifteen doubling times, a cloning efficiency test was
performed. Firstly, 9L, MCF-7, and MDCK cells were seeded into T12.5 cm2 flasks (Falcon).
At a confluence of 70 – 90%, the growth medium was discarded, and the cells were gently
washed with DPBS (without Ca2+ and Mg2+). The cells were detached using trypsin-EDTA,
the cell concentration was determined, and the cells were plated in triplicate into 100-mm
tissue culture dishes (BD Falcon), which were filled with 10 mL complete growth medium.
In total, eight densities of cells were chosen for each cell line ranging from 200 to 10,000
cells/plate. The cells were incubated for fifteen doubling times at 37ᵒC and 5% (v/v) CO2
(Heracell 150i). Then, the tissue culture dishes were washed with DPBS (with Ca2+ and
Mg2+) and stained with a solution of 25% crystal violet and 75% ethanol. Cell colonies were
counted by optical microscopy, provided that they contained at least fifty healthy cells.
Treatment with NPs
As described above, 9L and MDCK cells were seeded on T12.5 cm2 flasks, and
suspensions of Bi(OH)3 and α-Bi2O3 NPs were added at concentrations of 0, 6.25, 12.5, 25,
and 50 µg/mL. After 24 h of NP exposure, the growth medium was discarded, and the cells
were washed and trypsinized. The cells were then seeded at low densities (as determined
above) into tissue culture dishes and incubated for fifteen doubling times. For each
treatment, at least three different cell densities were seeded in triplicate. Then, the cells
were fixed and stained, the cell colonies were counted, and the SF was determined.
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3.6.6.2 MTT Proliferation Assay in Absence of Simulated Sunlight
The MTT proliferation assay is a quantitative calorimetric method based on the
reduction of water-soluble yellow tetrazolium salt to water-insoluble purple formazan,
which takes place in mitochondria of viable cells, as shown in Figure 3.28 [69].

Figure 3.28. Working principle of the MTT proliferation assay.
The reduction of MTT to formazan depends on mitochondrial oxidoreductase
enzymes. Since the metabolic activity of dying cells decreases, the amount of produced
formazan is directly proportional to the number of viable cells and can therefore be used to
determine cell viability [69]. The water-insoluble formazan crystals are typically dissolved
using DMSO, an acidified ethanol solution, or a solution of sodium dodecyl sulfate in
diluted hydrochloric acid [69, 70]. The absorbance of the light-sensitive purple solution
can then be determined at a wavelength between 500 – 600 nm, as schematically shown in
Figure 3.29 [70].
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Figure 3.29. Schematic procedure of the MTT proliferation assay.
Determination of optimum seeding density
To determine the optimum seeding density of cells that yields an absorbance of
approximately 1.0 after the incubation with MTT dye, a calibration curve was constructed
based on different seeding densities of HaCaT and MDCK cells. Firstly, the cells were
seeded in a 96-well plate and incubated at 37°C and 5% (v/v) CO2. Before the addition of
MTT, the culture medium was removed from each well and replaced with 100 µL of new
growth medium and 10 µL of MTT stock solution. The plate was incubated for 4 h at 37°C
and 5% (v/v) CO2 until a purple-coloured formazan product was formed. All but 25 µL of
the test solution was removed, and the formazan crystals were dissolved in 100 µL of
DMSO. After incubation at 37°C for 10 min, the well plate was centrifuged at 300 g at room
temperature for 5 min. Then, 100 μL of supernatant was transferred to a new well in a 96-
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well plate, and the absorbance was measured at a wavelength of 540 nm on a SpectraMax
384 Plaus (Molecular Devices) microplate.
Treatment with NPs
HaCaT and MDCK cells were seeded with an optimized seeding density (as
determined above) in 96-well plates and incubated at 37°C and 5% (v/v) CO2. Suspensions
of TiO2, TiO2/(BiO)2CO3, ZnO, and Bi(OH)3 NPs were added to the cells to yield
concentrations of 0, 5, 10, 25, 50, 100, 250, and 500 µg/mL and the cells were incubated for
24 h. As described above, at the end of the exposure, the culture medium was removed,
replaced with fresh medium, and supplemented with MTT. After 4 h of incubation, the
formazan was dissolved in DMSO. The well plate was incubated for 10 min, centrifuged (10
min, 1875 g, room temperature), and the absorbance of the supernatant was measured at
540 nm. The cell viability (in %) is the ratio of absorbance of the treatment (
absorbance of the control (

) to the

), as shown in Equation (3.20):
(3.20)

3.6.6.3 MTT Proliferation Assay under Exposure to Simulated Sunlight
MTT tests were performed with HaCaT cells, which, besides the treatment with
NPs, were irradiated with simulated sunlight. This experimental setup allows investigation
of the effects of photocatalytically active nanomaterials on cell viability.
Degradation of crystal violet
To ensure that the nanomaterials developed sufficient photocatalytic activity, TiO2
NPs were suspended in DPBS (with Ca2+ and Mg2+, 1 mg/mL), sonicated for 2 h, and added
to a solution of crystal violet in DPBS in a 96-well plate at concentrations of 25, 50, and 100
µg/mL. After a dark adsorption of 60 min, the absorbance was measured at 590 nm after
removal of the photocatalyst. The TiO2 NPs were then resuspended in the crystal violet
solution, and the 96-well plate was then placed (without the lid) on an ice block
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underneath the light source (300 W Sunlamp, Ultra-Vitalux®, OSRAM), which was pre-run
for 30 min to ensure stabilization of the output. The light emission profile of the lamp is
shown in Figure 3.30. The light intensity was measured using a calibrated UVA/B light
meter (model 850009, Sper Scientific) and was found to be 6 mW/cm2 at the surface of the
wells. The 96-well plate was irradiated for 15 min, which equals a dose of 5.4 J/cm 2.
Afterwards, the photocatalyst was removed via centrifugation (5 min, 1875 g, room
temperature), the absorbance of the crystal violet solution was measured, and the amount
of degraded crystal violet was determined.

Figure 3.30. Light emission profile of the OSRAM Ultra-Vitalux® 300 W Sunlamp [71].
Exposure of HaCaT cells to simulated sunlight
HaCaT cells were seeded in 96-well plates and the growth medium was replaced
with 100 µL of DPBS prior to the addition of the NP suspensions. Suspensions of TiO2 and
TiO2/(BiO)2CO3 NPs were added to the cells at concentrations of 25, 50, and 100 µg/mL.
This concentration range was chosen to ensure the observation of detectable
photocatalytic effects while keeping the toxicity related to the nanomaterials to a
minimum. The control cells were treated with the equivalent amount of PBS. The cells
were incubated with the NPs for 45 min at 37°C and 5% (v/v) CO2. The culture plate lid
was then removed, and the 96-well plate was placed on an ice block underneath the light
source. The cells were irradiated under the same conditions as described above (for
15 min with simulated sunlight at a light intensity of 6 mW/cm2, which equals a dose of
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5.4 J/cm2). After irradiation, DPBS was replaced with 100 µL of supplemented growth
medium, and the 96-well plate was incubated for 24 h before fresh medium and MTT dye
were added and the absorbance was measured, as described in section 3.6.6.2.
3.6.7 Detection of Intracellular Reactive Oxygen Species
Apoptotic cells are characterized by a change in nuclear morphology, which is
identifiable by fluorescence microscopy after DNA staining. While the budding type is
associated with an ROS-independent pathway of apoptosis, the cleavage type indicates a
ROS-dependent apoptotic pathway [72]. In addition, intracellular ROS can be detected
directly using dyes that show fluorescence changes in presence of ROS [72].
In this thesis, 9L and MDCK cells were double-stained using Hoechst 33342 and
DCFH2-DA. The staining procedure is described in section 3.6.7.1, while further
information on the dyes is provided in sections 3.6.7.2 and 3.6.7.3.
3.6.7.1 Fluorescence Microscopy
Fluorescence microscopy is widely used to not only observe fluorescence in biological
specimens, but also to image live cells and obtain morphological and structural
information. Although some biological structures, such as chlorophyll, have primary
fluorescence, the majority of biological specimens need to be linked with fluorescent
molecules (fluorochromes) to generate fluorescence [73].
Typically, the fluorescence microscope has emission and excitation filters, which
are able to separate the excitation and emission wavelengths, as shown in Figure 3.31 [73].
Since the objective acts as both a condenser lens (excitation light) and an objective lens
(emission light), a dichroic mirror is used to reflect shorter wavelengths of light and allow
longer wavelengths to pass [73]. This epi-illumination type of light pathway provides a
dark background, which in turn increases the visualization of fluorescence. The light
source is typically a mercury or xenon arc lamp [73].

149

Chapter 3 – Materials and Methodology

Figure 3.31. Working principle of a fluorescence microscope, adapted from [74].
First, 9L and MDCK cells were seeded on a NuncTM Lab-TekTM Chambered
Coverglass. Before the addition of Bi(OH)3 or α-Bi2O3 NPs at a concentration of 50 μg/mL
and after 2, 4, 6, 9, 12, 15, 18, 21, and 24 h of NP exposure, the cells were washed with
DPBS (with Ca2+ and Mg2+), stained with Hoechst stain (16 µM), and treated with DCFH2-DA
(10 μM). Emission images were obtained using a Leica – DMi8 fluorescence microscope
with attached environmental chamber (37ᵒC, 5% (v/v) CO2) and Leica LAS X software, as
shown in Figure 3.31. A minimum of 300 cells was counted in at least four randomly
selected microscopic fields, and the fraction of apoptotic nuclei with increased levels of
green fluorescence was determined [72, 75].
3.6.7.2 Staining with Hoechst 33342
Hoechst 33342 can be used for either fixed or live cell fluorescent staining of DNA.
Before it is applied to the biological specimen, the dye is yellow in colour, with excitation at
a wavelength of 350 nm [51]. Once in contact with cells, the cell-membrane-permeable
Hoechst 33342 binds to double-stranded DNA, preferably into the minor groove of
adenine-thymine regions, and emits blue fluorescence at a wavelength of 460 – 490 nm, as
shown in Figure 3.32 [51].
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Figure 3.32. Working principle of nuclear staining with Hoechst 33342 [76].
3.6.7.3 Staining with 2',7'-Dichlorodihydrofluorescein Diacetate
DCFH2-DA is typically used to identify intermediates of ROS in neutrophils and
macrophages. The dye is initially non-fluorescent and can pass through the plasma
membrane, which results in a de-esterification (Figure 3.33, gray marquees, top) and the
formation of 2',7'-dichlorodihydrofluorescein (DCFH2) by cytosolic esterases [75]. The
non-fluorescent DCFH2 undergoes a two-electron oxidation (grey marquees, centre) in the
presence of intracellular ROS to yield 2',7'-dichlorofluorescein (DCF), which is highly
fluorescent [75]. In aqueous solution, DCF has an absorption maximum at 503 nm and an
emission maximum at 523 nm [51]. The green fluorescence is typically monitored by
confocal or fluorescence microscopy, or by flow cytometry [75].
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Figure 3.33. Working principle of cell staining with 2',7'-dichlorodihydrofluorescein
diacetate.
3.6.8 In Vitro Drug Loading and Release Studies
The in vitro drug loading was performed in a solution of MTX with a pH of 7.4,
while the drug release was studied over the period of 72 h in release media (buffer
solutions) with pH of 3.6, 5.4, 7.4, and 9.4. The same buffer solutions were used for the
polymer swelling studies; their preparation is described in section 3.2.11.
3.6.8.1 In Vitro Drug Loading
Anti-cancer drugs such as MTX can be used to develop controllable drug release
delivery systems, which not only increases their efficiency, but could also lower systemic
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toxicity [77]. In this doctoral thesis, a nanocomposite based on δ-Ta2O5 and PAA hydrogel was
placed in a solution of MTX and allowed to swell until equilibrium was reached. This method
allows the preservation of the drug, as opposed to the addition of MTX during the hydrogel
synthesis, which requires temperatures > 80ᵒC [31, 78-80].
For each polymerization time, 200 mg of δ-Ta2O5-PAA NPs was added to 20 mL of a
solution of 10 mg/mL MTX in PBS. For the stock solution, 200 mg of MTX was dissolved in
6.67 mL of carbonate-bicarbonate buffer (pH = 9.4) and diluted with 13.33 mL of PBS. The
suspension was placed on an orbital shaker (Bioline) at a speed of 30 rpm and mixed for a
total of 48 h at 24ᵒC. Then, the suspension was allowed to sediment, and the supernatant
was decanted. The soaked NPs were rinsed with PBS and dried under vacuum until the
weight remained constant. The loading capacity (LC) was calculated using Equation (3.21),
and the entrapment efficiency (EE) was determined via Equation (3.22):
( )
( )

( )

(3.21)

( )

( )

( )

(3.22)

3.6.8.2 In Vitro Drug Release
To study the release profiles for the MTX-loaded δ-Ta2O5-PAA NPs, 10 mg of the dry
MTX-loaded NPs was added into glass vials, to which 10 mL of release medium was added.
The release medium varied in pH value (pH: 3.6, 5.4, 7.4, and 9.4). The reaction vials were
placed on an orbital shaker at a rotation rate of 50 rpm and a constant temperature of 37 ±
1ᵒC. After predetermined time intervals (0, 15, 30, 45 min, and 1, 2, 6, 12, 24, and 72 h), the
suspension was allowed to sediment for 2 min, and 5 mL aliquots were taken. UV-vis
spectroscopy was used to determine the concentration of MTX present in the supernatant
at a wavelength of 303 nm [81]. The absorbance was recorded on an UV-3600
spectrophotometer from Shimadzu over the range of 800 to 200 nm.
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To determine the concentration of MTX, a calibration curve was established with
MTX solutions of known concentration. The total amount of soaked MTX was estimated by
centrifugation of the 72 h sample at 5208 g for 10 min (room temperature). The remaining
pellet was suspended in 0.1 M NaOH and sonicated for 1 h. Then, methanol was added to
the solution, which was sonicated for an additional 1 h before the absorbance was
measured at 303 nm [81].
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4.1 Introduction
One of the major issues for the implementation and use of nanomaterials in
nanomedicine is nanotoxicity. Bismuth and its compounds are considered to be the least
toxic of the heavy metals. The study of toxicity of Bi (III) nitrate in human proximal tubular
cells showed the biocompatibility of Bi, even at the highest tested dose of 100 mM [1].
Bismuth is reasonably cheap, available in great amounts and many of its
compounds have already been used in medicines or cosmetics. Inorganic Bi salts, such as
bismuth subsalicylate (Pepto-Bismol®), tripotassium dicitrato bismuthate (De-Nol®), and
ranitidine bismuth citrate (Tritec®) are used for the treatment and prevention of gastric
and duodenal ulcers (Figure 4.1) [2]. Bismuth oxychloride (BiOCl) is used in mineral
powder in makeup, and bismuth (III) oxide (Bi2O3) has been used as an astringent [3, 4].

Figure 4.1. Commercially available (a) Pepto-Bismol® and (b) De-Nol® [5, 6].
Organobismuth compounds have antifungal and antimicrobial activity [7], and
have shown anti-tumour effects in various human cancer cell lines [7, 8]. Heterocyclic
organobismuth (III) can induce increased levels of intracellular ROS and the activation of
cascades and mitochondrial perturbations [7]. Bismuth (III) dithiocarbamate complexes
have been shown to be more effective than cisplatin, DOX, 5-FU, and etoposide, and in vivo
studies indicate significant anticancer activity against ovarian cancer OVCAR-3 and colon
carcinoma HT-29 cells [9].
Although organobismuth compounds are promising candidates for cancer
therapies, they are usually structurally complex, and their synthesis involves multiple
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steps [7, 8, 10]. For example, the molecular structure of PhBi(MeOx)2 is shown in Figure
4.2. Moreover, these compounds are chemically and physically less stable compared to
inorganic Bi compounds, which makes the latter ones preferable for further study [11].

Figure 4.2. Molecular structure of PhBi(MeOx)2. An X-ray crystallographic study has
shown that the molecule is a five coordinate monomer with distorted square pyramidal
stereochemistry. Adapted from [8].
4.1.1 Properties of Bismuth-Based Compounds
In this doctoral thesis, Bi(OH)3 and α-Bi2O3 NPs and nanocomposites based on TiO2
and (BiO)2CO3 have been synthesized and characterized. The properties of these Bi-based
compounds are described below.
4.1.1.1 Properties of Bi(OH)3
Bismuth (III) hydroxide (Bi(OH)3) is also found under the name of bismuth hydrate,
bismuth oxide hydrate, and bismuth oxyhydrate, and is typically a colourless powder [1214]. Little is known regarding its structure with early claims of the compound being
amorphous [13-16]. Later studies, however, suggested that crystalline forms of Bi(OH)3
exist [13, 14, 17], the formula of which can also be written as [

] (

) ×

,

underlining its structural relationship to the layered bismuth oxyhalides. In particular, its
structure is comprised of (

)– groups that are adjusted between layers of (

)

[13,

14]. Bi(OH)3 crystallizes in the tetragonal space group P4/mmm, as observed for bismuth
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oxychloride (BiOCl) [14]. Since no reference data exists for Bi(OH)3, Figure 4.3 displays a
projected ball model of BiOCl with (Bi2O2)2+ layers interleaved by slabs comprising Cl– ions.

Figure 4.3. Ball model of BiOCl; obtained via Materials Studio software using
Crystallography Open Database file 1011175.
It has been shown that the reflections in its X-ray diffraction pattern are broadened
when it is milled in a high energy ball miller for 15 min, reducing the particle size from 100
μm initially to sub-micrometre and nanosize [17].
Bi(OH)3 NPs can be synthesized using classical precipitation, where a base such as
ammonium hydroxide (Equation (4.1)) or sodium hydroxide (Equation (4.2)) is added to a
solution of bismuth (III) nitrate [18-20]:
(

)

(

)

(

)

→

(

)

( )

(

)

(

)

→

(

)

( )

(

)

(4.1)
(4.2)

Bi(OH)3 has also been synthesized via a hydrothermal method using bismuth (III) nitrate,
calcium nitrate, and ammonium hydroxide, yielding plate-like particles with a width of
approximately 10 nm and lengths on the microscale [14].
Applications
Bi(OH)3 is an inorganic intermediate usually that is used to obtain α-Bi2O3 after
annealing at 300°C [18, 19], or in compounds, such as bismuth subcarbonate ((BiO)2CO3)
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[21] and bismuth titanate (Bi4Ti3O12) [22]. It is also used on its own as a pigment, or in
various applications such as glasses and ceramics [12, 23]. A recent study shows an
attempt to synthesize nano-energetic systems based on aluminium and Bi(OH)3 (AlBi(OH)3) [17].
Furthermore, Bi(OH)3 has been used in combination with BiOCl to form
heterojunctions, which have been studied for their photocatalytic activity towards the
degradation of rhodamine B and acetophenone [13, 14]. While Bi(OH)3 and BiOCl showed
negligible efficiency, their heterojunction exhibited significant photoactivity [13, 14]. The
band gap of Bi(OH)3 has been determined theoretically with a band gap of 2.81 eV [13, 14].
Bi(OH)3 has already been used for biomedical applications, underlining its great
potential. A suspension of (BiO)2CO3 and Bi(OH)3 in water is typically used in milk of
bismuth, a protective agent used in the treatment of gastrointestinal diseases [24].
4.1.1.2 Properties of Bi2O3
Bismuth (III) oxide can exist in six crystalline polymorphic forms, most of which
are not stable at room temperature (Table 4.1).
Table 4.1. Polymorphs of Bi2O3 and the corresponding crystal systems and space groups.
Polymorph

Stability

Crystal system

Space group

References

α-Bi2O3

Stable

Monoclinic

P21/c

[25, 26]

β- Bi2O3

Metastable

Tetragonal

δ- Bi2O3

Stable

Face-centered cubic

̅

[27]

γ-Bi2O3

Metastable

Body-centered cubic

I23

[28]

ε- Bi2O3

Metastable

Orthorhombic

Pbnb

[27]

ω-Bi2O3

Metastable

Triclinic

P1

[29]
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At room temperature, only the α-Bi2O3 is stable, which when heated up to 727 °C
phase transitions into δ-Bi2O3, followed by a melting of Bi2O3 at 825°C [30, 31]. The crystal
structure of α-Bi2O3 is displayed in Figure 4.4.

Figure 4.4. Crystal structure of α-Bi2O3; obtained via Materials Studio software with data
from [32].
If δ-Bi2O3 is cooled to 639°C, a phase transition to γ-Bi2O3 occurs, after which – if
not cooled slowly enough – it transforms to the α-Bi2O3 at 500°C [26]. If δ-Bi2O3 is cooled to
639°C, a phase transition to β-Bi2O3 occurs, which is transformed to α-Bi2O3 at 303°C [26].
ε-Bi2O3 and ω-Bi2O3 have been obtained through hydrothermal treatment and the heating
of α-Bi2O3 on a beryllium oxide substrate to 800°C, respectively [27, 29].
Depending on the synthesis method, Bi2O3 has been obtained in several sizes and
shapes. The different synthesis strategies are mainly divided into four methods:


Classical precipitation [15],



Flame spray pyrolysis [33],



Solution combustion [34], and



Electrodeposition [35].

Stable α-Bi2O3 NPs are typically synthesized using classical precipitation and
further annealing of the obtained Bi(OH)3 NPs at temperatures above 300°C [18, 19]. This
synthesis method yields plate- or needle-like particles with a mean particle size of 50 nm
[36]. Although the use of sodium hydroxide as precipitating agent is associated with
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impurities such as sodium ions, it has been shown that, by using an additional ageing
process, crystalline α-Bi2O3 NPs can be obtained without annealing [37, 38].
By adding additional surfactants and dispersants to the precipitation, the shape
and size of α-Bi2O3 NPs can be controlled. For instance, the addition of PEG yields spherical
α-Bi2O3 NPs with a mean particle size of 60 nm [39]. Granular α-Bi2O3 NPs with a mean
particle size of 40 – 100 nm have been synthesized using polyvinylpyrrolidone (PVP) as an
additional dispersant, and the use of oleic acid resulted in α-Bi2O3 nanowires [38, 40].
Applications
Bi2O3 has unique optical, electrical, and ion-conducting properties and exhibits a
high refractive index, as well as high dielectric permittivity, photoconductivity, and
photoluminescence [41]. Its band gap depends on the particular polymorph and varies
between 2.00 – 3.96 eV [30] with α-Bi2O3 being a semiconductor with a direct band gap of
2.80 – 2.85 eV [40, 42]. All these unique properties make Bi2O3 a versatile material that has
been investigated for several applications, including superconductors [43], solid-state
electrolytes [41], electrical ceramics [44], gas sensors [38, 45], and photocatalysis [40, 46].
A recent study suggests dependence of the toxicity of α-Bi2O3 NPs on the processing
conditions, particularly the annealing atmosphere. It has been shown that annealing in
argon results in oxygen deficiency, which can in turn alter the intracellular interactions of
α-Bi2O3 NPs [47]. Compared to air-annealed α-Bi2O3 NPs, which showed biocompatibility of
70% and 80% in 9L glioma malignant cells and Madin-Darby Canine Kidney (MDCK) cells,
respectively, the argon-annealed α-Bi2O3 demonstrated biocompatibility of over 100% in
both cell lines [47]. It is assumed that the oxygen vacancies that are located on the surface
of the argon-annealed α-Bi2O3 are able to scavenge free ROS, which are typically associated
with NP toxicity [47].
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4.1.1.3 Properties of (BiO)2CO3
Bismuth carbonate, also known as bismuth subcarbonate, with the molecular
formula (BiO)2CO3 or Bi2O2CO3, crystallizes in the orthorhombic space group Imm2 [48].
Figure 4.5 shows a projected ball model of (BiO)2CO3 with (Bi2O2)2+ layers interleaved by
slabs comprising CO32– groups [49].

Figure 4.5. Ball model of (BiO)2CO3; obtained via Materials Studio software using
Crystallography Open Database file 9004677.
Several different synthesis methods have been reported to obtain (BiO)2CO3 NPs
with different particle sizes and structures, including nanotubes, nanoplates, nanosheets,
and hollow microspheres [50]. In the field of photocatalysis, more complex structures of
(BiO)2CO3 have been developed with flower- and persimmon-like morphologies. The
synthesis methods include:


Hydrothermal and solvothermal synthesis [21, 51],



Reflux method [52], and



One-pot template-free synthesis methods [53].
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In general, a precursor like bismuth citrate or bismuth nitrate is mixed with
reagents such as sodium carbonate, ammonium carbonate, and urea, which are further
accompanied by the addition of surfactants such as cetyltrimethylammonium bromide
(CTAB) to improve the uniformity of (BiO)2CO3 in size and shape [50]. A very simple
approach involves the refluxing of bismuth citrate and urea in ethylene glycol, yielding
(BiO)2CO3 nanotubes [52]. Nanostructures are also obtained via hydrothermal and
solvolthermal synthesis, whereas the one-pot template-free synthesis method typically
yields microstructures of (BiO)2CO3 [50].
Applications
(BiO)2CO3 has been widely investigated as an ingredient in protective agents for
gastrointestinal diseases [24], as filler in radiopaque catheters [54], and in pollution
prevention, as it shows photocatalytic and antibacterial activity [21, 52]. Moreover, it is
well known that the carbonate ion acts as a hydroxyl radical scavenger, reducing the
degradation of organic molecules in waste water (see section 2.3.4.4) [55, 56].
(BiO)2CO3 has a large band gap (2.9 – 3.6 eV) that is tuneable, depending on its
morphological properties [50]. Diverse (BiO)2CO3 nanostructures have been synthesized
and studied regarding their photocatalytic activity, using dyes such as rhodamine B, methyl
orange, and methylene blue [50, 51, 57]. The photocatalytic activity of (BiO)2CO3 has
typically been reported for a large concentration of the active material, 1 g/L [51, 58].
(BiO)2CO3 has been further investigated in combination with other materials to
form BiVO4/(BiO)2CO3 nanocomposites [59], (BiO)2CO3/BiOI heterojunctions [60], and αBi2O3/(BiO)2CO3 heterojunctions [61] as efficient photocatalysts for the removal of toxic
pollutants. Recently, a graphene and TiO2 co-modified (BiO)2CO3 heterojunction composite
was developed that displays a higher photocatalytic activity than the individual
compounds [62].
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4.1.2 Diagnostic Properties
Bi-based compounds have a high effective atomic number of Z = 83, making them
potential candidates for radiation-dose enhancement in radiation therapy. Furthermore,
Bi-based diagnostic agents are promising candidates to replace iodine-based CT contrast
agents, as well as gold and platinum NPs [63]. Bismuth NPs and bismuth(III) ions have
shown a significantly greater X-ray attenuation than iodine, particularly for large tube
potentials, which are used in clinical CT scanners [64]. Similarly, biocompatible dendrimerand polymer-stabilized bismuth sulphide NPs exhibit greater X-ray attenuation than
iodine-based CT contrast agents at the same molar concentration of the active element [65,
66]. For instance, PVP-coated Bi2S3 NPs displayed a fivefold better X-ray absorption than
iodine and experiments in mice indicate a good performance of the PVP-coated Bi2S3 NPs
as a blood pool agent [66]. In a different study, human-serum-albumin-coated Bi2O3 NPs
were explored as a contrast agent for X-ray imaging [67]. Moreover, Bi-based compounds
are known to exhibit contrast enhancement that varies little with the X-ray tube potential
[63, 64, 68].
Besides the use of single Bi-based compounds, the combination of BiOCl/Bi2O3
encapsulated in single-walled carbon nanotubes (~50 nm) has been investigated for
improved X-ray CT imaging in pig-bone-marrow-derived mesenchymal stem cells [69].
Moreover, these multifunctional materials showed high biocompatibility in vitro. Other
multifunctional nanohybrids are based on bismuth and iron and can provide, besides CT
contrast enhancement, also MRI contrast enhancement [68].

4.2 High Toxicity of Bi(OH)3 and α-Bi2O3 Nanoparticles Towards
Malignant 9L and MCF-7 Cells
This section discussed the materials characterization of Bi(OH)3 and α-Bi2O3 NPs,
which were obtained through a facile synthesis with an average single particle size of 6 –
10 nm. The synthesis procedure and all characterization methods are described in
171

Chapter 4 – Bismuth-Based Compounds for Biomedical Applications

CHAPTER 3. The antitumor activity of the Bi(OH)3 and α-Bi2O3 NPs was determined in vitro
using two different tumour cell lines: 9L gliosarcoma cells and MCF-7 human breast cancer
cells, exposed to the NPs with different concentrations. Biological interactions were also
studied in normal MDCK cells. The 9L cells have a fibroblast-like morphology and were
chosen due to their high radio-resistance and their use for both in vivo and in vitro models
[70]. MCF-7 cells were chosen as a human cancer cell line with epithelial-like morphology.
Apoptotic nuclear morphologies were determined in 9L cells using a double labelling with
Hoechst dye and DCFH2-DA.
4.2.1 Identification, Size, Morphology, and Surface Composition of Bi(OH)3 and
α-Bi2O3 Nanoparticles
The XRD patterns of the obtained nanomaterials are shown in Figure 4.6. The
diffraction pattern of the non-annealed Bi-based compound matches the XRD pattern
obtained elsewhere [17], which identifies the material as bismuth hydroxide. The annealed
material is identified as single phase α-Bi2O3 (JCPDS 01-076-1730), which is the most
stable polymorphic form at room temperature [71]. Since Bi(OH)3 is structurally not yet
well defined, no JCPDS file was found in literature, and Miller indices could not be assigned
to the reflections.

Figure 4.6. XRD patterns of Bi(OH)3 and α-Bi2O3 nanoparticles.
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Figure 4.7 presents TEM and high-angle angular dark-field (HAADF) images of both
nanomaterials. The average single particle size is 6.04 ± 0.89 nm for Bi(OH)3 and 10.13 ±
0.95 nm for α-Bi2O3, with round and ellipsoidal shape (left images). The HAADF images
(right images) show α-Bi2O3 NPs with interplanar spacing of 0.332 nm, which is in
accordance with the d-spacing of the (111) plane.

Figure 4.7. TEM (left) and HAADF STEM (right) images of (a) Bi(OH)3 NPs and (b) α-Bi2O3
NPs. The HAADF image of Bi(OH)3 NPs exposes lattice fringes spaces of 0.263 and 0.275
nm. The HAADF image of α-Bi2O3 NPs exposes lattice fringes spaces of 0.332 nm that
correspond to (111) planes.
Dynamic light scattering analysis was performed directly after sonication, in order
to examine the hydrodynamic diameters of both nanomaterials suspended in PBS; the
intensity-based size distributions of the particles are shown in Table 4.2. The results show
that both nanomaterials are present in form agglomerates: some of them are still in
nanoscale and some have sizes larger than 100 nm. The original dynamic light scattering
data is displayed in Figure 4.8. Although the stability of the NPs could potentially be
improved by stabilizing agents [72], the goal of this doctoral thesis was to avoid possible
effects of stabilizing agents on the cellular experiments, and to only study the interactions
of pristine Bi(OH)3 and Bi2O3 NPs with the cells.
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Table 4.2. Hydrodynamic diameters and intensities (Int) of Bi(OH)3 and α-Bi2O3
nanoparticles suspended in PBS after 2 h of sonication, determined via dynamic light
scattering. The concentration of both materials is 50 μg/mL.
Sample

Peak 1 (nm)

Int 1

Peak 2 (nm)

Int 2

Peak 3 (nm)

Int 3

Bi(OH)3

26.8 ± 2.0

6.3%

200.4 ± 23.8

24.3%

679.8 ± 121.1

69.4%

α-Bi2O3

86.4 ± 8.9

10.2%

322.5 ± 57.9

89.8%

Figure 4.8. Hydrodynamic diameter in PBS determined via dynamic light scattering of (a)
Bi(OH)3 and (b) α-Bi2O3 nanoparticles. The concentration of both nanomaterials is 50
μg/mL.
XPS was performed in order to investigate both the surface composition and the
properties within the nanomaterials. The high-resolution XPS spectra of the Bi 4f peak are
displayed in Figure 4.9(a). The peaks located at 158.10 ± 0.28 eV and 164.36 ± 0.75 eV can
be assigned to the binding energies of Bi 4f7/2 and Bi 4f5/2, respectively, with a separation of
6.26 ± 0.03 eV and full-width at half-maximum (FWHM) of 2.14 (58%) and 2.06 (42%) eV
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for the Bi(OH)3 NPs, and 2.26 (59%) and 2.07 (41%) eV for the α-Bi2O3 NPs [73, 74]. These
symmetric peaks are ascribed to Bi3+ ions in the Bi–O bonds, whereas no peaks with an
asymmetric shape could be identified as corresponding to metallic Bi [74].
Two Gaussian peaks were used to fit the experimental data in the high-resolution
XPS spectra of O 1s (Figure 4.9(b)). The peak at the lower binding energy of 530.23 ± 0.04
eV with a Full Width at Half Maximum (FWHM) of 2.77 eV (Bi(OH)3) and 2.9 eV (α-Bi2O3)
can be assigned to O2- ions in the Bi–O bonds [74]. A major O 1s peak at the binding energy
of 532.61 ± 0.13 eV (FWHM = 2.73 eV (Bi(OH)3) and 3.3 eV (α-Bi2O3)) can be identified as
onto the NP surface absorbed hydroxide species, as described for other metal oxides [74,
75]. The spectral area of the higher binding energy peak is significantly larger for the
Bi(OH)3 NPs, with 52% of the total O 1s area as compared to α-Bi2O3 NPs with 41%, which
can be explained by the presence of more hydroxyl groups on the surface of Bi(OH)3. The
XPS survey spectra and high-resolution XPS spectra of N 1s and C 1s are displayed in
Figure A1 in the Appendix I.

Figure 4.9. High-resolution XPS spectra of (a) Bi 4f and (b) O 1s of Bi(OH)3 (top) and αBi2O3 (bottom) nanoparticles.
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4.2.2 Cellular Uptake of Bi(OH)3 and α-Bi2O3 Nanoparticles
The relative cellular uptake was examined by comparing the mean SSC of the
untreated 9L, MCF-7, and MDCK cells with the mean SSC of the cells treated with either
Bi(OH)3 or α-Bi2O3 NPs at concentrations of 6.25, 12.5, 25, and 50 µg/mL after 24 h
exposure (Figure 4.10).

Figure 4.10. Relative internalization of Bi(OH)3 and α-Bi2O3 nanoparticles in 9L, MCF-7,
and MDCK cells after 24 h of exposure, with concentrations of nanoparticles of 0, 6.25,
12.5, 25, and 50 µg/mL, obtained through flow cytometry.
In general, the internalization of both nanomaterials increased relative to the
control and was dose-dependent. Furthermore, both NPs show a very similar relative
internalization in 9L and MCF-7 cells with the Bi(OH)3 NPs displaying a slightly greater
uptake compared to α-Bi2O3 NPs. In contrast, the nanomaterials show only a moderate
cellular uptake in MDCK cells.
Figure 4.11 displays live cell confocal images of 9L, MCF-7, and MDCK cells, nontreated and treated with Bi(OH)3 and α-Bi2O3 NPs at a concentration of 50 µg/mL. The
images are representative for a large number of cells and have been chosen to visually
show the uptake of the NPs into the cells. An exposure time of 4 – 8 h was chosen, since
significant changes in cellular uptake of both NPs were already observable. For both
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materials, all NPs initially within a certain distance of the cell were internalized into 9L
cells (top row, centre image), as indicated by the particle-free space around the cells.
Similar observations have been made with 1,2-dilauroyl-sn-glycero-3-phosphocholinemodified (DLPC-modified) bismuth NPs (denoted as Bi@DLPC NPs) towards MDA-MB-231
cells (breast cancer cells) [76].

Figure 4.11. Confocal images of 9L (top row), MCF-7 (centre row), and MDCK (bottom
row) cells without nanoparticles (control, left column), with Bi(OH)3 nanoparticles (centre
column), and with α-Bi2O3 nanoparticles (right column). The concentration of both
nanomaterials was 50 μg/mL, and the incubation time was 4 – 8 h. The black arrows
indicate non-internalized nanoparticles, while the red arrow show internalized
nanoparticles. The insets in each image show a close-up of a single cell.
Compared with 9L cells, it appears that the NPs do not internalize as fast into MCF7 cells, as indicated by the visibly larger amount of NPs located ultimately next to the cells
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for this early stage of NP incubation time (centre row, centre image). A similar trend is
observed for MDCK cells, in which the NPs do not internalize easily. These observations are
in agreement with the relative internalization obtained via flow cytometry.
4.2.3 Cytotoxicity of Bi(OH)3 and α-Bi2O3 Nanoparticles
In addition to the lactate dehydrogenase assay, the clonogenic assay is also used to
assess biocompatibility of NPs [76-81]. The surviving fractions of 9L, MCF-7, and MDCK
cells after 24 h treatment with Bi(OH)3 and α-Bi2O3 NPs at concentrations of 0 (control),
6.25, 12.5, 25, and 50 µg/mL using the clonogenic assay method are illustrated in Figure
4.12.
For both materials, the surviving fractions of the malignant cell lines significantly
decrease at higher concentrations of NPs, with a value of < 1% and < 10% in 9L and MCF-7
cells, respectively, at 50 µg/mL. This value was therefore chosen as a standard
concentration for further biological characterization. The IC50 values are shown in Table
4.3.
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Figure 4.12. Clonogenic assay of (a) 9L, (b) MCF-7, and (c) MDCK cells after 24 h exposure
with Bi(OH)3 and α-Bi2O3 nanoparticles at concentrations of 0, 6.25, 12.5, 25, and 50
µg/mL. The cells were trypsinized, plated at low density into 100 mm Petri dishes, and
incubated for 15 doubling times at 37°C and 5% (v/v) CO2. The surviving fraction was
obtained by comparing the plating efficiencies of the control and the treatment samples.
The * indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001, and **** indicates P <
0.0001 for the comparison with the ‘control’ (0 μg/mL). The b indicates P < 0.05, bb
indicates P < 0.01, bbb indicates P < 0.001, and bbbb indicates P < 0.0001 for the
comparison between the treatments (ns = not significant).
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Table 4.3. IC50 values for the inhibition of colony number of 9L, MCF-7, and MDCK cell
lines following exposure to Bi(OH)3 and α-Bi2O3 nanoparticles for 24 h.
Cell line

IC50 (µg/mL)
Bi(OH)3

α-Bi2O3

9L

6.35 ± 1.53

7.18 ± 0.94

MCF-7

16.80 ± 0.87

16.53 ± 0.79

MDCK

> 50

> 50

Organic bismuth compounds have been studied in breast (MDA-MB-435S, MCF-7,
EVSA-T), colon (Colo201, DLS-1, WIDR), renal (A498), pancreatic (MIA paca), lung (H226,
A549, H596), gastric (KATO3), cervical (Hela), and ovarian (IGROV) cancer, and
neuroblastoma (SK-N-SH), osteosarcoma (MG-63), fibrosarcoma (HT1080), and melanoma
(M19) [7, 82]. The greatest potency was observed against IGROV and MCF-7 cells, with IC50
values of < 0.005 μM and < 0.004 μM, respectively.
It was shown that Bi@DLPC NPs displayed negligible cytotoxicity towards MDAMB-231 and MCF-10A cells (breast epithelial cells) at concentrations of 0 – 500 μg/mL,
with a cell viability of 87% at the highest concentration [76]. Only when in combination
with near-infrared laser irradiation did the number of dead cells in MDA-MB-231 increase
[76]. Similarly, a theranostic system based on Bi NPs, which have been capped with thiol
ligands and surface-modified with poly(ethylene-glycol)-modified phospholipids (denoted
as Bi-SR-PEG NPs) showed no significant toxicity (< 10%) in murine breast cancer 4T1
cells, even at the highest concentration of 100 μg/mL [83], which emphasizes the use of Bi
NPs for biological application. Only after additional exposure of the cells and NPs to X-ray
irradiation with different radiation doses (0, 2, 4, and 6 Gy), did the surviving fraction
decrease to ~10% at the highest dose [83].
α-Bi2O3 NPs with a particle size of 50 – 80 nm have been studied in 9L cells and
exhibited a cytotoxicity of ≤ 30% at a concentration of 50 μg/mL. The difference in
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cytotoxicity, compared to our study, is possibly related to differences in the single particle
size of the NPs and their suspension preparation [78]. It has been shown that the
optimization of dispersion method is crucial for biological in vivo and in vitro studies [84].
Bi(OH)3 has been studied in L1210 mouse leukaemia cells and showed an IC50 > 5 μM. The
study, however, does not mention any structural, morphological or physical properties of
the Bi(OH)3 particles [8].
In this thesis, Bi(OH)3 NPs are very potent towards 9L and MCF-7 cells, even at the
lowest tested concentration. In contrast, CeO2 NPs for instance, showed a surviving fraction
of 9L cells of > 90% and > 60% after NP exposure for 24 h at a concentration of 50 and 500
µg/mL, respectively [85]. Even the additional irradiation of 9L cells exposed to CeO2 NPs
with 10 MV or 150 kVp X-ray beams with an absorbed dose up to 8 Gy did not yield in the
same mortality as observed for the Bi(OH)3 and α-Bi2O3 NPs.
Similarly, gold and silver NPs show a significantly reduced toxicity in MCF-7 cells
[86, 87]. For instance, the use of gold NPs at a concentration of 25 and 50 µg/mL yielded in
cell viability greater than 80 and 70%, respectively. Even the highest tested dose of 200
µg/mL did not result in cell viability lower than 50% [86]. In another study, the cell
viability of gold NPs was tested at concentrations of 0 – 200 μM/mL, and no significant
toxicity was observed, even at the highest concentration [87]. Similarly, the 24 h exposure
of MCF-7 cells to silver NPs at a concentration of 50 µg/mL resulted in cell viability greater
than 50% [88].
The use of ZnO NPs was shown to cause a toxicity similar to the one observed for
Bi(OH)3 and α-Bi2O3 NPs at a concentration of 25 and 50 µg/mL [89]. However, at lower
concentrations (< 12.5 µg/mL) the Bi(OH)3 NPs show a significantly increased efficiency
towards MCF-7 cells, in comparison to ZnO NPs, which highlights the overall high potency
of both Bi(OH)3 and α-Bi2O3 NPs towards 9L and MCF-7 cells. More importantly, this high
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potency is achieved without further treatment such as X-ray or near-infrared irradiation,
as for Bi@DLPC and Bi-SR-PEG NPs [76, 83].
In addition, both nanomaterials show a very low-to-moderate toxicity in MDCK
cells for the highest concentration of 50 µg/mL, with a surviving fraction of up to 95%
(Bi(OH)3) and 58% (α-Bi2O3), which could be related to the low internalization of the
nanomaterials. The biocompatibility of Bi-based NPs has been reported widely [76, 83].
4.2.4 Staining with Propidium Iodide
Figure 4.13 shows confocal images of 9L, MCF-7, and MDCK cells that were
untreated and treated with each NP at a concentration of 50 μg/mL and with the DNA stain
PI. After 24 h exposure of 9L cells to Bi(OH)3 NPs (Figure 4.13(a), centre column) and αBi2O3 NPs (right column), a significant number of cells with disordered areas of
dysfunctional cell membranes can be identified, whereas control 9L cells do not exhibit any
fluorescence (left column). Interestingly, the incubation with α-Bi2O3 NPs leads to a greater
number of cells with dysfunctional membranes than the exposure to Bi(OH)3 NPs, which
can be explained by a faster killing mechanism, since the clonogenic assays show a similar
high toxicity for both materials, with even higher mortality rates for the Bi(OH)3 NPs.
In contrast to 9L cells, the DNA stain with PI shows a reduced number of
dysfunctional cell membranes in MCF-7 cells (Figure 4.13(b)), indicating that the
mechanism of killing is slower than for 9L cells. The DNA stain with PI shows no noticeable
or only a very small number of dysfunctional cell membranes in MDCK cells for the Bi(OH)3
and α-Bi2O3 NPs, respectively (Figure 4.13(c)).
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Figure 4.13. Confocal images of (a) 9L, (b) MCF-7, and (c) MDCK cells stained with
propidium iodide without additives (control, left column) and after 24 h of incubation with
Bi(OH)3 nanoparticles (centre column) and α-Bi2O3 nanoparticles (right column). The
concentration of both nanomaterials was 50 μg/mL.
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To examine when cell death starts, 9L, MCF-7, and MDCK cells were imaged
repeatedly every 4 h for a total of 48 h after addition of Bi(OH)3 and α-Bi2O3 NPs at a
concentration of 50 μg/mL. After addition of the NPs, the 9L cells maintain their capacity to
grow and proliferate until an incubation time of 12 h (Bi(OH)3) and 8 h (α-Bi2O3) is reached
(Figures A2 – A4 in the Appendix I) [90-92]. Most of the cells start to lose their viability,
after approximately 20 h (Bi(OH)3) and 16 h (α-Bi2O3). Moreover, the cells do not recover
over the total incubation time of 48 h. In general, the α-Bi2O3 NPs show faster cell death,
which is in agreement with the results from the PI stain.
In contrast to 9L, MCF-7 and MDCK cells show a high viability over the whole
exposure of 48 h (Figures A5 – A10 in the Appendix I); however, the capacity of MCF-7 cells
to grow and proliferate seems to be reduced compared with control cells that were not
exposed to the nanomaterials [90-92].
4.2.5 Cell Cycle Population
Flow cytometry analysis was used to determine the DNA content and cell cycle of
9L (Figure 4.14(a)), MCF-7 (Figure 4.14(b)), and MDCK (Figure 4.14(c)) cells, untreated
(left panels) and treated with Bi(OH)3 (centre panels) and α-Bi2O3 (right panels) NPs at a
concentration of 50 μg/mL. The percentage of cells with apoptotic sub-G1 DNA content is
significantly increased for NP-treated 9L cells from 2.4 ± 0.9% for the control, to 22.0 ±
7.7% and 16.4 ± 5.8% for the treatment with Bi(OH)3 and α-Bi2O3 NPs, respectively. In
addition, the population of the G1 phase is significantly reduced, which indicates that the
cells have lost their metabolic activity, and the noticeable reduction of the S-phase suggests
the possible influence of both nanomaterials on the process of DNA replication.

184

Chapter 4 – Bismuth-Based Compounds for Biomedical Applications

Figure 4.14. Cell cycle distributions of (a) 9L, (b) MCF-7, and (c) MDCK cells without
nanoparticle treatment (left panels) and after exposure to Bi(OH)3 (centre panels) and αBi2O3 nanoparticles (right panels), with both at a concentration of 50 μg/mL for 24 h. The
cells were trypsinized, fixed with ethanol, stained with propidium iodide, and analyzed
using a flow cytometer. The percentages of cells in different phases in the populations are
indicated in each panel.
Similarly to 9L, MCF-7 cells show a noticeable increase in apoptotic sub-G1 DNA
content and a reduction of G1 phase after treatment with the NPs. However, the impact on
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the cell cycle is not as pronounced as in 9L cells and the S-phase shows a similar
population as in control cells. The findings support the observations from the confocal
imaging, which indicate a faster mechanism of killing of the NPs in 9L cells. In contrast to
9L and MCF-7 cells, the flow cytometric analysis of the DNA content of MDCK cells after 24
h of treatment with Bi(OH)3 and α-Bi2O3 NPs shows no significant difference compared to
the control.
4.2.6 Evaluation of Apoptotic Nuclear Morphologies and Intracellular Reactive
Oxygen Species
The two main apoptotic nuclear morphologies, namely budding and cleavage, are
easily recognisable after nuclear staining and are the result of two independent
morphological routes that are differently modulated by stress or physiological apoptogenic
agents like intracellular glutathione [93, 94].
Similarly to nanoceria (CeO2), which affects only the oxidation-dependent
apoptosis, we hypothesized that Bi(OH)3 and α-Bi2O3 NPs may also exhibit similar
behaviour, which is characterized by the cleavage morphology [95]. To analyse the
oxidative features of apoptotic cells, a double labelling was performed with Hoechst stain
to identify the nuclear morphology and the ROS dye H2DCFDA. It has been demonstrated
that the DCF signal in budding cells is comparable to that in viable cells, whereas the cells
in cleavage display stronger staining [95].
The relative intracellular levels of ROS in 9L and MDCK cells were quantified by
evaluating the effect of Bi(OH)3 and α-Bi2O3 NPs on the abundance of the cleavage cell
morphology in combination with the intensity of the DCF signal. The 9L cells were chosen
for the double labelling as the nanomaterials exhibited the greatest effect on these cells, in
comparison to MCF-7. MDCK cells were chosen, as the nanomaterials showed only low
toxicity in this cell line. Due to the very fast induction of apoptosis by both materials at a
concentration of 50 μg/mL in 9L cells, different incubation times of Bi(OH)3 and α-Bi2O3
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NPs, ranging from 0 to 24 h, were chosen in order to investigate the link between
intracellular ROS levels and cell death.
The emission images of 9L and MDCK cells without and with NP incubation for 21 h
(Bi(OH)3) and 15 h (α-Bi2O3) are shown in Figure 4.15 and Figure 4.16, respectively. These
particular incubation times with the NPs were chosen because they resulted in mostly
dead cells for 9L, as shown via live cell imaging.

Figure 4.15. 9L cells double-labelled (left columns), labelled with Hoechst stain alone
(centre columns; nuclear morphology) and with 2’,7’-dichlorodihydrofluorescein diacetate
alone (right columns; ROS content; 2’,7’-dichlorofluorescein (DCF) signal). The rows show
the control cells (top rows); cells after treatment with Bi(OH)3 nanoparticles for 21 h
(centre rows), and cells after treatment with α-Bi2O3 nanoparticles for 15 h (bottom rows).
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Figure 4.16. MDCK cells double-labelled (left columns), labelled with Hoechst stain alone
(centre columns; nuclear morphology) and with 2’,7’-dichlorodihydrofluorescein diacetate
alone (right columns; ROS content; 2’,7’-dichlorofluorescein (DCF) signal). The rows show
the control cells (top rows); cells after treatment with Bi(OH)3 nanoparticles for 21 h
(centre rows), and cells after treatment with α-Bi2O3 nanoparticles for 15 h (bottom rows).
Whereas the 9L control cells only show a weak DCF signal (Figure 4.15, top right
image), the incubation with Bi(OH)3 or α-Bi2O3 NPs leads to a significant increase in green
fluorescence (centre and bottom right images). Furthermore, the treatment of 9L cells with
each nanomaterial leads to the cleavage morphology of apoptotic nuclei (middle and
bottom row, centre column images, as indicated by the red arrows). The elevated levels of
ROS with no noticeable increase in budding but significant increase in cleavage
morphology of apoptotic nuclei suggest an apoptosis pathway dependent on ROS.
In contrast to 9L cells, the treatment of MDCK cells with either Bi(OH)3 or α-Bi2O3
NPs does not cause a significant increase in the DCF signal (Figure 4.16, centre and bottom
right images), compared to the untreated MDCK cells (top right image), which emphasizes
the high biocompatibility of both materials. Furthermore, MDCK cells do not exhibit a
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significantly increased number of apoptotic nuclei with either budding or cleavage
morphology when treated with Bi(OH)3 or α-Bi2O3 NPs (middle and bottom row, centre
column images), but show nuclei with similar shapes and sizes compared to untreated cells
(top centre image).
Figure 4.17 displays the additional number of 9L and MDCK cells (compared to the
control) that show cleavage due to the treatment with Bi(OH)3 or α-Bi2O3 NPs, which is
linked with increased intracellular levels of ROS. The number of 9L cells generating ROS
increases slowly in the early stages of NP incubation until a maximum is reached at
approximately 21 h (Bi(OH)3) and 15 h (α-Bi2O3), confirming a difference in the rapidity of
apoptosis induced by the two materials. As shown via live cell imaging, where cells lost
their capacity to grow and proliferate after approximately 20 h (Bi(OH)3) and 16 h (αBi2O3) of NP exposure, the obtained ROS profile suggests a strong correlation between cell
death and elevated intracellular levels of ROS. The decrease in the number of cells with
high ROS levels at longer exposure times can be explained by, firstly, the reduced number
of viable cells and, secondly, the washing off of loosely attached cells during the
preparation process for imaging.
In contrast to 9L, MDCK cells do not generate significantly more ROS than control
cells throughout the whole period of 24 h. The number of 9L and MDCK cells that show
budding morphology of apoptotic nuclei remains comparable to that for the control during
the whole period of 24 h (Figure 4.18).
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Figure 4.17. Additional number of apoptotic nuclei with cleavage morphology for 9L and
MDCK cells after treatment with 50 μg/mL of Bi(OH)3 and α-Bi2O3 nanoparticles for 0, 2, 4,
6, 9, 12, 15, 18, 21, and 24h, compared to non-treated cells. Cleavage frequencies among
the total cells were evaluated by Hoechst and 2’,7’-dichlorodihydrofluorescein diacetate
staining.

Figure 4.18. Additional number of apoptotic nuclei with budding morphology for 9L and
MDCK cells after treatment with 50 μg/mL of Bi(OH)3 and α-Bi2O3 nanoparticles for 0, 2, 4,
6, 9, 12, 15, 18, 21, and 24h, compared to non-treated cells. Budding frequencies among the
total cells were evaluated by Hoechst and 2’,7’-dichlorodihydrofluorescein diacetate
staining.
The relative number of 9L cells showing oxidation-dependent apoptosis is very
similar for both materials, although the relative internalization of Bi(OH)3 NPs in 9L cells is
significantly increased compared to α-Bi2O3 NPs. As mentioned in section 4.2.2, the relative
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cellular uptake of both nanomaterials in 9L cells is higher in comparison with MDCK cells.
In order to show that the generation of ROS occurs selectively in 9L cells and is not due to a
higher uptake of NPs, the concentrations of both Bi(OH)3 and α-Bi2O3 NPs in MDCK cells
were increased to a point where their relative internalization matched that of 9L cells,
which was obtained for 50 μg/mL and an incubation time of 24 h. A similar relative cellular
uptake of 495 ± 23% (Bi(OH)3) and 388 ± 11% (α-Bi2O3) in MDCK cells was achieved for a
concentration of 700 and 100 μg/mL, respectively, while using the same incubation time as
for 9L cells. This increased concentration of Bi(OH)3 and α-Bi2O3 NPs in MDCK cells did not
result in a larger number of nuclei with cleavage morphology, with 0.3 ± 0.8% and 0.8 ±
0.3%, respectively, for the exposure time of 24 h. Treatment of 9L cells with increased
concentrations of 700 µg/mL of Bi(OH)3 NPs and 100 µg/mL of α-Bi2O3 NPs showed that
the amount of nuclei with cleavage morphology remained constant with 22.5 ± 3.6% and
16.3 ± 1.8%, respectively.
The generation of ROS has been shown to be a mechanism of action of ZnO NPs
[96] that typically need to be internalized to induce elevated levels of intracellular ROS in
mouse macrophage Ana-1 cells [97]. The obtained results in this thesis suggest a similar
mechanism of action that involves the generation of ROS, as shown for 9L cells. The
observed toxicity can furthermore be affected by different internalization rates. As the
present results indicate, the nanomaterials do not internalize easily in MDCK cells and
cause only moderate to low toxicity, while the cellular uptake is significantly higher in
malignant cells. Further tests, however, are required to study the exact mechanism.
4.2.7 In Vitro Computed Tomography Imaging of Bi(OH)3 and α-Bi2O3
Nanoparticles
The anatomical contrast enhancement capability of Bi(OH)3 and α-Bi2O3 NPs was
demonstrated using a clinical CT scanner, with the resulting CT number as a function of the
Bi concentration, as shown in Figure 4.19 and Figure 4.20. The CT values in Hounsfield
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Units (HU) for each concentration were determined for multiple regions along the central
axis of the vial to account for possible sedimentation of the suspended composites (see red
dashed lines).

Figure 4.19. (a) Linear fitting of the CT number of Bi(OH)3 nanoparticles as a function of
the mass concentration of Bi in mg/mL at different tube potentials of 100, 120, and 135
kVp. The equation of linear regression and the coefficient of determination (R2) value are
indicated. (b) CT images of Bi(OH)3 nanoparticles with Bi mass concentrations of 0 – 8
mg/mL; the red dashed line indicates the area that was used to determine the CT number.
The tube potential varied between 100, 120, and 135 kVp.
The data was plotted and fitted to deduce the relation between the CT number and
the Bi concentration. The average CT number was chosen across the suspension height. In
general, the contrast increased with increasing concentration of bismuth. A noticeable
difference in CT number was observed at the highest concentration of 8 mg/mL for the
centre of the sediment and the centre of the suspension height. The CT number reached a
value of up to 3500 HU and 5000 HU for the sediment at a Bi concentration of 8 mg/mL for
Bi(OH)3 and α-Bi2O3 NPs, respectively.
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Figure 4.20. (a) Linear fitting of the CT number of α-Bi2O3 nanoparticles as a function of
the mass concentration of Bi in mg/mL at different tube potentials of 100, 120, and 135
kVp. The equation of the linear regression and the R2 value are indicated. (b) CT images of
α-Bi2O3 nanoparticles with Bi mass concentrations of 0 – 8 mg/mL; the red dashed line
indicates the area which was used to determine the CT number. The tube potential varied
between 100, 120, and 135 kVp.
X-ray attenuation also depends on the X-ray photon energy. Typically, for most
elements, including iodine, the X-ray attenuation decreases with increasing X-ray energy
(peak tube potential) [64]. It was shown that Bi2O3 NPs, which were stabilized with human
serum albumin, provided an enhanced contrast at a tube potential of 80 kVp and a
concentration of 3 mg/mL and 5 mg/mL with CT numbers of 260 HU and 380 HU,
respectively [67]. Dextran-coated bismuth iron oxide nanohybrids displayed similar CT
values of 50 – 300 HU at a concentration of 9.4 mg/mL, depending on the formulation of
the nanohybrids and the tube potential [68]. It was shown that iron oxide attenuates Xrays poorly, with a CT number of approximately 50 HU for tube potentials between 80 –
140 kVp [68]. The inclusion of bismuth yielded an increase in X-ray attenuation, which
increased gradually with the added amount of bismuth in the formulations. Similarly to the
results obtained in this doctoral thesis, the attenuation was strongest for small tube
potentials. For higher tube potentials, however, the attenuation did not change
significantly. This observation was also made for bismuth NPs and highlights the potential
of Bi-based nanomaterials for CT imaging [64].
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In contrast, iodine-based CT agents show a much greater decrease in CT number
for large X-ray tube potentials [63, 64, 68]. The superior contrast enhancement of the
Bi(OH)3 and α-Bi2O3 NPs across the diagnostic CT X-ray spectrum, ranging from 100 to 130
kVp, is of particular interest in a clinical setup [98]. Although it is beneficial for pediatric
patients to reduce the radiation dose, the ability to use high X-ray energies is important for
the imaging of large patients, as a sufficient penetration of X-rays needs to be ensured to
obtain images of the desired quality.
4.2.8 Conclusions
Although Bi(OH)3 and α-Bi2O3 NPs have not been explored as chemotherapeutic
agents for cancer treatment so far, they offer multiple attractive features such as: imaging,
possible radio-dose enhancement, and, as has been demonstrated for the first time in this
thesis, they exhibit high in vitro toxicity towards malignant cells, which makes them
promising theranostic systems for cancer treatment. With this combination of properties,
the use of anti-cancer drugs can potentially be refined and therefore, the spectrum of side
effects reduced while maintaining similar therapeutic effects.
The high mortality (> 90 - 99%) of chemo-resistant 9L glioma and MCF-7 breast
cancer cells after only 24 h of NP treatment indicates that both materials might exhibit high
toxicity in other cancer cell lines, which needs further investigation. Furthermore, the
successful transition into in vivo models needs to be demonstrated in order to fully
examine the anti-cancer activity. In contrast, the nanomaterials showed only low to
moderate toxicity in normal MDCK cells. Apoptosis of 9L cells was identified via cleavage
morphology of the nuclei and increased sub G1 levels, whereas the number of cells entering
the G1 and S phases was reduced.
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4.3 Biocompatible Bi(OH)3 Nanoparticles with Reduced Photocatalytic
Activity as Possible Ultraviolet Filter in Sunscreens
In this section, readily synthesized Bi(OH)3 nanoparticles with a particle size of
approximately 6 nm are investigated as a novel, multifunctional ultraviolet filter for
sunscreen with low photocatalytic activity. The synthesis procedure and all
characterization methods are described in CHAPTER 3. The SPF was determined in
accordance with ISO 24443:2012 for an in-house fabricated sunscreen containing
TiO2/Bi(OH)3 and compared to a ‘classical’ sunscreen of TiO2/ZnO. The physical properties
of the colourless Bi(OH)3 NPs alone, and in combination with photocatalytically active TiO2
and ZnO NPs, were investigated through monitoring of crystal violet degradation under
UVA/UVB irradiation and simulated solar irradiation. The cytotoxicity of the Bi(OH)3 NPs
was determined upon healthy HaCaT keratinocytes and MDCK cells using the MTT assay.
4.3.1 Overview of Tested Materials, Homemade Sunscreens, and Commercial
Sunscreens
In this section, an overview is presented of the different materials (M, Table 4.4),
homemade sunscreens (HS, Table 4.5), and commercial sunscreens (CS, Table 4.6) used.
The Bi(OH)3 (M1) NPs were the only material that was synthesized in this thesis. Details
about the Bi(OH)3 NP synthesis and the preparation of homemade sunscreens are
presented in CHAPTER 3. For all characterization techniques that involved combinations of
TiO2 and Bi(OH)3 NPs, or ZnO and Bi(OH)3 NPs, different concentrations of separately
suspended NPs were mixed mechanically.
The materials M1 – M3 were used for photocatalytic activity tests, which involve
the degradation of crystal violet. Furthermore, the UV filtering properties and the
cytotoxicity of these materials were investigated.
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Table 4.4. Overview of the materials (M) used.
ID

M1

Sample

Trade name/

Particle size (nm) and

Supplier

morphology

Synthesized in

6.04 ± 0.89

Bi(OH)3

–
this thesis

M2

Crystal phase

TiO2

(spherical)
24.08 ± 1.60

80% anatase,

(ellipsoidal, cubic)

20% rutile

Aeroxide®, P25

44.86 ± 6.38 (spherical,
M3

ZnO

Sigma Aldrich

Zincite
hexagonal, rectangular)

The homemade sunscreens HS1 and HS2 were used for photocatalytic activity
tests, which involve the exterior exposure of pre-painted steel panels. Furthermore,
rheological properties were determined, as well as the photoprotection efficiency (SPF).
The results were compared to those of the commercial sunscreen formulations.
Table 4.5. Overview of the homemade sunscreens (HS) used.
Particle size (nm) and
ID

UV filter

Trade name

TiO2

Eusolex® T-S

morphology

Crystal phase

Rod-like: 20 (width) and
Rutile
100 (length) [99]
HS1
30 – 200, (rod-like,
ZnO

Z-COTE® HP1

Wurtzite
isometric) [100]
Rod-like: 20 (width) and

TiO2

Eusolex® T-S

Rutile
100 (length) [99]

HS2
Synthesized in this
Bi(OH)3

6.04 ± 0.89 (spherical)
thesis (M1)
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The commercial sunscreens CS1 and CS2 were used for photocatalytic activity
tests, which involve the exterior exposure of pre-painted steel panels. In addition, the
inorganic sunscreen components were separated from these two sunscreens. Rheological
properties were tested of the commercial sunscreens CS3 and CS4.
Table 4.6. Overview of the commercial sunscreens (CS) used.
ID

UV filter

Sunscreen

Particle size (nm) and

Crystal phase

morphology
80% anatase,
CS1

TiO2

Nivea®

(SPF 50)

~ 25 (ellipsoidal, cubic)
20% rutile

CS2

Nivea® anti-age

Rod-like: 20 (width) and

(SPF 30)

100 (length) [99]

TiO2

Rutile

CS3

Organics

OMBRA® (SPF 50)

–

CS4

Organics

Auscreen® (SPF 50)

–

4.3.2 Identification, Size, Morphology, and Surface Composition of Bi(OH)3,
TiO2, and ZnO Nanoparticles
Figure 4.21 displays the XRD patterns of the synthesized Bi(OH)3 (M1) NPs and the
as-received TiO2 (M2) and ZnO (M3) nanopowders. The XRD pattern of the Bi(OH)3 NPs
shows reflections which are identified as single phase but are broadened due to the very
small particle size [17]. Since no JCPDS file can be assigned to the Bi(OH)3, the XRD pattern
is not indexed. The XRD pattern of the as-received ZnO NPs shows the single zincite
structure (JCPDS 00-036-1451), whereas the TiO2 NPs are composed of mixed phases of
anatase (JCPDS 01-075-2552) and rutile (JCPDS 01-075-1753).
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Figure 4.21. XRD patterns of Bi(OH)3 (M1, top), ZnO (M3, centre), and TiO2 (M2, bottom)
nanoparticles.
Figure 4.22 shows TEM images of all the nanomaterials. The Bi(OH)3 (M1) NPs are
mostly agglomerates ~100 nm in size, with an average single particle size of 6.04 ± 0.89
nm, and round and ellipsoidal shapes (left images). The chosen image does not represent
the average particle size of 6 nm, but still falls into the particle size distribution that varies
between 2 – 14 nm, as shown in Figure 4.23.

Figure 4.22. TEM images of Bi(OH)3 (M1), TiO2 (M2), and ZnO (M3) nanoparticles.
The TiO2 (M2) NPs are mostly spherical, ellipsoidal, and cubic in shape, with similar
particle sizes of 24.08 ± 1.60 nm (centre right image). The ZnO (M3) NPs are composed of
particles with various morphologies, such as ellipsoidal, cubic, spherical, and hexagonal,
with an average particle size of 44.86 ± 6.38 nm (Figure 4.23(c)). There is also a significant
amount of rectangular plate-like particles with an average length of 92.99 ± 20.97 nm and
width of 44.52 ± 5.50 nm, making the ZnO NPs the largest in comparison to the Bi(OH) 3
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and TiO2 NPs. Moreover, since the particle sizes vary greatly, the associated error is
consequently much higher. For the particle size distribution of the ZnO NPs, the crosssection of the rectangular-shaped particles was used to calculate an equivalent spherical
diameter.

Figure 4.23. Particle size distribution of (a) Bi(OH)3 (M1), (b) TiO2 (M2), and (c) ZnO (M3)
nanoparticles.
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The BET specific surface area of all materials was determined to be 47.8 ± 0.5 m2/g,
21.8 ± 0.2 m2/g, and 6.4 ± 0.1 m2/g for the TiO2 (M2), Bi(OH)3 (M1), and ZnO (M3) NPs,
respectively.
To investigate if the surface composition deviates from the bulk composition, XPS
analysis was performed. Figure 4.24 displays both the high-resolution XPS spectra of the O
1s peak and the deconvolution results for the Bi(OH)3 (M1), TiO2 (M2), and ZnO (M3) NPs.
The survey spectra of all nanomaterials are shown in Figure A11 in the Appendix I. The O
1s peak for all tested nanomaterials is resolved into multiple peaks with different
intensities relative to each other. The O 1s peaks for Bi(OH)3 at binding energies of 530.43
± 0.04 eV and 532.81 ± 0.13 eV can be assigned to O2- ions in Bi–O bonds [74] and
hydroxide species (Bi–OH) adsorbed on the NP surfaces [74, 75], respectively.
Similarly to Bi(OH)3, the O 1s peak for ZnO at 530.36 ± 0.25 eV represents O2- ions
in Zn–O bonds, and the peak at 531.95 ± 0.10 eV can be assigned to hydroxide and
chemisorbed oxygen species (Zn–OH) [101].
The O 1s spectrum of TiO2 displays peaks at 528.96 ± 0.08 eV associated with
lattice oxygen in Ti–O and at 530.90 ± 0.11 eV, which is ascribed to hydroxyl groups (Ti–
OH) on the surface, while the peak at 531.95 ± 0.16 eV corresponds to chemisorbed water
(Ti–OH2) [102].
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Figure 4.24. High-resolution XPS spectra of the O 1s region of (a) Bi(OH)3 (M1), (b) TiO2
(M2), and (c) ZnO (M3) nanoparticles.
4.3.3 Ultraviolet-Visible Study of Bi(OH)3, TiO2, and ZnO Nanoparticles
The UV-visible absorption spectra of Bi(OH)3 (M1), TiO2 (M2), and ZnO (M3) NPs
are shown in Figure 4.25. The absorption spectra were all obtained at the same
concentration (25 µg/mL) and indicate a higher and more selective absorbance of TiO2 NPs
within the UV region compared to ZnO and Bi(OH)3 NPs. A comparison of the latter two
201

Chapter 4 – Bismuth-Based Compounds for Biomedical Applications

shows a significant increase in the absorbance maximum for the Bi(OH)3 NPs, which is
similar to that of TiO2 in lower wavelengths < 300 nm, while the ZnO NPs show a reduced
and broader absorbance throughout the whole UV range. Therefore, TiO2 NPs are
considered UVB and UVA2 (320 – 340 nm) blocker, while ZnO NPs provide protection in
the UVB and UVA1 (340 – 400 nm) area [36]. According to these categories, Bi(OH)3 NPs
would – similarly to TiO2 – be a suitable blocker of UVB radiation, and thus, a potential
candidate as active sunscreen ingredient.

Figure 4.25. UV-visible absorption spectra of Bi(OH)3 (M1), TiO2 (M2), and ZnO (M3)
nanoparticles at 25 µg/mL in deionized water. The concentration of the combined
materials (ZnO and Bi(OH)3; TiO2 and Bi(OH)3) is 25 µg/mL each, implying a total
concentration of 50 µg/mL.
This observation is reflected in the increase of the optical direct band gap of the
Bi(OH)3 NPs with 4.06 ± 0.08 eV, compared to TiO2 NPs with 3.39 ± 0.07 eV and ZnO NPs
with 3.08 ± 0.05 eV. The band gaps were calculated using a Tauc plot (Figure 4.26). There
is no literature available in regard to the measurement or calculation of the band gap of
Bi(OH)3, and the results, which were obtained in this thesis, suggest the presence of a
direct band gap at 4.06 ± 0.08 eV.
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Figure 4.26. Tauc plots of Bi(OH)3 (M1), TiO2 (M2), and ZnO (M3) nanoparticles. The red
lines represent extrapolated band gaps corresponding to Bi(OH)3, TiO2, and ZnO
nanoparticles.
With its wide band gap, Bi(OH)3 NPs have a high optical transparency in the visible
light range, making it potentially viable as a cosmetic material. The band gaps are in
agreement with the literature, where the band gap for ZnO ranges from 3.1 to 3.3 eV [103].
The band gap for TiO2 ranges from approximately 3.0 eV (rutile), to 3.13 eV (brookite) and
3.2 eV (anatase) [104].
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The combination of materials, in particular TiO2 and Bi(OH)3, and ZnO and Bi(OH)3
with equal concentrations (each material = 25 µg/mL) results in absorption spectra that
show the characteristics of both materials. For instance, the combination of ZnO and
Bi(OH)3 NPs clearly shows the peak maximum at approximately 375 nm, which
corresponds to ZnO, and a linear increase in absorbance starting at approximately 300 nm,
which is ascribed to Bi(OH)3.
4.3.4 Photocatalytic Activity of Bi(OH)3, TiO2, and ZnO Nanoparticles under
Ultraviolet Irradiation
Intuitively, the presence of photocatalytically active anatase TiO2 would not be
expected in sunscreen formulations for topical application since TiO2, in particular the
anatase phase, is known to be a highly active photocatalyst, which generates •OH radicals
upon exposure to UV light [105]. Several recent studies, however, have confirmed the
presence of a highly photoactive P25 phase in commercial formulations [105-107].
4.3.4.1 Under Ultraviolet Exposure (300 nm and 350 nm)
The photoactivity of Bi(OH)3 (M1), TiO2 (M2), and ZnO (M3) NPs was evaluated
under UV irradiation using lamps with emission at 300 nm (UVB) and 350 nm (UVA), and
is shown in Figure 4.27(a). The exposure of a crystal violet solution with TiO2 (M2, 5 mg/L)
leads to significant degradation, with only 10% of the initial absorbance present after
irradiation with UV light for 30 min. Similarly, the addition of ZnO NPs, which are also
known for their photocatalytic activity, also resulted in degradation albeit at a reduced
rate.
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Figure 4.27. (a) Relative decrease in absorbance of crystal violet solutions containing only
the dye, ZnO (M3, 5 mg/L), TiO2 (M2, 5 mg/L), and Bi(OH)3 (M1) nanoparticles with
concentrations ranging from 1 to 5 mg/L, and combinations of M2 (5 mg/L) + M1 (1 – 5
mg/L) and M3 (5 mg/L) + M1 (5 mg/L) under ultraviolet light exposure (300 nm and 350
nm). The data represent the mean of three independently prepared samples. (b) Apparent
rate constant curves for the dye degradation shown in (a).
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In contrast, the exposure to Bi(OH)3 NPs at the same concentration leads to little
dye degradation over a similar period, meaning that the NPs do not generate many ROS
upon exposure to UV light. Moreover, the small photocatalytic activity of the Bi(OH)3 NPs is
most likely not related to the reduced number of active sites for the photo degradation
reaction in comparison to TiO2, since the surface area of the ZnO NPs is even smaller, with
the NPs displaying greater photodegradation than the Bi(OH)3 NPs. The large band gap of >
4 eV for Bi(OH)3 makes the excitation of electrons from the valence band to the conduction
band less likely.
When added to suspensions of TiO2 or ZnO prior to irradiation, the Bi(OH)3 NPs
cause a significant decrease in crystal violet degradation and apparent rate constant k, as
shown in Table 4.7. The plots used to find the apparent rate constant were calculated with
help of the Langmuir–Hinshelwood model [108] and are shown in Figure 4.27(b). More
importantly, the dye degradation is reduced close to that of M1 alone indicating almost
complete reduction of the photocatalytic activity of TiO2.
Since TiO2 is the more active photocatalyst, this reduction in activity was studied
further by varying the concentration of mechanically added Bi(OH)3 NPs. The reduction in
photocatalytic activity is greater for the addition of lower concentrations of Bi(OH)3 NPs.
This effect is most likely not only related to the effects of absorption and scattering from
the additional particles, as a substantial decrease in the degradation of crystal violet can
also be observed for the lowest concentration of Bi(OH)3 NPs used (1 mg/L).
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Table 4.7. Apparent rate constant k for the degradation of crystal violet solutions
containing TiO2 (M2, 5 mg/L), ZnO (M3, 5 mg/L), and Bi(OH)3 (M1) nanoparticles, in
concentrations ranging from 1 to 5 mg/L, and combinations of M2 (5 mg/L) + M1 (1 – 5
mg/L) and M3 (5 mg/L) + M1 (5 mg/L) under ultraviolet light exposure (300 nm and 350
nm), as shown in Figure 4.27. The errors indicated are the standard deviation obtained
through the linear regression.
Sample

k × 10-2 (min-1), UV irradiation (300 & 350 nm)

Dye only

0.05 ± 0.01

TiO2 (5 mg/L)

7.08 ± 0.22

ZnO (5 mg/L)

1.45 ± 0.07

Bi(OH)3 (5 mg/L)

0.89 ± 0.02

ZnO (5 mg/L) + Bi(OH)3 (5 mg/L)

0.52 ± 0.02

TiO2 (5 mg/L) + Bi(OH)3 (5 mg/L)

0.94 ± 0.03

Bi(OH)3 (2.5 mg/L)

0.36 ± 0.02

TiO2 (5 mg/L) + Bi(OH)3 (2.5 mg/L)

0.57 ± 0.03

Bi(OH)3 (1 mg/L)

0.13 ± 0.01

TiO2 (5 mg/L) + Bi(OH)3 (1 mg/L)

0.47 ± 0.02

CeO2, for instance, has the ability to ‘scavenge’ free radicals due to the presence of a
large number of surface defects on the surfaces of CeO2 NPs for small particle sizes, which
can lead to oxygen deficiencies and reversible oxidation state changes in the cation [95,
109]. This mechanism enables scavenging of excess free radical species, and consequently,
the photocatalytic activity of photocatalysts is reduced [110].
It is therefore likely that the reduced degradation of crystal violet is related to the
scavenging of •OH radicals generated from the photocatalytically active TiO2 and/or the
reduction of active surface sites on the TiO2 surface through the adsorption of Bi(OH)3 NPs.
Very low concentrations of Bi(OH)3 NPs are enough to reduce the photocatalytic activity of
TiO2 significantly: by adding a suspension of Bi(OH)3 NPs that resulted in a concentration
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of 1 mg/L to a suspension of TiO2 at a concentration of 5 mg/L prior to irradiation, the
degradation of crystal violet decreased by more than 90%. This ultimately means that in
the final suspension the ratio Bi(OH)3:TiO2 is 1:5.
There are no reports on the scavenging effects of Bi(OH)3 NPs, but the very small
diameter of the NPs suggests that the effect might be related to the surface properties of
the material. The Bi(OH)3 NPs display a very small particle size with low crystallinity,
resulting in the presence of more surface defects, which, in turn, can act as ROS scavengers.
4.3.4.2 Under Ultraviolet Exposure (350 nm)
In order to exclude the possibility that Bi(OH)3 NPs absorb the radiation in the UV
range and thus reduce the effective UV radiation for the TiO2 and ZnO NPs, photocatalytic
activity tests were performed with a modified UV range. As shown via UV-visible
spectroscopy, the band gap of Bi(OH)3 NPs lies at 305 nm (4.06 eV), and for TiO2 and ZnO
at 366 nm (3.39 eV) and 403 nm (3.08 eV), respectively. By limiting the UV radiation only
to lamps with an emission at 350 nm (UVA), the absorbance of UV radiation by Bi(OH)3
NPs can be minimized. At the same time, the energy is sufficient to induce photocatalytic
effects in TiO2 and ZnO NPs. The degradation of crystal violet, including the apparent rate
constant, is shown in Figure 4.28, which gives results for ZnO, TiO2, and Bi(OH)3 NPs at a
concentration of 5 mg/L.
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Figure 4.28. (a) Relative decrease in absorbance of crystal violet solutions containing only
the dye, Bi(OH)3 (M1, 5 mg/L), TiO2 (M2, 5 mg/L), and ZnO (M3, 5 mg/L) nanoparticles,
and combinations of M2 (5 mg/L) + M1 (5 mg/L) and M3 (5 mg/L) + M1 (5 mg/L) under
ultraviolet light exposure (350 nm). The data represent the mean of three independently
prepared samples. (b) Apparent rate constant curves for the dye degradation shown in (a).
The photodegradation properties of crystal violet, for all nanomaterials under light
irradiation at 350 nm are summarized in Table 4.8. The performance of the ZnO NPs
remains comparable to a full irradiation with both 350 (UVA) and 300 (UVB) nm lamps,
most probably due to the absorbance in the broader wavelength range, with the
absorbance maximum reached at approximately 375 nm, while TiO2 shows a clear
absorbance peak at wavelengths < 300 nm.
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Table 4.8. Apparent rate constant k for the degradation of crystal violet solutions
containing Bi(OH)3 (M1, 5 mg/L), TiO2 (M2, 5 mg/L), and ZnO (M3, 5 mg/L) nanoparticles,
and combinations of M2 (5 mg/L) + M1 (5 mg/L) and M3 (5 mg/L) + M1 (5 mg/L) under
ultraviolet light exposure (350 nm), as shown in Figure 4.28. The errors indicated are the
standard deviation obtained through the linear regression.
Sample

k x 10-2 (min-1), UV irradiation (350 nm)

Dye only

0.02 ± 0.01

TiO2 (5 mg/L)

1.25 ± 0.06

ZnO (5 mg/L)

1.00 ± 0.04

Bi(OH)3 (5 mg/L)

0.08 ± 0.01

TiO2 (5 mg/L) + Bi(OH)3 (5 mg/L)

0.34 ± 0.02

ZnO (5 mg/L) + Bi(OH)3 (5 mg/L)

0.01 ± 0.01

The addition of Bi(OH)3 NPs to the crystal violet solution results in very low dye
degradation with an apparent rate constant k = 0.08 ± 0.01 min-1, which is very similar to
the control sample of only crystal violet with k = 0.02 ± 0.01 min-1. It is therefore likely that
the irradiation at 350 nm does not lead to any significant absorbance by Bi(OH)3, and that
the decreased photocatalytic activity of TiO2 NPs can be assigned to either a mechanism
related to the active scavenging of photogenerated intermediates, or, more likely, the
decrease in active surface area through the physical adsorption of Bi(OH)3 NPs.
Consequently, the addition of a suspension of Bi(OH)3 (5 mg/L) to a suspension of ZnO (5
mg/L) appeared to completely inhibit crystal violet degradation, while addition of Bi(OH)3
to TiO2 (5 mg/L) reduced the photocatalytic activity by 70%.
4.3.5 Photocatalytic Activity of Bi(OH)3, TiO2, and ZnO Nanoparticles under
Simulated Solar Irradiation
In order to test the photocatalytic activity under conditions that are more realistic
for sunscreen applications, suspensions of Bi(OH)3 (M1), TiO2 (M2), and ZnO (M3) NPs in
presence of crystal violet were exposed to AM 1.5 G one sun (100 mW/cm2) for a total time
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of 6 h. The degradation curves and apparent rate constant curves are displayed in Figure
4.29, and highlight the degradation of crystal violet when exposed to TiO2 and ZnO NPs.

Figure 4.29. (a) Relative decrease in absorbance of crystal violet solutions containing
Bi(OH)3 (M1, 5 mg/L), TiO2 (M2, 5 mg/L), and ZnO (M3, 5 mg/L) nanoparticles under
exposure of AM 1.5 G one sun (100 mW/cm2). The data represent the mean of three
independently prepared samples. (b) Apparent rate constant curves for the dye
degradation shown in (a).
Although there is some visible decrease in dye degradation for the treatment with
Bi(OH)3 NPs, these NPs show a much lower photocatalytic activity compared to TiO2 and
ZnO NPs, especially in the early hours of irradiation (0 – 2 h) Table 4.9.
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Table 4.9. Apparent rate constant k for the degradation of crystal violet solutions
containing Bi(OH)3

(M1, 5 mg/mL), TiO2 (M2, 5 mg/L), and ZnO (M3, 5 mg/L)

nanoparticles under exposure to AM 1.5 G one sun (100 mW/cm2). The errors indicated
are the standard deviation obtained through the linear regression.
Sample

k × 10-2 (min-1), sunlight irradiation

Dye only

0.47 ± 0.10

TiO2 (5 mg/L)

46.67 ± 0.99

ZnO (5 mg/L)

18.91 ± 2.23

Bi(OH)3 (5 mg/L)

4.58 ± 0.12

4.3.6 Sun Exposure of Homemade Sunscreens and Commercial Sunscreens
One major drawback of modern sunscreen formulations is the aggressive
degradation of third party applications, such as surface coatings on wood and steel, which
is mediated by photocatalytic reactions [111, 112]. The photocatalytic mechanism includes
the formation of radicals if oxygen, water, and light are present.
In order to test the reduced photocatalytic activity of the Bi(OH)3 NPs in
comparison to the photocatalytically more active ZnO NPs, both homemade sunscreen
emulsions (with additional TiO2 NPs: HS1, HS2) were applied on dark blue pre-painted
steel sheets. The base emulsion was also tested to determine the photocatalytic activity of
the homemade sunscreens without added NPs. In addition, two commercially available
sunscreen formulations were tested: CS1 (Nivea® (SPF 50)) and CS2 (Nivea® anti-age (SPF
30)), which also have organic compounds in addition to TiO2 NPs as active ingredients.
The degradation of the test panels was assessed via determination of the gloss and
SEM imaging of the panel’s surfaces, as discussed below.
4.3.6.1 Gloss Readings of the Test Panels
After an exterior exposure of six and twelve weeks, a 30 mm wide test strip was cut
of each panel, and the gloss was measured (Figure 4.30). While the blank test panel
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maintained the same gloss after twelve weeks, the treatment with commercial sunscreen
CS1 (Nivea® (SPF 50)) lead to a significant decrease in gloss. In addition, the surfaces were
roughened and disfigured after only six weeks exposure, and the pigment started to
disappear

after

twelve

weeks

exposure,

which

underscores

the

aggressive,

photocatalytically initiated degradation [111].

Figure 4.30. Gloss readings of pre-painted steel panels without, and panels treated with
commercial sunscreen formulations (CS1: Nivea® (SPF 50); CS2: Nivea® anti-age (SPF
30)), the homemade base emulsion, and homemade sunscreens containing TiO2/ZnO (HS1)
and TiO2/Bi(OH)3 (HS2) after exposure to the Australian sun at a latitude of ~34.5°S
(Wollongong, NSW) for six and twelve weeks.
In contrast, steel panels that were treated with the homemade base emulsion (‘all
organic’) or the homemade sunscreens containing TiO2/ZnO and TiO2/Bi(OH)3, showed
only a small decrease in gloss and no visible signs of defects after the full exposure of
twelve weeks.
Interestingly, after twelve weeks of sun exposure, the gloss readings of the panels
treated with the base emulsion (26.1 GU), and the TiO2/ZnO (27.8 GU) and TiO2/Bi(OH)3
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(37.5 GU) emulsions are much higher than of the untreated control steel panels (22.7 GU).
An increase in gloss has been observed earlier [111] and is associated with a very strong
adhesion of the emulsion to the surface of the panels, which leads to a reduced removal
due to rainfall over the whole tested exposure time.
While the ingredients of sunscreen formulations have particles with sizes of 200 –
300 nm (TiO2), the matting agents, which were used to coat the steel panels before the
sunscreen formulations were applied, are made of particles large in size (7 – 10 µm) and
irregular in shape, which ultimately leads to a roughening of the panels [111]. The
homemade sunscreens reduced the initial roughness of the pre-painted steel panels, which
leads to a higher gloss reading than for the untreated panels.
In the period of twelve weeks, however, the homemade sunscreens can lose their
adhesion to the surface of the panels, which ultimately results in a decrease in gloss
reading that is not related to the photocatalytic activity of the sunscreen ingredients [111].
The coating with the base emulsion, for instance, yields reduced gloss of the panels,
although it does not contain any photocatalytically active inorganic particles.
The overall higher gloss readings without any significant disfiguration of the
sample’s surface of the homemade sunscreen containing TiO2/Bi(OH)3 indicates a reduced
photocatalytic activity in comparison to the homemade sunscreen containing TiO2/ZnO.
This conclusion is also supported by the fact that the only difference of the emulsion is the
replacement of ZnO NPs with Bi(OH)3 NPs, while keeping all other ingredients the same.
Furthermore, it has been shown that – similarly to TiO2 – ZnO NPs can be photocatalyticly
active, reducing the gloss data in comparison to untreated steel panels [111, 113].
Since the reduction in gloss of the panels is attributable to both photocatalytically
active sunscreen ingredients and the loss of adhesion of the applied sunscreen to the
panel’s surface [111], the panels have also been characterized via SEM, as shown below.
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4.3.6.2 Scanning Electron Microscopy Imaging of the Test Panels
After an exterior exposure of twelve weeks, SEM images of the test panels were
collected to investigate the surface morphology (Figure 4.31). The untreated control test
panel (top row, left image) maintained a smooth surface after the exposure, with the
surface coating still intact. The panels treated with the commercial sunscreens, however,
showed signs of photocatalytic degradation: while the treatment with CS2 (top row, centre
image) results in minor damage to the panel’s surface, the treatment with CS1 (top row,
right image) clearly leads to the degradation of the surface coating of the steel panels. It
has been shown that the photocatalytically active particles will first destroy the sunscreen
matrix, followed by a decomposition of the coating [111].

Figure 4.31. SEM images of pre-painted steel panels without, and panels treated with,
commercial sunscreen formulations (CS1: Nivea® (SPF 50); CS2: Nivea® anti-age (SPF
30)), the homemade base emulsion, and homemade sunscreens containing TiO2/ZnO (HS1)
and TiO2/Bi(OH)3 (HS2) after exposure to the Australian sun at a latitude of ~34.5°S
(Wollongong, NSW) for twelve weeks.
Similarly, the steel panels treated with the homemade TiO2/ZnO emulsion (HS1,
bottom row, centre image) display a visible surface roughness, although it is lower in
comparison to a treatment with CS1.
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In contrast, panels coated with the base emulsion prepared in this work (‘all
organics’; bottom row, left image) and the TiO2/Bi(OH)3 emulsion (HS2, bottom row, right
image) showed no visible degradation of the panel surface, underlining the lack of
photocatalytic activity of the TiO2/Bi(OH)3 emulsion in comparison to the TiO2/ZnO
emulsion. This conclusion is also supported by the fact that the only difference in the
emulsions is the replacement of ZnO NPs with Bi(OH)3 NPs, while keeping all other
ingredients the same.
These results support the findings that were obtained from the photocatalytic
degradation of crystal violet. Compared with TiO2 and ZnO, Bi(OH)3 NPs showed the lowest
photocatalytic activity and more importantly, Bi(OH)3 NPs were able to reduce the
photocatalytic activity of TiO2 NPs. It was previously shown that the formation of defects is
associated with the photocatalytic activity of particular sunscreen components and that
the photocatalytic degradation accelerates the weathering of the coating by 100 fold [111].
4.3.6.3 Separation of Inorganic Sunscreen Components
The difference in photostability of the tested commercial sunscreens is related to
the phase of the TiO2 NPs present in the formulations. The separation of the sunscreen
ingredients and the XRD analysis of the inorganic components identified either the rutile
phase or a combination of rutile and anatase TiO2 [106, 111, 114]. In the present case,
sunscreen CS1 contains an anatase and rutile composite phase similar to M2, while
sunscreen CS2 contains a single rutile TiO2 phase as shown in Figure 4.32.
Generally, anatase TiO2 is photocatalytically more active than rutile TiO2 [114,
115], but the mixed phase with 85% anatase and 15% rutile is particularly active [116].
The homemade TiO2/ZnO (HS1) and TiO2/Bi(OH)3 (HS2) sunscreens have Eusolex® T-S as
ingredient, which is an inorganic UV filter composed of rutile type TiO2 and thus, less
photocatalytically active.
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Figure 4.32. XRD patterns of the extracted inorganic components of commercial
sunscreens (CS1: Nivea® (SPF 50), bottom; CS2: Nivea® anti-age (SPF 30), centre), and the
TiO2-based homemade sunscreen (HS, top).
4.3.7 Rheological Properties of Homemade Sunscreens and Commercial
Sunscreens
An important factor that needs consideration when formulating sunscreen
products is their uniformity, which is related to rheology. The dependence of the viscosity
on the shear rate is shown in Figure 4.33 and was measured for the homemade sunscreens
of TiO2/ZnO (HS1) and TiO2/Bi(OH)3 (HS2), as well as for two commercially available
sunscreen products. In order to classify the spreadability of the homemade emulsions, two
sunscreen products (CS3, CS4) with different viscosity were chosen.
The commercial sunscreen, which is dispensed directly from the bottle (CS3:
OMBRA® (SPF 50)), showed the highest viscosity, while the sunscreen applied through a
spray dispenser (CS4: Auscreen® (SPF 50)) displayed the lowest viscosity. Both homemade
sunscreen emulsions of TiO2/ZnO and TiO2/Bi(OH)3 exhibit a viscosity in between the two
commercially available sunscreen products, which emphasizes the adequate spreadability
of the homemade emulsions and the associated eligibility for the use in sunscreen
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formulations. More importantly, both homemade emulsions demonstrate comparable
rheological properties, exhibiting greater viscosity for lower shear rates.

Figure 4.33. Viscosity measurements of two commercially available sunscreens (CS3:
OMBRA® (SPF 50); CS4: Auscreen® (SPF 50)) and homemade sunscreens containing
TiO2/ZnO (HS1) and TiO2/Bi(OH)3 (HS2).
While both commercial sunscreens show a linear relationship between the
viscosity and the shear rate, the homemade sunscreens show non-linearity for higher
shear rates. The increase in viscosity is associated with the presence of agglomerates of
NPs, since the concentration of ceramic NPs is 8 wt.%. This effect is less pronounced for the
homemade emulsion of TiO2/Bi(OH)3, which underscores the greater homogeneity in
comparison to the ‘classical’ emulsion of TiO2/ZnO.
The relationship between the shear rate and the shear stress is shown in Figure
4.34. All tested sunscreen formulations exhibited nonlinear behaviour and consequently
can be referred to as non-Newtonian fluids [117]. The flow index
deviation of a system from Newtonian behaviour, which is found for

classifies the
= 1 [118].

Pseudoplasticity or shear thinning is typically indicated by n < 1, whereas shear thickening
is present for values of

> 1 [119].
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Figure 4.34. Rheograms of two commercially available sunscreens (CS3: OMBRA® (SPF
50); CS4: Auscreen® (SPF 50)) and homemade sunscreens containing TiO2/ZnO (HS1) and
TiO2/Bi(OH)3 (HS2).
As displayed in Table 4.10, the sunscreens showed a flow index ranging from 0.24
to 0.68, indicating pseudoplastic behaviour for all tested sunscreens. The more viscous
OMBRA® (SPF 50) sunscreen displayed the lowest flow index, which agrees with the
generally lower flow rate of thicker bases. The advantage of a pseudoplastic fluid lies in its
shear thinning properties, allowing for it to be easily spread on the skin, while
simultaneously preventing the applied film from running, as its viscosity instantly
increases when no shear is applied [120]. In contrast, a Newtonian fluid runs quickly once
applied to the skin, consequently reducing the protective effect of the applied film [121].
It is important to note that the flow index of the homemade TiO2/Bi(OH)3 (HS2)
sunscreen is very similar to that of the commercially available Auscreen® (SPF 50)
sunscreen, whereas the ‘classical’ homemade sunscreen of TiO2/ZnO (HS1) exhibits a
significantly greater flow index closer to those of Newtonian fluids.
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Table 4.10. Flow index (

) and consistency index (K) of two commercially available

sunscreens (CS3: OMBRA® (SPF 50); CS4: Auscreen® (SPF 50)) and the homemade
sunscreens of TiO2/ZnO (HS1) and TiO2/Bi(OH)3 (HS2). The errors indicated are the
standard deviation obtained through the linear regression.
Sample

K

OMBRA® (SPF 50) (CS3)

0.238 ± 0.003

3175.411 ± 63.955

Auscreen® (SPF 50) (CS4)

0.455 ± 0.001

29.000 ± 1.682

TiO2/ZnO emulsion (HS1)

0.679 ± 0.016

62.765 ± 6.475

TiO2/Bi(OH)3 emulsion (HS2)

0.481 ± 0.023

180.082 ± 27.271

The consistency index K of the formulations was calculated to range between 29 for
the Auscreen® (SPF 50) sunscreen and 3175 for the more viscous OMBRA® (SPF 50)
sunscreen. These values are in agreement with commonly reported consistency indexes
[119]. Generally, a high consistency index is associated with low spreadability, which is in
agreement with the obtained results. More importantly, the homemade TiO2/Bi(OH)3
(HS2) sunscreen showed a consistency index significantly smaller than that of the OMBRA®
(SPF 50) sunscreen, which underscores the improved spreadability properties of the
TiO2/Bi(OH)3 sunscreen.
It was further shown that the viscosities of seven tested sunscreen formulations
had a correlation with their SPF values: an increased SPF value always coincided with a
higher viscosity [119]. These findings are in agreement with the obtained results for the
two homemade sunscreens: the TiO2/Bi(OH)3 (HS2) sunscreen with a larger SPF value also
shows greater viscosity in comparison to the ‘classical’ sunscreen with TiO2/ZnO (HS1)
(see section 4.3.8).
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4.3.8 Photoprotection of Homemade Sunscreens
The UV absorbance of the ‘classical’ sunscreen made of TiO2/ZnO (HS1), and of the
sunscreen made of TiO2/Bi(OH)3 (HS2) was determined in vitro over the entire UV
spectrum (290 – 400 nm) using substrate spectrophotometry.
According to the recommendation of the European Commission, the ‘classical’
sunscreen with a measured SPF of 39.02 ± 1.26 can be classified in the category of ‘high
protection’ [100]. In addition, this sunscreen shows the characteristics of a broad spectrum
sunscreen which can give photoprotection against longer UV wavelengths, since the critical
wavelength of 372.88 ± 0.07 nm is higher than 370 nm. The UVA-PF is 14.99 ± 0.39.
The sunscreen made of TiO2 and Bi(OH)3 is significantly more efficient in the UVA
and UVB range, with a SPF of 49.93 ± 1.66, which represents an increase of 28% compared
to the ‘classical’ sunscreen. Furthermore, the TiO2/Bi(OH)3 sunscreen shows a UVA-PF of
16.57 ± 0.38, which is equivalent to an increase of 11% in comparison to the TiO2/ZnO
sunscreen. The UVA-PF is 33.2% of the total SPF for the TiO2/Bi(OH)3 sunscreen and
therefore falls within the recommendations of the United States Food and Drug
Administration (FDA) [122].
The obtained SPF is significantly larger than previously reported SPF values, such
as for CeO2 NPs. For instance, it was shown that a sunscreen of TiO2 and calcium-doped
CeO2 NPs resulted in a maximum SPF of approximately 40 with a UVA-PF of approximately
11.5 [123].
The critical wavelength of the TiO2/Bi(OH)3 sunscreen was determined to be
372.01 ± 0.08 nm, resulting in broad-spectrum protection according to the FDA [122].
Since the critical wavelength only depends on the shape and width of the absorbance
spectrum, and not on the amplitude or the thickness of sunscreen application, the
protection in the high-wavelength UVA region of both tested sunscreens is underlined.
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An in-vitro study of 59 commercially available sunscreen products with UVA-filters,
such as TiO2 and ZnO, showed that only 10% of the tested sunscreens had a critical
wavelength ≥ 370 nm [117]. This study demonstrates that a simple addition of long
wavelength UVA active ingredients does not ensure true broad-spectrum protection, and
thus underscores the importance of the obtained results for the homemade sunscreen of
TiO2/Bi(OH)3.
4.3.9 Cytotoxicity of Bi(OH)3, TiO2, and ZnO Nanoparticles in HaCaT and MDCK
Cells
In order to be considered a potential material in sunscreen formulations, the
Bi(OH)3 NPs need to be biocompatible. The cytotoxicity of Bi(OH)3 (M1), TiO2 (M2), and
ZnO (M3) NPs was determined using the MTT assay, which is often employed to evaluate
the effects of anticancer drugs [96].
Mitochondria are crucial for the maintenance of cellular function via aerobic
adenosine triphosphate production and are therefore targets for toxic injury by numerous
types of compounds [124]. Since the reduction of the tetrazolium salt occurs only in
functional mitochondria, a decrease in MTT dye reduction indicates mitochondrial damage.
Non-cancerous human skin cells (HaCaT) and dog kidney cells (MDCK) were
chosen, which were exposed to the NPs for 24 h at concentrations ranging from 5 to 500
µg/mL (Figure 4.35). While HaCaT keratinocytes are typically used to examine potential
adverse effects of NPs in sunscreens [125, 126], MDCK cells are typically used to determine
biocompatibility of nanomaterials since kidney cells represent a possible detoxification
route [127, 128]. So in addition to providing the essential results on HaCaT cells, the MDCK
results provide a point of reference for other workers in the NP research area.
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Figure 4.35. Effects of Bi(OH)3 (M1), TiO2 (M2), and ZnO (M3) nanoparticles on the
mitochondrial function in non-cancerous human skin (HaCaT) cells and dog kidney
(MDCK) cells. The cells were treated with the nanoparticles at concentrations of 0
(control), 5, 10, 25, 50, 100, 250, and 500 µg/mL for 24 h. At the end of exposure, the
mitochondrial function was determined using the MTT reduction assay. The data are
presented as the mean of three independently prepared experiments.
In general, a reduction in cell viability was observed in a dose-dependent manner
for all the tested nanomaterials, which was more distinct in MDCK cells. The results
indicate a significant decrease in mitochondrial activity for the ZnO NPs, with a cell
viability of 48.7% and 0.5% in HaCaT and MDCK cells, respectively, at the highest tested
concentration of 500 µg/mL. The TiO2 NPs demonstrate only moderate cytotoxicity with a
cell viability ranging between 61.5 – 71.2% at the same concentration. Similar findings
regarding the cytotoxicity of ZnO and TiO2 NPs in HaCaT cells are described in the
literature [125].
The Bi(OH)3 NPs exhibited only a minor change in the reduction of MTT dye for all
the tested concentrations in both cell lines, indicating that the mitochondrial function was
not altered much at these doses. At the highest tested dose of 500 µg/mL, the NPs showed
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a cell viability of 83.5% and 82.5% in HaCaT and MDCK cells, respectively. The high
biocompatibility of Bi(OH)3 NPs compared to the controls points to their suitability for use
in sunscreens as opposed to ZnO NPs.
4.3.10 Conclusions
The free radical generating properties of the TiO2 and ZnO NPs currently used in
some commercial sunscreen products could have the potential to cause adverse health
effects, either through the direct interaction of these radicals with human tissue, or
through the accelerated decomposition of other organic compounds within the
formulation. These reactions not only have the potential to decrease the SPF of the
formulation more rapidly, but also yield products with unknown effects on the human
body.
In this thesis, the potential of colourless Bi(OH)3 NPs that were synthesized
through a facile, low-temperature route as an active ingredient in sunscreen formulations
was investigated. The Bi(OH)3 NPs showed low photocatalytic activity throughout the
whole UV-visible spectrum, and more importantly, they were able to reduce the
photocatalytic activity of TiO2 and ZnO NPs. It was also shown that sunscreen formulations
containing TiO2/Bi(OH)3 have better photostability than commercially available sunscreen
formulations, while displaying excellent rheological properties.
With its comparable absorbance to ZnO and TiO2 in the UV region, and its
significantly increased SPF and UVA-PF, Bi(OH)3 NPs offer a novel and cost-effective
approach to improve the UV blocking properties of commercial sunscreen formulations
and act as an antioxidant stabilizer for the organic components of the product, reducing the
potential harm of these products to the health of the consumer.
Moreover, the Bi(OH)3 NPs exhibited high biocompatibility in healthy HaCaT and
MDCK cells, while introduction of ZnO NPs resulted in a significant decrease in cell viability
over the exposure time of 24 h at the same tested concentrations.
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4.4 TiO2/(BiO)2CO3 Nanocomposites for Ultraviolet Filtration with
Reduced Photocatalytic Activity
In this section, the UV blocking properties and photocatalytic activity of
nanocomposite materials consisting of TiO2 NPs and homogeneously attached (BiO)2CO3
clusters with a size < 10 nm onto their surfaces is presented. The nanocomposites were
prepared using a facile precipitation approach with different atomic ratios of Bi/Ti of 0.02,
0.04, and 0.08. The synthesis procedure and all characterization methods are described in
CHAPTER 3. The photocatalytic activity of the TiO2/(BiO)2CO3 nanocomposites and pristine
TiO2 NPs were investigated through monitoring crystal violet degradation under UVA/UVB
irradiation and simulated solar irradiation. The cytotoxicity was determined in normal
HaCaT and MDCK cells using the MTT assay at a concentration ranging from 5 to 500
µg/mL and an exposure time of 24 h.
4.4.1 Identification,

Size,

Morphology,

and

Surface

Composition

of

TiO2/(BiO)2CO3 Nanocomposites
Figure 4.36 displays the XRD patterns of the commercial TiO2 NPs and the
synthesized nanomaterials, which can be identified as nanocomposites of the type
TiO2/(BiO)2CO3. The XRD pattern of the TiO2 NPs shows reflections attributed to the
anatase

(JCPDS

01-075-2552)

and

rutile

(JCPDS

01-075-1753)

phases.

The

nanocomposites do not alter the diffraction patterns of the core materials, but lead to
additional reflections in the XRD pattern which are assigned to (BiO)2CO3 (JCPDS 00-0411488). Moreover, the relative intensity of the reflections increases with increased bismuth
present in the nanocomposite.
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Figure 4.36. XRD patterns of commercial TiO2 NPs, and the TiO2/(BiO)2CO3
nanocomposites Bi/Ti 2, 4, and 8 at.%.
Typically, the synthesis of (BiO)2CO3 requires the use of templates or hydrothermal
treatments. In this work, however, the TiO2 NPs act as primary nucleation centres during
the nanocomposite synthesis. It was shown that TiO2 NPs can act as substrate seeds on
which a single spherical domain of inverse spinel iron oxide can be epitaxially grown [129].
The seeds can act as efficient catalysts and provide a lower energy barrier for
heterogeneous nucleation, in comparison to homogeneous nucleation [130].
The two-step precipitation method used in this work includes the addition of
excess ammonium hydroxide, which was used as the precipitating agent, yielding
(BiO)2CO3. It has been shown that the concentration of precipitating agent has a significant
influence on the physical properties of (BiO)2CO3 NPs [131]. Since no carbon source was
added to the reaction mixture, the carbonate formation occurred due to the presence of
aqueous CO2. In aqueous solution, carbonic acid, carbon dioxide, bicarbonate, and
carbonate exist together in a dynamic equilibrium, as shown in Equation (4.3), Equation
(4.4), and Equation (4.5) [132]:
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In acidic environments, the equilibrium shifts to CO2 (aq), while the addition of a
base can shift the equilibrium to the carbonate. In this work, (BiO)2CO3 clusters were
precipitated using a very slow and dropwise addition of 30% NH4OH, increasing the pH
value gradually. The reaction was complete at a pH of 8 – 9. These principles of carbonate
equilibrium chemistry were already used to monitor the rate of inorganic carbon uptake
by a variety of algal species [133].
The BET specific surface area of all materials was measured and is displayed in
Table 4.11. TiO2 NPs typically show a high specific surface area close to 50 m2/g [134]. The
nanocomposites display a small decrease in surface area, associated with the coverage of
the TiO2 surface by the (BiO)2CO3 clusters, due to the increase in the overall size of the NPs.
Table 4.11. BET surface areas of TiO2/(BiO)2CO3 nanocomposites.a)
Sample

BET surface area (m2/g)

TiO2

47.8 ± 0.5

Bi/Ti 2 at.%

47.2 ± 0.5

Bi/Ti 4 at.%

45.5 ± 0.5

Bi/Ti 8 at.%

43.6 ± 0.4

a)

Data provided for the pure TiO2 NPs, and the TiO2/(BiO)2CO3 nanocomposites with

different Bi/Ti atomic ratios. The indicated errors are the standard deviation.

Figure 4.37 and Figure 4.38 show SEM and STEM images of the pure TiO2 NPs, and
the TiO2/(BiO)2CO3 nanocomposites with Bi/Ti atomic ratios of 0.02, 0.04, and 0.08. The
commercial TiO2 is made up of mostly rectangular, spherical, ellipsoidal, and prism-like
particles with an average particle size of 23.39 ± 8.59 nm. Figure 4.37 shows the SEM
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images of the nanocomposite with Bi/Ti atomic ratios of 0.02, 0.04, and 0.08. For all
nanocomposites, the SEM analysis does not show any significant difference in morphology
to uncoated TiO2.

Figure 4.37. SEM images of TiO2 NPs (left), and the TiO2/(BiO)2CO3 nanocomposites with
different Bi/Ti atomic ratios.
The STEM images of the TiO2/(BiO)2CO3 composites clearly show that the surfaces
of the TiO2 NPs are covered with very small ( < 10 nm) (BiO)2CO3 clusters (Figure 4.38).
The coverage with the (BiO)2CO3 clusters is homogeneous and increases with added
(BiO)2CO3. The HAADF image of the nanocomposite with Bi/Ti 8 at.% (right image) reveals
the interface between TiO2 and (BiO)2CO3 clusters and shows rutile TiO2 with interplanar
spacings of 0.30 and 0.33 nm, which is in accordance with the d-spacings of (001) and
(110) planes, respectively.

Figure 4.38. HAADF STEM images of TiO2 NPs (left), the TiO2/(BiO)2CO3 nanocomposites
with different Bi/Ti atomic ratios. The HAADF image of the nanocomposite with Bi/Ti 8
at.% (right) exposes lattice fringes spaces of 0.30 and 0.33 nm, corresponding to (001) and
(110) planes of rutile TiO2, respectively.
The high resolution EDS mapping indicates that the uncoated TiO2 NPs feature no
Bi (Figure 4.39) while a significant proportion of Bi can be found on the surfaces of the
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particles for the TiO2/(BiO)2CO3 nanocomposites. The EDS maps of the nanocomposites
displayed a homogeneous distribution of the Bi on the surfaces of the TiO2 particles.
Uncovered TiO2 NPs were not found anywhere in the imaged specimens, even for the
composite with the smallest amount of (BiO)2CO3 (Bi/Ti 2 at.%). The Bi/Ti ratio of each of
the composites was measured from EDS measurements. The obtained ratio for the 2, 4 and
8 at.% nanocomposites was 1.73 ± 0.1, 3.76 ± 0.1, and 8.11 ± 0.25 at.%, respectively.

Figure 4.39. TEM images with high resolution EDS mapping of (a) TiO2 NPs, (b)
TiO2/(BiO)2CO3 sample Bi/Ti 2 at.%, (c) TiO2/(BiO)2CO3 sample Bi/Ti 4 at.%, and (d)
TiO2/(BiO)2CO3 sample Bi/Ti 8 at.%.
The surface composition of the nanocomposites was characterized using high
resolution XPS. Figure 4.40 displays the high resolution XPS spectra of the Bi 4f orbitals
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(left column) and the C 1s orbital (right column), and the peak deconvolution results for
the pure TiO2, and TiO2/(BiO)2CO3 nanocomposites. While the TiO2 NPs do not display any
Bi 4f orbitals, the presence of (BiO)2CO3 clusters in Bi/Ti 2 at.% yields a significant signal of
the two symmetric Bi 4f peaks with a binding energy of 159 eV (Bi 4f7/2) and 164 eV (Bi
4f5/2), which indicates the presence of Bi–O bonds with bismuth in the +3 oxidation state,
as found in (BiO)2CO3 [53, 74]. The intensity of the Bi 4f peak increases with increasing
atomic ratio of Bi/Ti in the nanocomposite materials.
Two Gaussian peaks were used to fit the experimental data in the high resolution
XPS spectra of C 1s (right column). The peak at the lower binding energy of 284.83 eV can
be assigned to C–C bonds in adventitious carbon [53]. The second C 1s peak at 287 eV is
ascribed to the C–O bonds that are usually present in CO32-, as found in (BiO)2CO3 [53].
Similarly to the Bi 4f peak, the carbonate-related peak increases in intensity with
increasing amounts of (BiO)2CO3 on the surface of TiO2. The carbon element in pure TiO2
corresponds mainly to adventitious hydrocarbon and is not related to the presence of
(BiO)2CO3.
All XPS data are summarized in Table 4.12.The XPS analysis supports the findings
from the XRD and TEM analysis and confirms the presence of (BiO)2CO3 in the
nanocomposite materials. The XPS spectra for N 1s, O 1s and Ti 2p are shown in Figure A12
in the Appendix I. There were no peaks detected in the N 1s area, which excludes the
presence of bismuth oxynitrates [135].
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Figure 4.40. High resolution XPS spectra of the Bi 4f (left column) and C 1s (right column)
regions of TiO2 NPs, and TiO2/(BiO)2CO3 nanocomposites with different Bi/Ti atomic
ratios.
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Table 4.12. High resolution XPS data of Bi 4f and C 1s of TiO2 NPs and the TiO2/(BiO)2CO3
nanocomposites with different Bi/Ti atomic ratios.a)
Sample

Bi 4f5/2 (eV)

Bi 4f7/2 (eV)

C 1s C-O (eV)

–

–

286.92 ± 0.28

Bi/Ti 2 at.%

164.68 ± 0.45

159.31 ± 0.28

287.57 ± 0.24

Bi/Ti 4 at.%

164.85 ± 0.40

159.34 ± 0.21

287.56 ± 0.24

Bi/Ti 8 at.%

165.85 ± 0.39

160.51 ± 0.43

287.25 ± 0.23

TiO2

a)

The C 1s peak of adventitious carbon for all samples is found at 284.83 eV.

4.4.2 Optical Properties and Band Gap of the TiO2/(BiO)2CO3 Nanocomposites
The UV-visible absorption spectrum of each investigated material was measured in
order to determine its UV filtering properties and the effects of the (BiO)2CO3 formed onto
the TiO2 surface on the optical band gap (Figure 4.41).

Figure 4.41. (a) UV-visible absorption spectra and (b) Tauc plots of TiO2 NPs, and
TiO2/(BiO)2CO3 nanocomposites with different Bi/Ti atomic ratios. The absorption spectra
were recorded at a concentration of NPs of 25 µg/mL in DI water.
TiO2 NPs are a common additive to commercial sunscreen formulations with a high
and selective absorbance within the UV region (Figure 4.41(a)). The TiO2/(BiO)2CO3
nanocomposites exhibit a very similar absorption over the entire UV range as compared to
uncoated TiO2 NPs, with only slightly reduced intensities, depending on the amount of
(BiO)2CO3 clusters present. The reduced absorbance in the visible range is related to the
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presence of more transparent (BiO)2CO3 in comparison to TiO2, which is of advantage in
regard to potential application in sunscreen formulations [50]. Moreover, there is only a
very small blue shift identified for all tested nanomaterials.
These findings suggest that the (BiO)2CO3 clusters have a negligible impact on the
optical properties of the heterojunctions. This is most accurately reflected in a minor
increase in the optical band gap of the nanocomposite materials, ranging from 2.69 to 2.83
eV compared to the TiO2 NPs with an optical band gap of 2.68 ± 0.08 eV, as seen in Table
4.13. The band gaps of all the materials were calculated using Equation (3.8) and represent
indirect band transitions. The Tauc plots are shown in Figure 4.41(b).
Table 4.13. Band gaps of TiO2/(BiO)2CO3 nanocomposites.a)
Sample

Band gap (eV)

TiO2

2.68 ± 0.08

Bi/Ti 2 at.%

2.83 ± 0.09

Bi/Ti 4 at.%

2.79 ± 0.07

Bi/Ti 8 at.%

2.69 ± 0.05

a)

Data provided for the pure TiO2 NPs, and the TiO2/(BiO)2CO3 nanocomposites with

different Bi/Ti atomic ratios. The indicated errors are the standard deviation.

4.4.3 Photocatalytic Activity of the TiO2/(BiO)2CO3 Nanocomposites under
Ultraviolet Exposure (300 nm and 350 nm) and under Simulated Solar
Irradiation
Each of the nanocomposite materials and the pure TiO2 NPs were tested for their
photocatalytic activity within a broad UVA/UVB spectrum and under simulated solar light
irradiation. Crystal violet was utilized as an indicator of the photocatalytic activity and the
associated production of hydroxyl radicals (see section 3.4.4).
The discoloration of crystal violet in the absence of any photocatalyst was
negligible, both under UV and under solar light irradiation. Upon addition to the crystal
233

Chapter 4 – Bismuth-Based Compounds for Biomedical Applications

violet solution of a suspension of TiO2 at a final concentration of 5 mg/L, the reaction
mixture degraded almost completely due to photocatalytic reactions when exposed to UVA
and UVB light for 30 min, as shown in Figure 4.42(a).

Figure 4.42. (a) Relative decrease in absorbance of crystal violet solutions containing TiO2,
and TiO2/(BiO)2CO3 nanocomposites with different Bi/Ti atomic ratios under UV light
exposure (300 nm and 350 nm). The concentration of all materials is 5 mg/L. The data
represent the mean of three independently prepared samples, which were measured
separately. (b) Apparent rate constant curves for the UV-visible dye degradation of crystal
violet, as shown in (a).
The photocatalytic activity of TiO2 is generally linked to the particular phase: while
anatase TiO2 exhibits strong photocatalytic activity, the rutile phase is less active [112,
115]. Here, commercial Aeroxide® P25 was used, which is a combination of both anatase
and rutile TiO2. The addition of 5 mg/L of the nanocomposite materials resulted in a
significant decrease in degradation of crystal violet in comparison to the pure TiO 2,
suggesting a reduction in photocatalytic activity.
Furthermore, the reduction in the degradation of crystal violet increased with
increasing amounts of (BiO)2CO3 clusters on the surface of TiO2. More interestingly, there is
only a small difference in degradation between the nanocomposites, which indicates that a
coating with (BiO)2CO3 that results in a Bi/Ti atomic ratio of 0.02, leads to a significant
reduction in the photocatalytic activity of the TiO2 NPs, without affecting the UV blocking
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properties of TiO2. The apparent rate constant k for each of the materials was calculated
using the Langmuir-Hinshelwood model and is shown in Table 4.14. whereas the plots are
displayed in Figure 4.42(b) [136].
Table 4.14. Apparent rate constant k for the degradation of crystal violet solutions
containing TiO2, and TiO2/(BiO)2CO3 nanocomposites under irradiation by UV light
(300 nm and 350 nm) and AM 1.5 G one sun (100 mW/cm2). The concentration of all
materials is 5 mg/L. The errors indicated are the standard deviation obtained through the
linear regression.
Sample

k × 10-2 (min-1), UV irradiation

k × 10-2 (min-1), sunlight irradiation

Dye only

0.02 ± 0.01

0.47 ± 0.10

TiO2

6.64 ± 0.22

44.81 ± 0.82

Bi/Ti 2 at.%

1.15 ± 0.04

11.43 ± 0.18

Bi/Ti 4 at.%

1.03 ± 0.04

10.57 ± 0.18

Bi/Ti 8 at.%

0.92 ± 0.03

9.93 ± 0.3

As displayed in Figure 4.43, the degradation of crystal violet under simulated solar
light irradiation showed a similar trend to that under UV light in the same system, for an
exposure time of 6 h. TiO2 displays close to 100% degradation after 6 h of simulated solar
light irradiation. The apparent rate constants for the nanocomposite materials are 3.9 – 4.5
times smaller than for the pure TiO2, further confirming the photodegradation protection
provided by (BiO)2CO3 at small concentrations.
The decrease in photocatalytic activity can be attributed to a number of factors,
such as a decrease in the BET specific surface area, although the coating with (BiO)2CO3 in
Bi/Ti 2 at.% leads to a decrease in the BET specific surface area of less than 1.5% in
comparison to TiO2. Yet, the photocatalytic activity of that nanocomposite is reduced by
over 55% compared to TiO2. Furthermore, the (BiO)2CO3 clusters, which are located on the
surface of TiO2, can absorb incoming UV light, reducing the overall radiation that reaches
TiO2. It is shown, however, that even the very small addition of (BiO)2CO3 to TiO2 which
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results in Bi/Ti 2 at.% is sufficient to cause a significant decrease in the degradation of
crystal violet. Further addition beyond Bi/Ti 2 at.% has a negligible effect. Therefore, the
reduction in photocatalytic activity does not appear to be related to a decrease in the
surface area or increased absorption of UV radiation by the (BiO)2CO3 clusters.

Figure 4.43. (a) Relative decrease in absorbance of crystal violet solutions containing TiO2,
and TiO2/(BiO)2CO3 nanocomposites with different Bi/Ti atomic ratios under exposure of
AM 1.5 G one sun (100 mW/cm2). The concentration of all materials is 5 mg/L. The data
represent the mean of three independently prepared samples, which were measured
separately. (b) Apparent rate constant curves for the dye degradation of crystal violet
under exposure to AM 1.5 G one sun (100 mW/cm2), as shown in (a).
Another explanation for the observed reduced dye degradation can be the very
small size of the (BiO)2CO3 clusters (< 10 nm), which leads to their very high
surface/volume ratio. Due to the low crystallinity, the surface is enriched with defects,
which can act as ROS scavengers, as shown for CeO2 NPs [95, 137]. More importantly, it is
widely known that carbonate acts as a hydroxyl radical scavenger. Once the carbonate is in
contact with hydroxyl radicals, the formation of carbonate radicals is observed, as shown
in Equation (2.5) [138, 139]. The carbonate radical is very selective and typically prolongs
degradation processes [55, 56].
Typically, nanomaterials are designed that increase the photocatalytic activity with
the goal of improving the catalyst efficiency [140, 141]. Although the use of (BiO)2CO3 NPs
236

Chapter 4 – Bismuth-Based Compounds for Biomedical Applications

for photocatalytic purposes is widely reported, (BiO)2CO3 can also be used as a
photoprotector, reducing the photocatalytic activity of the strong photocatalyst TiO2.
(BiO)2CO3 is a weak photocatalyst on its own, especially at low concentrations such as
those used in this work. Noticeable photocatalytic degradation of rhodamine B [58] and
methyl orange [52] under UV-visible light irradiation was achieved at concentrations of 1.0
and 0.1 g/L, respectively. The application of (BiO)2CO3 clusters as a photoprotector is of
interest and importance, since TiO2 NPs are widely used as the active component in
sunscreen formulations, although it is known that they generate free radicals [111, 142].
4.4.4 In Vitro Cell Viability in HaCaT and MDCK Cells
The in vitro cell viability was determined in non-malignant human skin cells and
kidney (MDCK) cells in in two different settings: under the absence of simulated sunlight
(HaCaT and MDCK) and under presence of simulated sunlight (HaCaT). HaCaT
keratinocytes are typically used to investigate possible adverse effects of NPs in
sunscreens [125]. MDCK cells are used to examine the biocompatibility of NPs, since the
kidney represents a possible detoxification route [127, 128].
As of now, bismuth oxychloride (BiOCl) is the only bismuth-based compound that
has been studied in HaCaT cells, although without the application of UVA and UVB light and
simulated sunlight [143]. Neither the toxicity of (BiO)2CO3 in HaCaT cells, nor the inhibition
of photo-induced toxicity of TiO2 due to the presence of (BiO)2CO3 upon irradiation with
simulated sunlight has yet been reported, which ultimately highlights the novelty of the
presented work.
4.4.4.1 In the Absence of Simulated Sunlight
The cytotoxicity of the commercial TiO2 NPs, and the TiO2/(BiO)2CO3
nanocomposite materials was determined using the MTT assay, which is based on the
conversion of MTT into formazan crystals by viable cells [144]. HaCaT and MDCK cells
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were exposed to the NPs for 24 h at concentrations ranging from 5 to 500 µg/mL (Figure
4.44).
In general, the reduction of cell viability was observed in a dose-dependent manner
for all tested nanomaterials. In both cell lines, the pristine TiO2 NPs displayed the highest
cytotoxicity of all the tested materials. Nevertheless, at the highest tested concentration of
500 µg/mL, the decrease in mitochondrial activity is still moderate for the TiO2 NPs, with
cell viability of 71.2 ± 4.5% and 61.5 ± 6.6% in HaCaT and MDCK cells, respectively. The
TiO2/(BiO)2CO3 nanocomposites show cell viabilities that lie above that for the TiO2 NPs. In
addition, the biocompatibility of the nanocomposites increases with increasing atomic
ratio of Bi/Ti.

Figure 4.44. Effects of the commercial TiO2 NPs, and TiO2/(BiO)2CO3 nanocomposites with
different Bi/Ti atomic ratios on the mitochondrial function in non-cancerous a) HaCaT
human skin cells and b) dog kidney (MDCK) cells. The cells were treated with the NPs at
concentrations of 0 (control), 5, 10, 25, 50, 100, 250, and 500 µg/mL for 24 h. At the end of
exposure, the mitochondrial function was determined using the MTT reduction assay. The
data are represented as the mean of three independently prepared experiments.
4.4.4.2 In the Presence of Simulated Sunlight
To confirm that the toxicity of TiO2 is reduced by the inhibition of photocatalytic
activity due to (BiO)2CO3, cell viability assays with HaCaT have been performed under
presence of TiO2, TiO2/(BiO)2CO3 (Bi/Ti 8 at.%), and simulated sunlight.
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To ensure that the chosen concentrations of tested nanomaterials are sufficient to
induce detectable photocatalytic effects, the degradation of crystal violet was evaluated in
presence of TiO2 NPs at 25, 50, and 100 µg/mL and simulated sunlight for 15 min (Figure
4.45). A concentration of 25 µg/mL has been shown to be sufficient to cause a degradation
of crystal violet of over 33%.

Figure 4.45. Degradation of crystal violet solutions containing TiO2 NPs at concentrations
of 25, 50, and 100 µg/mL upon irradiation with simulated sunlight (300 W Sunlamp, UltraVitalux®, OSRAM) for 15 min.
The HaCaT cell viability following exposure to TiO2 or TiO2/(BiO)2CO3 (Bi/Ti 8
at.%) NPs at concentrations of 25, 50, and 100 µg/mL with and without additional
simulated sunlight irradiation is shown in Figure 4.46. When compared to the toxicity of
the nanomaterials alone (non-irradiated), it is clearly visible that the additional exposure
to simulated sunlight initiates processes that cause a higher toxicity in HaCaT cells. For
instance, at a concentration of 100 µg/mL, the cell viability after treatment with only TiO2
NPs is high with a survival of 86.4 ± 2.9%, while after additional irradiation with simulated
sunlight the cell viability decreases to 64.1 ± 4.4%. This increase in cell mortality is most
likely related to the photocatalytic activity of TiO2 and the subsequent generation of ROS,
while the composite is capable of inhibiting a significant amount of photocatalysis [145,
146]. In particular, for the same conditions, the treatment with TiO2/(BiO)2CO3 results in a
cell viability of 74.5 ± 4.7% after irradiation with simulated sunlight.
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More interestingly, it is further shown that a significant effect of photocatalysis can
only be observed at concentrations ≥ 50 µg/mL, which implies that the impact of
photocatalytic activity of TiO2 on the viability of HaCaT cells is negligible at concentrations
≤ 25 µg/mL.

Figure 4.46. Viability of HaCaT cells following exposure to TiO2 or TiO2/(BiO)2CO3 (Bi/Ti 8
a.%) NPs with and without additional simulated sunlight irradiation (300 W Sunlamp,
Ultra-Vitalux®, OSRAM) for 15 min. The viability was assessed using the MTT assay and the
tested concentrations were 25, 50, and 100 µg/mL. The data are expressed as percentage
of viable cells compared to control cells that have not been exposed to nanomaterials.
The decrease of cell viability of human skin fibroblasts upon exposure to TiO2 NPs
and UV light has been reported widely [145-147]. For instance, the use of rutile TiO2 and
anatase TiO2 at concentrations of 50 and 100 µg/mL was assessed in HaCaT cells under
UVA irradiation with doses of 0 – 10 J/cm2 [146]. No significant toxicity was found towards
HaCaT cells exposed to TiO2 at a concentration of 100 µg/mL without irradiation. Upon
irradiation with UVA, however, the anatase TiO2 treatment resulted in a decrease in cell
viability of over 40% at the highest tested dose of 10 J/cm2, while rutile TiO2 displayed
phototoxicity of less than 20% [145].
Interestingly, the use of a mixture of anatase and rutile (P25), similarly to this
work, showed a decrease in cell viability of over 80 and 85% for a dose of 5.4 and 10 J/cm 2,
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respectively. Although the results in this work show higher cell viability at a dose of 5.4
J/cm2, the observed trend highlights the need of more research into the reduction of
photocatalytic activity of TiO2, in particular P25, which is still widely applied in commercial
sunscreen formulations [111, 142].
The phototoxicity is generally linked to the generation of ROS in presence of UVA
[145, 146]. In particular, an increase in accumulation of intracellular ROS levels by 1.8-fold
has been observed in HaCaT cells after 24 h exposure to 200 µg/mL of P25 and irradiation
with UVA (365 nm) [146].
4.4.5 Conclusions
The commonly used TiO2 NP additives in sunscreen formulations pose a potential
health risk in regard to their ability to generate free radical species that, in turn, can cause
cyto- and genotoxicity, either directly through penetration into deep skin tissue or
indirectly through the degradation of organic sunscreen additives. The latter case could
result in the formation of intermediates with unknown toxicity, which – besides the
reduction of SPF – can cause adverse side effects.
By reducing the photocatalytic activity of TiO2 NPs and simultaneously maintaining
the UV filtering properties, the health risk of these sunscreen additives can be minimized.
Using a simple two-step precipitation approach, TiO2/(BiO)2CO3 nanocomposites were
synthesized with different atomic ratios of Bi/Ti (0.02, 0.04 and 0.08). The (BiO)2CO3
clusters are smaller than 10 nm and are evenly distributed throughout the surfaces of the
TiO2 NPs.
It is demonstrated that, by introducing a small amount of (BiO)2CO3 clusters onto
the surface of TiO2, which results in an atomic ratio of Bi/Ti of 0.02, its photocatalytic
activity was decreased and its biocompatibility in healthy cells increased, while
maintaining its size, morphology, and UV blocking ability. Moreover, the nanocomposites
displayed a reduced toxicity in HaCaT cells upon irradiation with simulated sunlight in
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comparison to TiO2 NPs, which indicates that the composites are capable of reducing the
photo-induced generation of ROS.
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5.1 Introduction
Similar to bismuth, tantalum and its compounds have also shown great
biocompatibility [1, 2]. Tantalum is a shiny, blue-grey transition metal that is chemically
inert, and, when in contact with air, it usually forms a protective layer of Ta2O5 on its
surface [3]. Despite its much higher cost in comparison to Bi-based materials, tantalum is
highly corrosion- and temperature-resistant and thus, finds applications in aircraft
engines, in the chemical industry, and as a component in laboratory equipment [3]. Due to
its high biocompatibility, tantalum is used for surgical implants and coatings [1, 3].
5.1.1 Properties of Ta2O5
Ta2O5 is a transition metal oxide that can exist in multiple structural polymorphs,
including low-temperature (L) and high-temperature (H) phases, as displayed in Table 5.1.
The identification of Ta2O5 structures has been a subject of on-going research for over 50
years and has resulted in the description of multiple L-phases, in which multiple integers
(5, 8, 11, 13, 14, 19, 22, and 25) of the parameter b of the orthorhombic sub-cell have been
found to result in slight variations of the overall L-Ta2O5 structure [4, 5].
Table 5.1. Polymorphs of Ta2O5 and the corresponding crystal systems and space groups.
Polymorph

Other names

Crystal

Space group

References

I41/amd

[6, 7]

system
High-temperature
α-Ta2O5

Tetragonal
(H-Ta2O5)

Pccm (11L-Ta2O5)

Low-temperature
β-Ta2O5

Orthorhombic
(L-Ta2O5)

C112/m (19L-Ta2O5)

[4-6, 8, 9]

δ-Ta2O5

–

Hexagonal

P6/mmm

[8-10]

Z- Ta2O5

–

Monoclinic

C2

[11]

Trigonal Ta2O5

–

Trigonal

R3

[5]
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On the nanoscale, the irreversible transition from δ-Ta2O5, the crystal structure of
which is shown in Figure 5.1, to β-Ta2O5 occurs at a temperature ≥ 750°C [8]. The
reversible transition of β-Ta2O5 to α-Ta2O5 has been observed at 1320°C [6]. Trigonal Ta2O5
thin films were obtained upon thermal deposition of amorphous precursors on Si(001)
wafers [5].

Figure 5.1. Crystal structure of δ-Ta2O5; obtained via Materials Studio software with data
from [9].
To synthesize Ta2O5, tantalum alkoxides such as tantalum ethoxide (Equation (5.1))
or halides, such as tantalum chloride (Equation (5.2)), are used, which, once dissolved,
form a Ta2O5 precipitate after the addition of water. The subsequent annealing of the Ta2O5
precursor at 730°C leads to crystalline δ-Ta2O5 NPs [12]:
(

)

()
()

()
()

→

( )

→

( )

(
(

)

)

(5.1)
(5.2)

Applications
Ta2O5 is chemically inert [13], biocompatible [2], shows good radiopacity [14], and
is nearly insoluble, except in very strong bases and hydrofluoric acid [15, 16]. Its
extraordinary corrosion resistance makes Ta2O5 a valuable material for laboratory
equipment [17], whereas its high refractive index enables the use of Ta2O5 for the
preparation of photographic lenses and coatings [18].
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In addition, Ta2O5 displays great dielectric properties [17, 19] and promising
piezoelectric behaviour in form of thin films [5], which are typically obtained using
metalorganic vapour phase epitaxy (MOVPE) [20]. Together with its wide band gap of 3.9 –
4.0 eV for the bulk material [21, 22], these properties have led to the use of Ta2O5 in
electronics, particularly in tantalum capacitors [17, 20], and its investigation as a memory
device [23].
Diagnostic properties
Ta-based compounds have a high effective atomic number of Z = 73 and density of
16.6 kg/m3, and have been investigated for dose enhancement on radio-resistant 9L rat
gliomasarcoma cancer cells in an megavolt photon field [12] and their ability to increase
anatomical contrast [13, 24]. In vitro studies have shown that, for equal molar
concentrations of tantalum and iodine, the image contrast was larger with tantalum across
the diagnostic X-ray spectrum [13].
The easily modifiable surfaces of Ta2O5 allow loading with anti-cancer drugs, which
is typically achieved with conjugation or encapsulation by a polymer layer [25]. These
core-shell structures can further be of benefit for CT imaging, as they can be administered
intravenously and display subsequent renal clearance [13, 26].
5.1.2 Polymers and Hydrogels
Studies of polymers for personalized and tailored medicine have been extensively
reported. On the nanoscale, polymers can improve the half-life, solubility, and stability of
drug delivery systems, while reducing potential side effects [27-29]. The polymers that are
used for the design of drug delivery systems can be divided into two categories [30]:


Natural polymers, and



Synthetic polymers.

Protein based natural polymers include collagen, albumin, and gelatin, while
natural polysaccharides are typically complexly branched agarose, hyaluronic acid,
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dextran, chitosan, and cyclodextrins [30]. A selection of synthetic polymers used for the
design of drug delivery systems is displayed in Table 5.2.
Table 5.2. Selection of synthetic polymers that are used for drug delivery systems.
Commercial name
Poly(ethylene glycol)
(PEG)
Poly(ethylene imine)
(PEI)
Poly(lactic acid)

IUPAC name

Chemical structure

Poly(oxyethylene)

[31, 32]

Poly(iminoethylene)

[31]

Poly(2-

(PLA)

hydroxypropionic acid)

Polyvinylpyrrolidone

1-Ethenylpyrrolidin-2-

(PVP)

one

Poly(acrylic acid)
(PAA)
Poly(vinyl alcohol)
(PVA)

References

Polyacrylic acid

[33]

[34]

[35, 36]

[37]

1-Hydroxyethylene

Besides their individual use, these polymers can be coupled with other polymers,
also in form of copolymers, to increase the hydrophilic properties of the nanocarriers [33].
5.1.2.1 Properties of Poly(acrylic acid)
PAA is a biodegradable, water-soluble, and bioadhesive polymer, which does not
require further treatment after insertion into the body [38, 39]. Due to the hydrophilic
carboxylic acid present in the polymeric material, PAA as a hydrogel is able to hold large
amounts of water in its three-dimensional network and to reversibly deswell [39]. Other
common water-soluble polymers, such as PVA, PVP, PEG, polyacrylamide, and some
polysaccharides, can also form hydrogels.
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The great advantage of hydrogels is their tailorable design, enabling the control of
responses to environmental changes, which can cause shrinking or swelling of the
hydrogel. The stimuli include [35, 40]:


Physical stimuli: temperature, electric and magnetic fields, light, pressure,
sound.



Chemical stimuli: solvent composition, ionic strength, pH value.

The shrinking and swelling of PAA, in particular, depends on the pH value: an
alkaline environment leads to swelling of the PAA, while acidic conditions cause a
shrinking of the polymer (Figure 5.2) [41]. This phenomenon is mostly linked to the
presence of carboxylic groups that are able to associate with water molecules.

Figure 5.2. Principle of pH-dependence on the swelling behaviour of hydrogels.
Because of these unique properties, hydrogels have found applications in artificial
muscles and tissue engineering [42, 43], food additives [44], pharmaceuticals [45],
diagnostics [46], drug delivery [47], and in the separation of biomolecules or cells [48]. For
instance, PAA-coated Pt NPs have been explored as a radiosensitizer, where the polymer
coating improves the diffusivity through the cell membrane and the binding to DNA, which
is damaged upon exposure to radiation via secondary radiation [49, 50].
5.1.2.2 Polymerization of Acrylic Acid Monomers
Acrylic acid (AA) is a monomer and intermediate that is used in acrylic esters for
superabsorbent polymers, plastics, and synthetic rubber (Figure 5.3) [51]. Structurally, the
AA monomers consist of an alkene chain and a carboxylic moiety, which remains intact
after polymerization and can be used for further functionalization. After polymerization, a
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three-dimensional network is typically generated via cross-linkage of polymeric chains
through covalent bonds in particular, but also hydrogen bonds, van der Waals bonds, or
physical adsorption.

Figure 5.3. Acrylic acid monomers can either react via addition polymerization or
esterification to form poly(acrylic acid) or acrylic esters, respectively. Adapted from [51].
The polymerization of AA takes place via addition polymerization, also known as
polyaddition, and does not produce any condensates [51]. Polyaddition is typically based
on the formation of radicals, whereas condensation polymerization generates small low
molecular weight molecules and can be achieved via radical polymerization, cationic
addition polymerization, and anionic addition polymerization [52].
The radical polymerization can typically be initiated using organic peroxides [52]
or via the absorption of visible, UV, or gamma irradiation [53]. The polymerization
proceeds as follows [52]:
1. Initiation: generation of radicals that act as active centres.
2. Chain growth: the active centre of the growing polymer can attack a new
monomer, resulting in a polymer that is one repeat unit longer. The active centre is
transferred to the new polymer end.
3. Chain termination: disproportionation or combination of radicals lead to the loss
of active centres.
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Although an initiator is usually added for the conventional batch polymerization of
AA, the monomer itself shows very high reactivity at elevated temperatures and is
characterized by a high polymerization rate [54, 55]. The exothermic nature of the
polymerization therefore requires precise temperature control to avoid the formation of
clumps or a gel [55].
5.1.3 Drug Delivery Systems Based on Hydrogels
Due to their water absorption capability, hydrogels are excellent candidates for
drug delivery systems, as they can incorporate large amounts of drugs, which can be
released in response to physical or chemical stimuli. Moreover, due to their watersolubility and biocompatibility, the removal of hydrogels from biological systems is not
required [38]. The principle of drug delivery systems based on hydrogels is displayed in
Figure 5.4.

Figure 5.4. Principle of drug release of a drug-loaded nanoparticle-poly(acrylic acid)
(PAA) conjugate.
5.1.3.1 Principle of Drug Loading and Drug Release
In general, there are two methods to load hydrogels as drug carriers. In the first
method, the drug is added to the monomer mixture during polymerization, which allows
trapping of the drug within the polymer matrix. Since the conditions of the polymerization
reaction may have deleterious effects on the drug properties, this method is not always
favoured [56]. In the second approach, the hydrogel is placed in a solution containing the
drug, and allowed to swell until equilibrium is reached [36, 56-58].
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Once the drug is loaded into the system, its release can be studied in different
release environments, i.e. different pH values. This is of importance, since the pH values of
different cellular compartments differ, as displayed in Table 5.3.
Table 5.3. pH values of different intracellular and extracellular compartments [58].
Compartment

pH value

Blood plasma

7.4

Extracellular tumour matrix

5.8 – 7.2

Endosome

5–6

Lysosome

4–5

Stomach

1.5 – 3.5

5.1.3.2 Existing Systems Based on Poly(acrylic acid)
Various systems have been developed that contain PAA as a hydrogel matrix [35,
36, 58-62]. For instance, PAA-coated magnetite (Fe3O4) NPs were synthesized, loaded with
bleomycin, and the drug release was studied at a pH of 7.5 [59]. In another study, PAAcoated magnetite NPs were loaded with DOX, and the release was monitored at a pH of 4.2
and 7.4 [60]. More recently, systems have been developed that contain two or more
polymers, with a view to controlling the drug loading and tailoring the pH-response.
Example 1
Polyelectrolyte hydrogels based on cationic guar gum and AA, which provides
anionic properties, have been shown to be highly sensitive to changes in the pH
environment [35]. The loading and release of ketoprofen as a model drug indicated that the
pH also influences the drug release kinetics. For instance, with alkaline pH of the release
medium, Case II transport was observed, which suggest that the drug transport strongly
depends on macromolecular chain relaxation. At lower pH values, the transport
mechanism appeared to be both diffusion and relaxation controlled.
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Example 2
CaF2:Ce3+/Tb3+-PAA composite spheres were synthesized and loaded with DOX, and
the electrostatic interactions between the drug and the polymer were studied [58]. The
presence of PAA prevented the initial burst release of DOX, and the inorganic
CaF2:Ce3+/Tb3+ provided green fluorescence upon excitation with UV light. The release of
DOX increased with decreasing pH from 7.4 to 4.0 and 2.0 (Figure 5.5).

Figure 5.5. Release of DOX from CaF2:Ce3+/Tb3+-PAA composites in PBS buffer with
pH = 7.4, 4.0, and 2.0. Adapted from [58].

5.2 Development

of

pH-Sensitive

Methotrexate-Loaded

δ-Ta2O5–

Poly(acrylic acid) Nanocomposite with Controlled Drug Release
This work shows a route that uses the high surface area available in individual
Ta2O5 nanoparticles with a particle size of 27 nm to polymerize a nanometric layer of PAA
with a thickness of 2 – 8 nm, by applying different polymerization times ranging from 1 to
5 h. The synthesis procedure and all characterization methods are described in CHAPTER
3. The evolution of the polymer layer with the polymerization time was assessed and
further correlated with the loading capacity of MTX that was measured by swelling of the
hydrogel in the drug solution at pH 7.4. The drug release of MTX was studied at different
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pH values, ranging from 3.6 up to 9.4 for a total of 72 h, and the released amount of MTX
was determined via UV-vis spectroscopy.
5.2.1 Identification, Size, Morphology, and Surface Composition
XRD was used to determine the phase of the Ta2O5 NPs before and after PAA
polymerization on the surface of the NPs. The obtained diffraction patterns (Figure 5.6)
show the presence of a single δ hexagonal phase with all reflections matching the JCPDS
card no. 00-019-1299. Furthermore, the coating of δ-Ta2O5 with PAA preserves the
crystalline phase. The crystallite size was determined using the Scherrer equation and
showed a mean size of 26.7 ± 5.4 nm for δ-Ta2O5.

Figure 5.6. XRD patterns of δ-Ta2O5 NPs and δ-Ta2O5-PAA nanocomposites with
polymerization times of 1, 2.5, and 5 h.
SEM and TEM images of the δ-Ta2O5 NPs and the δ-Ta2O5-PAA nanocomposites are
shown in Figure 5.7. The NPs are mostly spherical and ellipsoidal in shape and tend to
form agglomerates > 100 nm in size, which is observed for both δ-Ta2O5 and δ-Ta2O5-PAA
and is related to their high surface energy39. The single particle size of the uncoated δTa2O5 NPs varies between 13 – 57 nm with an average particle size of 26.6 ± 5.9 nm.
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These findings indicate that the δ-Ta2O5 NPs are an excellent candidate for the
design of theranostic systems, since it has been shown that a particle size of up to 50 nm
results in high cellular uptake [63].

Figure 5.7. (a) SEM and (b) TEM images of δ-Ta2O5 NPs and δ-Ta2O5-PAA nanocomposites
with polymerization times of 1, 2.5, and 5 h. The green arrows indicate the PAA layers. (c)
Particle size distribution of uncoated δ-Ta2O5 NPs. A total of 100 particles were measured,
and the relative frequency was plotted as a function of particle size. (d) Plot of the layer
thickness as a function of the polymerization time.
The TEM images of the δ-Ta2O5-PAA nanocomposites, which were obtained after
different polymerization times, show homogeneous coverage of the surfaces of individual
δ-Ta2O5 NPs with layers of PAA. The layer thickness increases with increasing
polymerization time: while polymerization for 1 h yields a polymer thickness of 2.1 ± 0.7
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nm, a polymerization time of 2.5 and 5 h leads to a thickness of 3.9 ± 0.9 nm and 8.2 ± 1.4
nm, respectively.
The surfaces of the individual δ-Ta2O5 NPs were activated to induce preferential
polymerization sites for the AA monomer to start to polymerize, as shown in Figure 5.8.
This approach ensures that the polymer chains grow around each individual ceramic
particle, avoiding the wrapping of clusters of δ-Ta2O5 [64, 65]. The thickness of the layer
has a direct impact on the amount of drug which can be accumulated and, consequently,
influences the drug release properties.

Figure 5.8. Expected reaction for the as-prepared δ-Ta2O5 nanoparticles when dispersed
in methanol (left) and etched with hydrochloric acid for 25 min (= surface activation). After
centrifugation (centre), the hydroxyl-terminated nanoparticles were transferred into an
acrylic acid (AA) solution (= physical adsorption of monomer) and heated up to 83 °C
(right) for different polymerization times (= thermal induced chain polymerization).
5.2.2 Fourier-Transform Infrared Spectroscopy
FTIR spectroscopy was used to confirm that PAA was successfully immobilized on
δ-Ta2O5 NPs. Figure 5.9 shows the FTIR spectrum of uncoated δ-Ta2O5 NPs with
characteristic bands at around 880 and 680 cm-1, which are assigned to the Ta-O-Ta bridge
and stretching vibrations of Ta-O bonds, respectively [66].
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Figure 5.9. FTIR spectra of δ-Ta2O5 NPs and δ-Ta2O5-PAA nanocomposites with
polymerization times of 1, 2.5, and 5 h. The dotted line indicates the wavenumber below
which the absorption bands of δ-Ta2O5 outweigh the absorption bands related to PAA.
The FTIR spectra of the δ-Ta2O5-PAA nanocomposites show the presence of Ta-O
and Ta-O-Ta vibrations in low wavenumbers < 900 cm-1, which overlap with the stretching
and bending vibrations related to PAA. Typically, O-H out-of-plane bending, and CH2 and CCOOH stretching is observed at 914 and 797 cm-1, respectively [67]. Besides these bands,
all other characteristic absorption bands that correspond to PAA are present in the δTa2O5-PAA nanocomposites: the absorption bands at 2946, 1451, and 1108 cm-1
correspond to CH2 or CH stretching, CH2 stretching, and C-CH2 stretching, respectively [67,
68]. In addition, the absorption bands at 1704 and 1240 cm-1 are ascribed to the C-O
stretching and C=O stretching, respectively [67]. It was interesting to observe that the
vibration band with a maximum at 1704 cm-1 increased with the polymerization time.
Furthermore, the O-H stretching vibrations at 3085 and 2598 cm-1 confirm the presence of
PAA on the surfaces of the δ-Ta2O5 NPs [67].
The monomer AA typically shows absorption bands at 1600 – 1680 cm-1, which are
assigned to C=C stretching [69]. The absence of these absorption bands in the FTIR spectra
of the δ-Ta2O5-PAA nanocomposites indicates a complete polymerization. The increase in
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polymerization time generally leads to an increase in the intensity of the absorption bands
of the characteristic functional groups, without changing their wavenumber.
5.2.3 Thermal Stability of δ-Ta2O5-Poly(acrylic acid) Nanocomposites
The stability of the nanomaterials was investigated by TGA, and the mass loss of
organics was determined for all thermogravimetric curves (Figure 5.10). Uncoated δ-Ta2O5
NPs did not show any mass loss for the entire temperature scan range, while the δ-Ta2O5PAA nanocomposite materials exhibited characteristic mass losses that were due to the
presence of the polymer on their surfaces. To determine when the mass losses occurred,
the derivative weight was plotted versus temperature [70].

Figure 5.10. (a) TGA curves of δ-Ta2O5 NPs and δ-Ta2O5-PAA nanocomposites with
polymerization times of 1, 2.5, and 5 h. (b) First derivative of the TGA curve of δ-Ta2O5-PAA
with 5 h polymerization time.
A mass loss starting at 126°C can be observed for all polymer nanocomposite
materials and corresponds to the loss of unbound water. The amount of water was
determined to be 0.1, 1.4, and 4.3 wt. % for the δ-Ta2O5-PAA nanocomposite with a
polymerization time of 1, 2.5, and 5 h, respectively. For all the PAA-containing materials,
three additional mass losses were identified at 253, 295, and 530°C, which are related to
the release of organic compounds. The second mass loss can be attributed to the formation
of PAA anhydride, and the third mass loss corresponds to the degradation of the PAA
anhydride [71]. The fourth mass loss is ascribed to the thermal decomposition of PAA [72].
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The amount of organics significantly increases with increasing polymerization
time, with a total mass loss of organics of 1.4, 8.7, and 34.4 wt. % for the nanocomposites
with a polymerization time of 1, 2.5, and 5 h, respectively (Figure 5.11).

Figure 5.11. Plot of the organics content as a function of the polymerization time.
5.2.4 Surface Composition Before and After Polymerization
The surface composition of the δ-Ta2O5 NPs was evaluated via XPS and compared
to δ-Ta2O5 after additional treatment with HCl to show that latter sample’s surfaces are
functionalized with hydroxyl groups, which facilitate the layer-by-layer polymerization of
AA onto the NPs. Figure 5.12 displays the survey spectra and the high-resolution XPS
spectra of the O 1s and C 1s regions for the nanomaterials before and after polymerization.
The survey spectra show typical peaks that can be ascribed to the presence of
carbon, oxygen, and tantalum. All XPS data are summarized in Table A1 and A2 in the
Appendix II. The peaks at lower binding energy of ~285 and ~286 eV can be assigned to
CH2 and CH, respectively [71]. The peak at ~288 eV is ascribed to C–O bonds, which
indicates the presence of adventitious carbon. The nanocomposites display an additional
peak at ~290 eV, which corresponds to the O–C=O groups that are found in PAA [71].
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Figure 5.12. (a) XPS survey spectra of δ-Ta2O5 NPs, δ-Ta2O5 NPs after HCl treatment, δTa2O5-PAA 1 h, and δ-Ta2O5-PAA 2.5 h. High-resolution spectra of δ-Ta2O5 NPs, δ-Ta2O5 NPs
after HCl treatment, and δ-Ta2O5-PAA nanocomposites with polymerization times of 1 and
2.5 h for b) the C 1s region and c) the O 1s region.
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Table 5.4 displays the C 1s envelope ratios for all samples and shows – besides the
increase in the ratio of C/O from ~143% (δ-Ta2O5) to ~217% (δ-Ta2O5-PAA) – an increase
in the amount of CH bonds that are typically found in the polymer backbone chains,
underlining the successful polymerization of PAA on the NP surfaces. The O 1s envelope
ratios are shown in Table 5.5. These findings are further supported by the presence of an O
1s peak at ~534 eV for the O–C=O group, which is only found in the δ-Ta2O5-PAA
nanoconmposites [71].
Table 5.4. XPS analysis including the C 1s region of δ-Ta2O5 NPs (before and after
treatment with HCl) and δ-Ta2O5-PAA nanocomposites with polymerization times of 1 and
2.5 h.
Sample

XPS C 1s envelope ratios (%)

C/O ratio (%)

CH2

CH

C–O

O–C=O

δ-Ta2O5

61.05

25.24

13.71

–

145.38

δ-Ta2O5 (HCl treated)

55.87

28.51

15.62

–

140.92

δ-Ta2O5-PAA 1 h

41.70

44.81

9.13

4.36

216.94

δ-Ta2O5-PAA 2.5 h

40.39

40.40

13.81

5.40

218.17

Table 5.5. XPS analysis including the O 1 s region of δ-Ta2O5 NPs (before and after
treatment with HCl) and the δ-Ta2O5-PAA nanocomposites with polymerization times of 1
and 2.5 h.
Sample

XPS O 1s envelope ratios (%)
Ta–O

Ta–OH or C–OH

C=O

δ-Ta2O5

65.71

34.29

–

δ-Ta2O5 (HCl treated)

77.31

22.69

–

δ-Ta2O5-PAA 1 h

86.84

10.68

2.48

δ-Ta2O5-PAA 2.5 h

81.87

16.09

2.04
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The O 1s spectra also display peaks that correspond to Ta–O bonds and –OH groups
at a binding energy of ~531 and 533 eV, respectively [73]. The presence of hydroxyl
groups on the surface of δ-Ta2O5 after treatment with HCl is of particular importance, since
the –OH groups act as activation sites that react with the AA monomers on the NP surfaces
to form a layer of PAA, as shown via TEM (Figure 5.7).
5.2.5 Swelling Properties of δ-Ta2O5-Poly(acrylic acid) Nanocomposites
Investigation of the swelling behaviour of PAA-containing nanomaterials is of
importance, since the swelling property influences the diffusion of small molecules
through the polymer matrix. It has been shown that the more PAA that is present in the
hydrogel, the larger is the affinity of the hydrogels for water, which ultimately results in
higher swelling ratios (SR) [35]. The swelling kinetics of the δ-Ta2O5 NPs and the δ-Ta2O5PAA nanocomposites for a time frame of 0 – 48 h at 37°C and pH 7.4 are displayed in
Figure 5.13. As the thickness of the polymer layer increases, the volume of hydrogel
increases, consequently increasing the swelling ratio. In general, the swelling ratio
increases rapidly in the first 4 h and reaches equilibrium after around 24 h.

Figure 5.13. (a) Swelling ratio (SR) of δ-Ta2O5 NPs and δ-Ta2O5-PAA nanocomposites with
polymerization times of 1, 2.5, and 5 h. The swelling properties were measured at 37ᵒC at
pH 7.4 for 48 h. (b) The influence of the pH value of the buffer solution on the swelling
ratio of the δ-Ta2O5-PAA nanocomposite that was synthesized with a polymerization time
of 5 h. The swelling properties were measured at 37ᵒC at pH 3.6, 5.4, 7.4, and 9.4 for 48 h.
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To study the effect of pH on the swelling ratio, the nanocomposite with highest
amount of PAA (δ-Ta2O5-PAA 5 h) was chosen and exposed to buffer solutions with
different pH (pH 3.6, 5.4, 7.4, and 9.4) at 37ᵒC. The swelling kinetics are shown in Figure
5.13. The pH value has a significant impact on the swelling behaviour of the δ-Ta2O5-PAA
nanocomposite. The difference in swelling ratio is ascribed to the accessibility of free
volume for the expanded polymer matrix, the polymer chain relaxation, and the availability
of ionizable functional groups [35]. For instance, the presence of carboxyl groups can lead
to the formation of hydrogen bonds with water. In addition, the swelling behaviour
depends on the network swelling pressure, the dissociation equilibrium, the presence of
ions in the swelling medium, and impurities [74].
The carboxylic acid group in PAA tends to dissociate at pH values greater than 4.5,
which ultimately leads to an increase in osmotic pressure inside the polymer matrix and
explains the low swelling ratio in the buffer solution of pH 3.6 [35]. With increasing pH, the
dissociation of carboxylic groups increases, which leads to negatively charged polymer
chains that repel each other. The higher the pH of the buffer solution, the more the
carboxylic groups will dissociate, and the more the polymer chains will repel each other,
leading to more free space within the polymer network [35], ultimately leading to an
increase in the swelling ratio.
5.2.6 Methotrexate

Loading

Capacity

of

δ-Ta2O5-Poly(acrylic

acid)

Nanocomposites
Different polymerization times during the δ-Ta2O5-PAA synthesis lead to
composites with different polymer layer thicknesses (Figure 5.7), which affects the drug
loading capacity. The MTX entrapment per 1 mg of nanocomposite, and the loading
capacity and entrapment efficiency of all tested samples were determined and are listed in
Table 5.6. Since a weight ratio of drug/composite of 1/1 was chosen, the entrapment
efficiency is equivalent to the loading capacity. The loading capacity increased with
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increasing layer thickness of PAA in the nanocomposites: while the drug loading capacity
was 1.2% for a polymerization time of 1 h, it increased to 7.7% and 12.6% for a
polymerization time of 2.5 and 5 h, respectively.
Table 5.6. Loading capacity (LC) and entrapment efficiency (EE) of δ-Ta2O5 NPs and δTa2O5-PAA nanocomposites with different polymerization times at a weight ratio of
MTX/composite of 1/1 (10 mg/mL).
Sample

PAA/ 1 mg

MTX/ 1 mg

MTX

MTX

MTX/ 1 mg

(TGA) [µg]

(weight)

LC and

LC and

(UV-vis)

[µg]

EE [%]a)

EE [%]b)

[µg]

–

11.5 ± 0.7

1.2 ± 0.1

–

8.3 ± 1.31

δ-Ta2O5-PAA 1 h

22.3 ± 0.5

21.3 ± 2.5

2.1 ± 0.3

95.5 ± 11.2

20.2 + 2.9

δ-Ta2O5-PAA 2.5 h

101.2 ± 2.1

76.6 ± 9.3

7.7 ± 0.9

75.7 ± 9.2

67.5 ± 5.6

δ-Ta2O5-PAA 5 h

399.4 ± 8.2

126.4 ± 8.7

12.6 ± 0.9

31.6 ± 2.2

118.0 ± 4.1

δ-Ta2O5

a) Normalized

to mass of composite; b) Normalized to mass of PAA.

When the hydrogel is placed into the aqueous solution containing MTX, the
polymer network starts to swell, and the drug molecules fill the space between the
polymer chains. The thicker the polymer layer, the larger is the swelling ratio (Figure
5.13). The MTX molecules and PAA chains experience electrostatic repulsion at a pH of 7.4,
however, which could explain the low increase in loading capacity for the nanocomposite
with thickest polymer layer [58, 75, 76]. The effects are described in more detail in section
5.2.8.
The MTX entrapment per 1 mg of nanocomposite was also determined via UV-vis
spectroscopy after the in vitro drug release experiments and the treatment of the
composites with 0.1 M NaOH. The calibration curve of different concentrations of MTX was
determined and is shown in Figure 5.14. The MTX entrapment obtained via UV-vis
spectroscopy is similar to the value calculated through the dry weight of the composite
after the drug loading (Table 5.6).
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Figure 5.14. (a) Absorbance of MTX solution at concentrations ranging from 2.5 to 45 µM.
(b) Calibration curve and equation for the calculation of MTX concentration.
The reported drug loading capacities for similar systems range from 12 – 80%,
based on the delivery system components, the drug entrapment method, the incubation
time, and the drug concentration used for the entrapment [58, 60, 76, 77]. For instance, it
was shown for DOX as a model drug and a system consisting of mesoporous silica and PAA,
that by increasing the weight ratio of drug/hydrogel from 0.1 to 0.25, 0.5, and 1.0, the
loading capacity increased from 2.2 to 11.3, 24.5, and 40.2%, respectively [57]. The
entrapment efficiency also increased from 25.1 to 51.2, 64.8, and 80.4%, respectively [57].
Magnetite NPs functionalized by PAA showed an entrapment efficiency towards Bleomycin
of 52.44%; the drug loading concentration was 10 mg/mL [59]. Therefore, a weight ratio of
MTX/composite of 1/1 and a concentration of MTX of 10 mg/mL were chosen. It should be
noted, however, that δ-Ta2O5 contributes significantly to the overall mass of the composite
and therefore, reduces the overall drug loading capacity. When normalized to the mass of
polymer present in 1 mg of composite, the loading capacity and entrapment efficiency of
MTX increased up to 95% for the composite with the thinnest PAA layer (Table 5.6).
5.2.7 Effect of Poly(acrylic acid) Layer Thickness on the Release of
Methotrexate from δ-Ta2O5-Poly(acrylic acid) Nanocomposites
The calibration curve used to determine the MTX concentration and the release
kinetics of MTX from δ-Ta2O5 and the δ-Ta2O5-PAA nanocomposites in phosphate buffer
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solution with pH 7.4 at 37°C is shown in Figure 5.14. The corresponding drug release
kinetic data is displayed in Figure 5.15 and Table 5.7 and was obtained by fitting the drug
release experimental data to the Ritger-Peppas equation, as shown in Equation (5.3):

(5.3)
where

is the total amount of drug,

is the amount of drug released at time t,

is a

kinetic constant, and n is the diffusion exponent. The fractional amount of drug released is
expressed by

/

, and for the modelling, only fractions < 0.6 were considered [78].

Figure 5.15. In vitro release profiles of methotrexate-soaked δ-Ta2O5 NPs and δ-Ta2O5-PAA
nanocomposites with different polymerization times of 1, 2.5, and 5 h in buffer solution
with pH 7.4. The drug release was monitored at 37ᵒC for 72 h.
Besides the diffusion of water into the hydrogel, the Ritger-Peppas model considers
the swelling as water enters, the formation of the gel, the diffusion of the drug out of the
hydrogel, and the dissolution of the polymer matrix. The diffusion exponent is used to
characterize the release mechanism for a thin hydrogel: a value of n = 0.5 indicates Fickian
diffusion, and a value of n = 1 points to Case II (relaxational) transport, which leads to a
zero-order release [35, 78]. When 0.5 < n < 1, anomalous transport is observed [35, 78].
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Table 5.7. Drug release kinetic data for δ-Ta2O5-PAA nanocomposites with different
polymerization times. The kinetic constant kkin and the diffusion exponent n were obtained
from the fit of the drug release experimental data to the Ritger-Peppas equation.
Sample

kkin

n

R2

Transport mechanism

δ-Ta2O5-PAA 1 h

1.54 ± 0.01

0.54 ± 0.03

0.990

Diffusion and relaxation

δ-Ta2O5-PAA 2.5 h

1.60 ± 0.01

0.61 ± 0.03

0.992

Diffusion and relaxation

δ-Ta2O5-PAA 5 h

1.78 ± 0.02

0.71 ± 0.05

0.987

Diffusion and relaxation

For all tested samples, a burst release of MTX occurred in the first hour, which is
due to desorption of MTX from the gel surface. The following release of the drug was
slower and yielded a total release of MTX of 100% for the δ-Ta2O5 NPs, and 85.6, 88.8, and
91.8% for the δ-Ta2O5-PAA nanocomposites with a polymerization time of 1, 2.5, and 5 h,
respectively. The fast release of MTX from the uncoated δ-Ta2O5 NPs is related to the
absence of a hydrogel layer.
When the MTX-loaded hydrogel is placed in the release medium, the polymer starts
to swell, followed by polymer chain relaxation and volume expansion. This enables the
trapped MTX to diffuse into the external release medium [75]. The swelling ratio increased
rapidly in the first hour and is therefore another explanation for the initial burst release of
MTX. The observed release rate tends to increase with increasing polymer layer thickness,
which is directly connected to the increase in drug loading [79].
The analysis of the release data showed that it essentially follows a non-Fickian
process, since the diffusion exponent n had a value > 0.5 for all the synthetized samples.
The drug release kinetics of δ-Ta2O5 NPs was impossible to determine due to the boost of
drug release to the buffer solution that started immediately after immersion of the
particles in the media. A value for n between 0.54 and 0.71 (Table 5.7) was obtained for all
the nanocomposites and indicates that the drug transport mechanism appears to be
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anomalous: the drug release is controlled by a coupled effect of Fickian diffusion and chain
relaxation of the hydrogels.
5.2.8 Effect of pH on the Drug Release Kinetics
To evaluate the effects of pH on the overall drug release and its mechanism, the
drug release from δ-Ta2O5-PAA (5 h polymerization time) was studied in release buffers
with pH of 3.6, 5.4, 7.4, and 9.4. The drug release profiles are shown in Figure 5.16. The
experimental data was fitted to the Ritger-Peppas model (Equation (5.3)) and is listed in
Table 5.8.The drug release from the nanocomposites follows a similar profile for all tested
pH values, starting with the initial burst release of MTX, which is followed by the slow
release at longer incubation times.

Figure 5.16. In vitro release profiles of methotrexate-soaked δ-Ta2O5-PAA with longest
polymerization time of 5 h in buffer solutions with pH values of 3.6, 5.4, 7.4, and 9.4. The
drug release was monitored at 37ᵒC for 72 h.
Greater drug release was observed as the pH value of the buffer solution was
increased. While the total release of MTX is only 79.1% at a pH of 3.6, the drug release
increases to 84.4, 91.8, and 96.0% for pH of 5.4, 7.4, and 9.4, respectively. Moreover, the
initial burst release of MTX was significantly reduced for the lowest pH of 3.6. It was shown
that the swelling of the PAA nanolayer is the principal parameter ruling drug release [80].
Since the swelling ratio increases with increasing pH of the buffer solution, more
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incorporated drug can be released from the hydrogel as the structure becomes more open.
The importance of the swelling behaviour of the hydrogel regarding drug release has been
reported in the literature. For instance, hydrogels that were synthesized with cross-linking
agents displayed a significantly slower drug release than unmodified hydrogels. The drug
release was significantly hindered as the hydrogel cross-linking density was increased
[75].
Table 5.8. Drug release kinetic data for the δ-Ta2O5-PAA nanocomposite with 5 h
polymerization time, exposed to different pH environments. The kinetic constant kkin and
the diffusion exponent n were obtained from the fit of the drug release experimental data
to the Ritger-Peppas equation.
Release medium

kkin

n

R2

Transport mechanism

pH 3.6

1.39 ± 0.01

0.28 ± 0.03

0.966

Diffusion

pH 5.4

1.61 ± 0.01

0.54 ± 0.03

0.992

Diffusion and relaxation

pH 7.4

1.78 ± 0.02

0.71 ± 0.05

0.987

Diffusion and relaxation

pH 9.4

1.88 ± 0.01

0.84 ± 0.01

0.999

Relaxation

In addition to the effect of the swelling ratio on the drug release, the presence of
electrostatic interactions between the drug and the hydrogel can also influence the drug
release [58, 75, 76], as schematically shown in Figure 5.17. MTX has three pKa values at 3.8,
4.8, and 5.6, while the dissociation of the carboxylic group of PAA takes place at pKa of 4.25
[81]. At pH 3.6, the nitrogen atom in the pteridin ring should be mainly protonated, while
the carboxylic groups on the hydrogel are hardly ionized. This leads to the presence of
weak hydrogen bonding between the carboxylic groups of MTX and PAA. At pH 5.4, the
carboxylic groups on the PAA chains should be partly deprotonated to form carboxylate
anions, which leads to fewer hydrogen bonds. Moreover, the carboxylic groups of the MTX
molecule start to dissociate, which causes further negative charge and consequently,
increases the electrostatic repulsion between the MTX molecule and the PAA chains. This
ultimately results in an increase in drug release rate.
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At pH of 7.4 and 9.4, the nitrogen atom of the pteridine ring should be mostly
deprotonated, which further increases the electrostatic repulsion between the MTX
molecule and the PAA. The increase in pH shifts the equilibrium further to dissociated
components and increases the electrostatic repulsion and the release of MTX. Moreover,
the solubility of PAA increases with increasing pH, which can lead to the degradation and
erosion of the polymer matrix and thus, to the increased release of entrapped MTX,
especially for long incubation times [82, 83]. The principle of electrostatic repulsion and
attraction has been shown to play an important role in controlled drug release. DOX, for
instance, is a chemotherapeutic drug that has no carboxylic groups and its amino group is
mostly protonated (pKa 8.2). When combined with PAA, different pH sensitivity can be
obtained: the release of DOX is faster at pH 4.2 and slows down at a higher pH of 7.4 [60].

Figure 5.17. (a) Structure of methotrexate. (b) Schematic route of the methotrexate (=
drug) loading and release from the nanocomposites containing poly(acrylic acid) (PAA) at
different pH values (3.6, 5.4, 7.4, and 9.4).
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The analysis of the drug release kinetic data indicates that the release mechanism
strongly depends on the pH of the release medium, as shown in the literature [35, 56, 75].
The diffusion exponent n increased as the pH of the release medium became more alkaline,
which underlines the pH sensitivity of PAA-containing hydrogels. For a pH of 3.6, the
release followed Fickian diffusion (n < 0.5). With regard to the release of MTX, Fick’s law
includes the adsorption of buffer on the polymer matrix and the simultaneously desorption
of MTX via diffusion [56]. For pH values of 5.4 and 7.4, the increase in the diffusion
coefficient (n = 0.54 ± 0.03 to 0.71 ± 0.05) indicates that the release mechanism is a result
of the contributions of both Fickian diffusion and relaxation of polymer chains. At a pH of
9.4, the extensive ionization of the functional groups significantly influences the polymer
chain relaxation and consequently, leads to a transport mechanism that is closer to Case II
transport (n = 0.84 ± 0.01). Such an increase in the diffusion exponent to values close to 1
at high pH has been reported [64, 78].
5.2.9 In Vitro Computed Tomography Imaging of δ-Ta2O5 Nanoparticles and δTa2O5-Poly(acrylic acid) Nanocomposites
The anatomical contrast enhancement capability of uncoated δ-Ta2O5 NPs and the
δ-Ta2O5-PAA nanocomposite with high polymerization time (5 h) was demonstrated using
a clinical CT scanner, with the resulting CT number as a function of the tantalum
concentration, as shown in Figure 5.18 and Figure 5.19. The CT values in HU for each
concentration were determined for multiple regions along the central axis of the vial to
account for possible sedimentation of the suspended composites (see red dashed lines).
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Figure 5.18. (a) Linear fitting of the CT number of δ-Ta2O5 nanoparticles as a function of
the mass concentration of Ta in mg/mL at different tube potentials of 100, 120, and 135
kVp. The equation of linear regression and the coefficient of determination (R2) value are
indicated. (b) CT images of δ-Ta2O5 nanoparticles with Ta mass concentrations of 0 – 8
mg/mL; the red dashed line indicates the area that was used to determine the CT number.
The tube potential varied between 100, 120, and 135 kVp.

Figure 5.19. (a) Linear fitting of the CT number of δ-Ta2O5-PAA nanoparticles (5 h
polymerization) as a function of the mass concentration of Ta in mg/mL at different tube
potentials of 100, 120, and 135 kVp. The equation of the linear regression and the R2 value
are indicated. (b) CT images of δ-Ta2O5-PAA nanoparticles (5 h polymerization) with Ta
mass concentrations of 0 – 8 mg/mL; the red dashed line indicates the area which was
used to determine the CT number. The tube potential varied between 100, 120, and 135
kVp.
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In general, the contrast increased with increasing concentration of tantalum, and
the suspension remained stable up to a concentration of 8 mg/mL for the δ-Ta2O5-PAA
nanocomposite. For the uncoated δ-Ta2O5 NPs, however, a noticeable difference in CT
number was observed at the highest concentration of 8 mg/mL for the centre of the
composite sediment and the centre of the suspension height, which ultimately underlines
the stabilization effect of PAA on the suspension.
The data was plotted and fitted to deduce the relation between the CT number and
the Ta concentration. The average CT number was chosen across the suspension height. It
should be noted that the CT number reached a value of 1000 – 2000 HU in the sediment at
a Ta concentration of 8 mg/mL for uncoated δ-Ta2O5, which highlights the potential of
Ta2O5 as an anatomical contrast enhancement agent. These results agree with reported CT
numbers for Ta-containing compounds and underline the improved suspension stability
and reduced beam hardening in comparison to previously reported Bi2O3 NPs [84, 85].
X-ray attenuation also depends on the X-ray photon energy. Typically, for most
elements, including iodine, the X-ray attenuation decreases with increasing peak tube
potential. In vitro studies have shown that for the same concentration of tantalum and
iodine, the tantalum produced a significantly greater image contrast than iodine across the
diagnostic CT X-ray spectrum, ranging from 80 to 140 kVp [13, 86].
In contrast to iodine, tantalum has a k-edge within the diagnostic X-ray spectrum,
which ultimately results in an increase in attenuation at discrete energy levels near the kedge [13]. Upon application of a polychromatic X-ray spectrum, the image contrast remains
relatively constant for different tube potentials, as attenuation at discrete energy levels
below and above the k-edge contribute to the net attenuation. The superior contrast
enhancement and contrast-to-noise ratio of δ-Ta2O5-PAA for high X-ray energies are of
particular interest in a clinical setup [86]. Although it is beneficial for pediatric patients to
reduce the radiation dose, the ability to use high X-ray energies is important for the
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imaging of large patients, as a sufficient penetration of X-rays needs to be ensured to
obtain images of the desired quality.
5.2.10 Conclusions
In order to design a theranostic system with controlled drug release properties, δTa2O5-PAA nanocomposites were prepared through the polymerization of AA on the
surfaces of individual δ-Ta2O5 NPs. By varying the polymerization time, different layer
thicknesses of PAA on the surfaces of the ceramic particles were obtained, which
ultimately had an impact on the drug loading capacity.
MTX-loaded δ-Ta2O5-PAA matrices were prepared by soaking δ-Ta2O5-PAA in a
solution of MTX, and the release mechanism was studied by the Ritger-Peppas model. It
was demonstrated that the δ-Ta2O5-PAA nanocomposites were highly sensitive to different
pH environments. Firstly, the swelling ratio increased with increasing pH of the swelling
medium. Secondly, an acidic release medium slowed down the release of MTX, while more
alkaline pH values led to a quick release of MTX from the MTX-loaded δ-Ta2O5-PAA
matrices. The diffusion exponent n increased from 0.28 to 0.84, which suggests that, with
increasing pH, polymer chain relaxation contributes to the transport mechanism. These
results indicate that such a system may, under certain conditions, provide release
characteristics approaching zero-order release.
Furthermore, the δ-Ta2O5-PAA nanocomposites showed a contrast enhancement
for tube potentials ranging from 100 to 135 kVp in vitro. The image consistency at high Xray energies is of particular interest in a clinical setup, as it ensures sufficient penetration
of X-rays in larger patients.
The results obtained in this research work lead to the conclusion that δ-Ta2O5-PAA
nanocomposites can be successfully used as drug delivery systems, providing imaging,
therapeutic, targeting, and potentially, radiation dose enhancement functionalities on one
single platform.
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6.1 Thesis Conclusions
6.1.1 Theranostic Nanoparticles
In this doctoral work, various aspects related to the fabrication and
characterization of nanomaterials for biomedical applications have been explored and
developed. Recently, work in the area of theranostic materials has been focussed not only
on the development of systems with therapeutic and diagnostic features, but also on the
addition of more features such as selectivity and targeting functions. Various current stateof-the-art nanomaterials were thoroughly reviewed in regard to their advantages and
disadvantages compared to other multifunctional materials used in the field of cancer
research. Typically, organic NPs, inorganic NPs, or a combination of multiple materials are
used to incorporate many features into one single platform and optimize their
physiological interactions [1, 2].
A classical precipitation synthesis method was used to fabricate Bi(OH)3 and αBi2O3 NPs. Only a small number of reports exist on the overall physicochemical
characterization of Bi(OH)3, particularly with regard to its cellular interactions. In contrast,
α-Bi2O3 has been studied widely regarding its physical and chemical properties, although
less consideration has been given to its bioactivity. This work sought to evaluate, for the
first time, the use of Bi(OH)3 and α-Bi2O3 NPs as chemotherapeutic agents. It was
demonstrated that both types of NPs exhibit high in vitro toxicity towards malignant 9L
and MCF-7 cells, which makes them promising theranostic agents for cancer treatment.
More importantly, these nanomaterials showed only low to moderate toxicity in normal,
non-cancerous, MDCK cells, which also suggests high selectivity. It is commonly known
that inorganic nanomaterials such as ZnO NPs mediate their toxicity through the
generation of ROS [3, 4]. In this doctoral thesis, the first insights were gleaned regarding
the apoptotic pathway of the tested malignant 9L cells, which was found to be oxidationdependent. Cleavage was identified in 9L cells after exposure to the NPs, while no
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significant increase in cleavage was observed in MDCK cells. The enhancement of
anatomical contrast is also demonstrated in this work. Considering the potential radiation
dose enhancement properties of Bi-based materials [5], these theranostic materials could
potentially display four different functions: therapeutics, selectivity, imaging, and radiation
dose enhancement. With this combination of properties, current cancer therapies can
potentially be refined, and therefore, the spectrum of side effects can be reduced while
maintaining similar therapeutic effects.
In this doctoral thesis, nanocomposites in the form of δ-Ta2O5-PAA were
synthesized for the first time and loaded with the chemotherapeutic drug MTX, which is
known to also provide targeting features [6, 7]. The novelty of this work lies also in the
synthesis method, which includes activation of the surfaces of the δ-Ta2O5 NPs prior to the
polymerization of acrylic acid on the surface of δ-Ta2O5, resulting in controllable layer-bylayer-formation of PAA. It was demonstrated that the δ-Ta2O5-PAA nanocomposites were
highly sensitive to different pH environments, which is desirable, as it provides the ability
to reduce the dosage frequency and systemic toxicity of the administered drugs. While an acidic
release medium slowed down the release of MTX, alkaline pH values caused a quick release of
MTX from the MTX-loaded δ-Ta2O5-PAA matrices. Via the Ritger-Peppas model, it was shown
that, with increasing pH, polymer chain relaxation contributes to the transport mechanism.
In addition, the Ta2O5-PAA nanocomposites displayed anatomical contrast enhancement
and provided image consistency at high X-ray energies, which is highly valuable in a
clinical setup, as it ensures sufficient penetration of X-rays in larger patients. This
theranostic system potentially displays four different features on one single platform:
while the imaging and radiation dose enhancement properties are ascribed to δ-Ta2O5 [8],
the therapeutic and targeting features are associated with MTX [6, 7].
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6.1.2 Nanoparticles as Ultraviolet Filters in Sunscreens
This doctoral work has also highlighted the main challenges related to the current
state-of-the-art of commercial sunscreens that typically contain photosensitive organic UV
filters, or worse, photoactive inorganic UV filters, such as TiO2 and ZnO NPs [9]. The
photocatalytic activity associated with the NPs reduces the overall photoprotection and
lowers the SPF as a consequence of photogenerated ROS, which can cause further damage
through the generation of unknown by-products with unknown toxicity [10-12]. ZnO NPs
in particular have been shown to exhibit intrinsic geno- and cytotoxicity, which ultimately
resulted in the search for alternative materials [13-15].
In this doctoral thesis, the UV protective and photocatalytic properties of Bi(OH)3
NPs have been investigated for the first time. Bi(OH)3 NPs are colourless, exhibit a
comparable absorbance in the UV region to ZnO and TiO2 NPs, and display greater
biocompatibility than TiO2 and ZnO NPs, which makes them highly attractive as a potential
ingredient in sunscreens. The Bi(OH)3 NPs showed low photocatalytic activity throughout
the whole UV-visible spectrum and, more importantly, were able to reduce the
photocatalytic activity of TiO2 and ZnO NPs. In order to determine the suitability of Bi(OH)3
NPs as an alternative to ZnO NPs as an active UV filter in sunscreens and, especially, to
compare their performance to commercially available sunscreens, sunscreen emulsions
were prepared in-house containing a mixture of either TiO2/Bi(OH)3 or TiO2/ZnO. The
homemade sunscreen made of TiO2/Bi(OH)3 displayed rheological properties comparable
to those of commercial sunscreens and significantly increased photostability, SPF, and
UVA-PF when compared to the classical combination of TiO2/ZnO or other commercial
sunscreens. Considering the excellent performance of Bi(OH)3, this material offers a novel
and cost-effective approach to improving the UV-blocking properties of commercial
sunscreen formulations, with the added benefit of acting as an antioxidant stabilizer for the
organic components of sunscreens, reducing their potential harm to the health of the
consumer.
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Examining the development of nanocomposites based on TiO2 and (BiO)2CO3 as an
alternative to the introduction of a completely novel inorganic UV filter was also a primary
aim of this doctoral work. Due to the complex and especially long-lasting process required
for approval of new compounds for biomedical applications, alternative approaches exist
to reduce the photocatalytic activity of TiO2 NPs while maintaining their UV filtering
properties. Typically, thin coatings based on silica, aluminium oxide, aluminium hydroxide,
methicone, and poly(methacrylic acid) are used [16, 17]. To further explore the
possibilities of Bi-based compounds, (BiO)2CO3 clusters with a size < 10 nm were
precipitated onto the surfaces of TiO2 NPs for the first time. Reports have previously
indicated that (BiO)2CO3 acts as a photocatalyst when used in large concentrations,
although its activity at low concentrations had not been determined. The TiO2/(BiO)2CO3
nanocomposites were synthesized via precipitation without the application of templates or
hydrothermal processes, which are typically used to obtain (BiO)2CO3 [18, 19]. By
introducing only a small amount of (BiO)2CO3 clusters onto the surface of TiO2, its
photocatalytic activity was decreased and its biocompatibility in healthy cells increased,
while maintaining its size, morphology, and UV blocking ability. Moreover, the
nanocomposites displayed reduced toxicity in HaCaT cells upon irradiation with simulated
sunlight, when compared to TiO2 NPs, which indicates that the composites are capable of
reducing the photo-induced generation of ROS. The TiO2/(BiO)2CO3 nanocomposites are
therefore a promising novel material for further investigation as an active UV filtering
additive in sunscreens.

6.2 Future Prospects
6.2.1 Theranostic Nanoparticles
Despite the many decades of research on therapeutic NPs, there are still
uncertainties about their mechanism of action and their physiological interactions. Once
inside the body, the NPs can interact with various substances in the blood and cells, while
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being exposed to different pH environments, which affects the stability, aggregation, and
agglomeration of the nanomaterials [20]. As a result, the materials can change in size,
dissociate, or dissolve, forming unknown by-products whose bioactivity and interactions
are yet largely unknown. This doctoral work aims to provide the first insights into the
physicochemical properties of Bi- and Ta-based nanomaterials and their mechanism of
action in the cellular environment in vitro. Due to the promising obtained results, further
studies in an advanced setting would be beneficial, including the use of more experiments
such as caspase activity assays in vitro, or in vivo studies.
As for the study of Bi(OH)3 and α-Bi2O3 NPs, a possible mechanism of action was
proposed for the extreme toxicity observed in 9L cells. By using self-developed
experiments, the first insights into the processes involved in the cell death were obtained.
Although the toxicity of the NPs can be connected to increased ROS levels, the mechanism
of action can also be related to other factors, such as the different natures of the
investigated cell lines, differential gene expression and sensitivity responses to stimuli,
different pH environments, or differences in cellular uptake. Since only initial experimental
evidence is provided in this work, biological in vitro testing with cell lines of the same
origin should be performed in order to ultimately answer these questions. Unfortunately,
such cell lines were not available for this doctoral thesis. More importantly, more cell lines
need to be tested to verify the early claims made in this work regarding the selective
toxicity of Bi(OH)3 and α-Bi2O3 NPs. While radiation dose enhancement by α-Bi2O3 NPs has
recently been reported [5], this feature needs to be further evaluated using Bi(OH)3 NPs.
Since 9L cells are known to be highly radiation-resistant, this cell line could be a preferred
starting point.
Future consideration can also be given to improvement of the stability of the
Bi(OH)3 and α-Bi2O3 NPs, which tend to agglomerate in suspension. To avoid possible
effects of stabilizing agents on the cellular experiments that were carried out in this
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doctoral thesis, the use of stabilizing agents was avoided. The goal was to study the
interactions of pristine Bi(OH)3 and Bi2O3 NPs with the cells. To increase cellular uptake
and stabilize the particles in suspension, future work can involve suitable surface coatings
that do not affect the NPs’ bioactivity [21]. This approach would also be suitable with
regard to the long-term goal of intravenous delivery of the NPs, such as with currently used
chemotherapeutic drugs.
The structural characterization of Bi(OH)3 NPs also lacks detail: while the literature
for all the other Bi- and Ta-based compounds that were investigated in this doctoral thesis
provides sufficient data regarding their crystal structure, no information was available for
Bi(OH)3. Since Bi(OH)3 NPs exhibit great potential for application in cancer treatment and
as an inorganic UV filter in sunscreens, it could be beneficial to further research their
crystal structure. Unfortunately, it wasn’t possible to further characterize the Bi(OH)3 NPs
during this doctoral thesis.
In this doctoral work, a thorough study was conducted on the loading and release
of MTX in δ-Ta2O5-PAA nanocomposites, as well as their contrast-enhancing properties.
Future work can include the optimization of synthesis time of the δ-Ta2O5-PAA
nanocomposites. For instance, the influence of the organic polymerization rate on the
kinetics of drug release can be studied using real time FTIR. In addition, delivery kinetics
between physisorbed and chemisorbed hydrogels can be elaborated in further studies.
To fully investigate the efficiency of the nanometric theranostic system, the
nanocomposites should also be characterized biologically. The therapeutic effects of δTa2O5-PAA nanocomposites can be evaluated through in vitro experiments in cancer and
normal cells, followed by the characterization of the targeting function currently attributed
to MTX [6, 7]. In order to fully characterize the theranostic system, in vitro tests would be
required to assess its capability for radiation dose enhancement.

299

Chapter 6 – Conclusions and Future Prospects

6.2.2 Nanoparticles as Ultraviolet Filters in Sunscreens
Similarly to the use of NPs as therapeutic agents, their topological application in
form of sunscreen emulsions also suffers from well-known difficulties. Reports regarding
the skin penetration of NPs and, in particular, their cytotoxicity vary significantly, making
it challenging to find full acceptance for their use in healthcare [17, 22-24]. This
inconclusiveness can be related to missing guidelines for skin toxicity, sensitization, and
corrosion, as well as to the use of different testing protocols, cell lines, and unrealistic dose
exposure [25-28]. In order to provide a better comparison to other reports in the research
on NPs for medical application, MDCK and HaCaT cells were chosen to investigate the
cytotoxicity of Bi(OH)3 and TiO2/(BiO)2CO3 nanomaterials. The results obtained in this
doctoral work justify further studies regarding the effects of the Bi-based nanomaterials in
animal models in vivo, such as on pig skin, which is often used to evaluate the skin
penetration of NPs. This setup can also be utilized to examine their photoprotection in vivo.
The sunscreen emulsions made of TiO2 and Bi(OH)3 NPs showed excellent
photoprotection and rheological properties, and much lower photoactivity and
photodegradation

when

compared

to

commercial

sunscreens.

Their

excellent

performance, especially in comparison to the classical combination of TiO2/ZnO, justifies
further in vitro testing. Considering the bioactivity of Bi(OH)3, which was evaluated as part
of this doctoral work, the Bi(OH)3 NPs should be tested in skin cancer cells, where they
could potentially induce apoptosis, as was shown in 9L and MCF-7 cells. As shown in this
doctoral thesis, Bi(OH)3 NPs exhibit high biocompatibility in normal skin cells, which
justifies initiating in vivo tests to further investigate their properties.
This doctoral work also showed that the TiO2/(BiO)2CO3 nanocomposites exhibit
significantly reduced photocatalytic activity when compared to pristine TiO2 NPs, while
still having comparable UV blocking properties. Future investigations should focus on the
various mechanisms of action, which was not possible to do during this doctoral thesis
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work, as the resources were not available. For instance, the scavenging properties of the
carbonate ion could be studied via ESR. Moreover, the band structure of (BiO)2CO3 should
be investigated, since the reduced photocatalytic activity of TiO2/(BiO)2CO3 may be
associated with the band structures of TiO2 and (BiO)2CO3. Similarly to the study of Bi(OH)3
NPs as a potential UV filter, the nanocomposites can also be incorporated into sunscreen
emulsions, and both their photoprotection and photodegradation could be investigated
and compared to commercial sunscreen formulations.
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APPENDIX I

Figure A1. (a) XPS survey spectra and high-resolution XPS spectra of (b) C 1s and (c) N 1s
regions of Bi(OH)3 (top) and α-Bi2O3 (bottom) nanoparticles.
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Figure A2. BF images of untreated 9L cells, incubated for a total time of 48 h.
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Figure A3. BF images of 9L cells incubated with Bi(OH)3 nanoparticles at a concentration
of 50 μg/mL for a total time of 48 h.
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Figure A4. BF images of 9L cells incubated with α-Bi2O3 nanoparticles at a concentration of
50 μg/mL for a total time of 48 h.
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Figure A5. BF images of untreated MCF-7 cells, incubated for a total time of 48 h.

308

Appendix I

Figure A6. BF images of MCF-7 cells incubated with Bi(OH)3 nanoparticles at a
concentration of 50 μg/mL for a total time of 48 h.
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Figure A7. BF images of MCF-7 cells incubated with α-Bi2O3 nanoparticles at a
concentration of 50 μg/mL for a total time of 48 h.
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Figure A8. BF images of untreated MDCK cells, incubated for a total time of 48 h.

311

Appendix I

Figure A9. BF images of MDCK cells incubated with Bi(OH)3 nanoparticles at a
concentration of 50 μg/mL for a total time of 48 h
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Figure A10. BF images of MDCK cells incubated with α-Bi2O3 nanoparticles at a
concentration of 50 μg/mL for a total time of 48 h.
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Figure A11. XPS survey spectra of (a) Bi(OH)3 (M1), (b) TiO2 (M2), and (c) ZnO (M3)
nanoparticles.
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Figure A12. High-resolution XPS spectra of the N 1s (left column), O 1s (centre column),
and Ti 2p (right column) regions for TiO2 nanoparticles, and TiO2/(BiO)2CO3
nanocomposites with different Bi/Ti atomic ratios.

315

Appendix II

APPENDIX II
Table A1. High resolution XPS data for the C 1s region of Ta2O5 NPs (before and after
treatment with HCl) and the Ta2O5-PAA nanocomposites with polymerization times of 1
and 2.5 h.
Sample

CH2 (eV)

CH (eV)

C–O (eV)

O–C=O (eV)

δ-Ta2O5

284.8

286.0

288.4

–

δ-Ta2O5 (HCl treated)

284.8

285.9

288.1

–

δ-Ta2O5-PAA 1 h

284.8

286.1

288.5

290.0

δ-Ta2O5-PAA 2.5 h

284.8

286.0

288.2

290.1

Table A2. High resolution XPS data for the O 1s region of Ta2O5 NPs (before and after
treatment with HCl) and the Ta2O5-PAA nanocomposites with polymerization times of 1
and 2.5 h.
Sample

Ta–O (eV)

Ta–OH or C–OH (eV)

C=O (eV)

δ-Ta2O5

530.0

532.2

–

δ-Ta2O5 (HCl treated)

530.4

532.5

–

δ-Ta2O5-PAA 1 h

531.6

533.2

534.1

δ-Ta2O5-PAA 2.5 h

531.4

533.1

534.1
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